PCT WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 6 :
C12N 15/54, 9/10, 5/10, 15/85, A61K 38/43, C12Q 1/68

A2

(11) International Publication Number: **WO 98/00551**

(43) International Publication Date: 8 January 1998 (08.01.98)

(21) International Application Number: PCT/US97/11761

(22) International Filing Date: 3 July 1997 (03.07.97)

(30) Priority Data:
08/675,499 3 July 1996 (03.07.96) US
08/812,008 5 March 1997 (05.03.97) US

(71) Applicant *(for all designated States except US)*: MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH [US/US]; 200 First Street S.W., Rochester, MN 55905 (US).

(72) Inventors; and

(75) Inventors/Applicants *(for US only)*: MCDONALD, John, A. [US/US]; 9335 East Adobe Drive, Scottsdale, AZ 85255 (US), SPICER, Andrew, P. [GB/US]; Apartment 2105, 10255 East Via Linda, Scottsdale, AZ 85258 (US). AUGUSTINE, Mary, Louise [US/US]; Apartment 1012, 3015 North Hayden Road, Scottsdale, AZ 85251 (US).

(74) Agent: EMBRETSON, Janet, E.; Schwegman, Lundberg, Woessner & Kluth, P.O. Box 2938, Minneapolis, MN 55402 (US).

(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, ARIPO patent (GH, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).

Published

Without international search report and to be republished upon receipt of that report.

(54) Title: GENE ENCODING HYALURONAN SYNTHASE

(57) Abstract

An isolated and purified DNA molecule encoding hyaluronan synthase-2 (Has2) is provided, as is purified and isolated Has2 polypeptide. Also provided is an isolated and purified DNA molecule encoding hyaluronan synthase-3 (Has3), as is purified and isolated Has3 polypeptide.



FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

GENE ENCODING HYALURONAN SYNTHASE

Background of the Invention

Hyaluronan (HA, hyaluronic acid) is a linear unbranched polymer made up of repeating disaccharide units of D-glucuronic acid (β1→ 3) N-acetylglucosamine (β1→4). HA biosynthesis requires two enzyme activities; the transfer of UDP-N-acetylglucosamine (UDP-GlcNAc) and UDP-glucuronic acid (UDP-GlcUA), respectively, to the growing HA chain. HA is synthesized at the inner face of the plasma membrane and is subsequently extruded to the outside of the cell. HA is a major constituent of the extracellular matrix during embryonic development. For example, within the developing embryo, HA accumulates at sites of cell migration and proliferation, and has been proposed to play important roles in craniofacial, limb, neural tube, and heart development. In particular, HA is essential for the formation of endocardial cushions, the structures required for septation and the development of heart valves. In adults, HA is a major constituent of the extracellular matrix of most tissues and organs, and a critical component of the vitreous humor of the eye, joint fluid and cartilage.

HA is highly biocompatible and completely biodegradable, and has demonstrated beneficial effects when administered to the joints of arthritic race horses and to perforated rat tympanic membranes. HA has also been employed to protect eye tissue during artificial intraocular lens implantations, as a delivery agent for drugs and to prevent post-operative scarring.

Genes which encode HA biosynthetic enzymes have been identified in bacteria, e.g., Group A *Streptococcus* (Wessels et al., Infect. Immun., 62, 433 (1994); DeAngelis et al., J. Biol. Chem., 268, 19181 (1993); DeAngelis et al., Biochemistry, 33, 9033 (1994)). Polymerization of HA by *S. pyogenes* occurs through the action of a single enzyme, HA synthase, encoded by the *hasA* gene.

The *S. pyogenes* HA synthase is localized to the membrane and is predicted to have several transmembrane domains and a large intracellular loop encompassing the active site of the enzyme. Purified immobilized HasA has been shown to be sufficient for HA polymerization *in vitro* (DeAngelis et al., Biochemistry, 33, 9033 (1994)). The transfer of the *hasA* gene and a second gene, *hasB*, into heterologous bacterial species results in the synthesis of an HA capsule (DeAngelis et al., J. Biol. Chem., 268, 19181 (1993)). The *hasB* gene encodes a UDP-glucose dehydrogenase, which converts UDP-glucose to UDP-glucuronic acid (UDP-GlcUA), a subunit of HA.

However, there is evidence that other genes are also involved in bacterial HA biosynthesis. A protein originally identified in *Streptococcus equisimilis* as HA synthase (Lansing et al., Biochem. J., 289, 179 (1993)) has no sequence similarity to *S. pyogenes* HasA but has significant sequence similarity to bacterial proteins involved in oligopeptide binding and transport. Although the total amount of HA synthesized by bacterial cells overexpressing the *S. equisimilis* HA synthase increased, the length of the resultant HA chains was significantly shorter, suggesting that the increase may be a function of an elevation in the rate of HA transport from the cell (O'Regan et al., Int. J. Biol. Macromol., 16, 283 (1994)). Thus, rather than being directly involved in HA biosynthesis, the *S. equisimilis* HA synthase may be involved in the transport of HA, or may participate in HA synthesis as an accessory molecule, rather than as the synthase itself.

While both bacterial and animal sources of HA exist, high molecular weight HA is difficult and costly to isolate and purify due to the fact that HA is complexed with proteoglycans. Moreover, both bacterial and animal sources of HA are increasingly under more stringent regulatory controls due to fear of contamination with identifiable, or as yet unidentified, infectious or toxic agents. Furthermore, the extensive purification process of HA polymer from cells results in an HA polymer of considerable molecular weight polydispersity.

Thus, there is a need to isolate and purify genes that encode eukaryotic HA biosynthetic enzymes or proteins associated with the extracellular accumulation of HA.

Summary of the Invention

The present invention provides an isolated and purified DNA molecule comprising a preselected DNA segment encoding eukaryotic, preferably mammalian, hyaluronan synthase-2 (Has2), a biologically active variant thereof or a biologically active subunit thereof. A preferred embodiment of the invention is a DNA molecule comprising a preselected DNA segment, e.g., SEQ ID NO:1, that encodes murine hyaluronan synthase-2. A murine hyaluronan synthase-2 having SEQ ID NO:2 has 21% identity and 28% similarity to Streptococcal HasA, and 55% identity and 73% similarity to murine Has1 (Itano et al., J. Biol. Chem., 271, 9875 (1996); SEQ ID NO:3). Because the deduced amino acid sequence of Has1 is distinct from the murine hyaluronan synthase-2 having SEQ ID NO:2, there appears to be more than one mammalian gene encoding an enzyme or protein which is associated with HA biosynthesis and/or extracellular HA accumulation. Another preferred embodiment of the invention is a DNA molecule comprising a preselected DNA segment, e.g., SEQ ID NO:23, that encodes human hyaluronan synthase-2, a polypeptide which does not have amino acid sequence identity with the human homolog of murine Has 1 (Itano et al., BBRC, 222, 816 (1996); SEQ ID NO:55). Also provided is an isolated and purified DNA molecule comprising a preselected DNA segment which encodes a protein that increases the amount of extracellular hyaluronan produced by cultured primate cells transformed so as to express said DNA segment.

Further provided is an isolated and purified DNA molecule comprising a DNA segment encoding eukaryotic, preferably mammalian, hyaluronan synthase-3 (Has3), or a biologically active variant thereof or a biologically active subunit thereof. A preferred embodiment of the invention includes a preselected DNA segment comprising SEQ ID NO:31 which encodes a hyaluronan synthase-3 comprising SEQ ID NO:32. Another preferred embodiment of the invention

includes a DNA molecule comprising a preselected DNA segment comprising SEQ ID NO:25 which encodes a hyaluronan synthase-3 comprising SEQ ID NO:29. The DNA molecules of the invention are double-stranded or single-stranded, preferably, they are cDNA.

An isolated and purified DNA molecule, such as a probe or a primer. e.g., an oligonucleotide, of at least seven, preferably at least fifteen, nucleotide bases which hybridizes under stringent conditions to the DNA molecules of the invention, or RNA molecules derived from these DNA molecules, is also provided by the invention. The term "stringent conditions" is defined hereinbelow. The probes or primers of the invention have at least about 80%, preferably at least about 90%, identity to the above-disclosed DNA sequences, or sequences complementary thereto. A preferred embodiment of the invention includes a probe or primer which has at least about 80%, preferably at least about 90%, more preferably at least about 95%, identity to 1) SEQ ID NO:1, 2) SEQ ID NO:23, 3) SEQ ID NO:25, 4) SEQ ID NO:26 or 5) SEQ ID NO:31, or a sequence complementary thereto. The probes or primers of the invention may be detectably labeled or have a binding site for a detectable label. The probes or primers are useful to detect, quantify and/or amplify DNA strands with complementary to sequences related to hyaluronan synthase-2 or hyaluronan synthase-3 in eukaryotic tissue samples. The probes and primers of the present invention are also useful for detecting RNA molecules resulting from transcription of the DNA molecules of the present invention. The uses of probes and primers, as well as their isolation, purification and conditions under which they are employed for the detection or amplification of a specific gene, are well known in the art.

The present invention also provides isolated and purified DNA molecules which provide "anti-sense" mRNA transcripts of the DNA sequences, including SEQ ID NO:1 or SEQ ID NO:31, which, when expressed from an expression cassette in a host cell, can alter HA expression.

The present invention also provides an expression cassette comprising a promoter which is functional in a host cell operably linked to a preselected DNA

segment encoding hyaluronan synthase-2. Preferably, the expression cassette comprises a preselected DNA segment encoding murine hyaluronan synthase-2. Another preferred embodiment of the invention is an expression cassette comprising a preselected DNA segment encoding human hyaluronan synthase-2.

The present invention further provides an expression cassette comprising a promoter which is functional in a host cell operably linked to a preselected DNA segment encoding hyaluronan synthase-3. Preferably, the expression cassette comprises a preselected DNA segment encoding murine hyaluronan synthase-3. Another preferred embodiment of the invention is an expression cassette comprising a preselected DNA segment encoding human hyaluronan synthase-3. Such expression cassettes can be placed into expression vectors which can then be employed to transform prokaryotic or eukaryotic host cells. It is envisioned that the vectors of the invention may be useful to transform mammalian cells *in vivo*, or *in vitro* with subsequent introduction of the transformed cells to a host organism. The *in vivo* delivery of the vectors may be accomplished by methods well known to the art, including, but not limited to, viral- or liposome-mediated delivery. The present cassettes can also contain a functional DNA sequence which is a selectable marker gene or reporter gene, as described below.

Also provided is a transformed host cell, the genome of which has been augmented by a preselected DNA sequence encoding hyaluronan synthase-2, a preselected DNA sequence encoding hyaluronan synthase-3, or a combination thereof. Preferably, the preselected DNA sequence is integrated into the chromosome of the transformed host cell, and is heritable.

Expression of mouse hyaluronan synthase-2 or mouse hyaluronan synthase-3 in COS-1 cultured primate cells results in the formation of large well-pronounced HA coats, as described hereinbelow. Moreover, HA coat formation in COS cells transfected with an hyaluronan synthase-2 expression vector occurred in the absence of HA receptor expression, exogenously added HA, or proteoglycans. This suggests that hyaluronan synthase-2 expression leads to the synthesis of HA, in a form which is extruded through the plasma membrane and

may associate with the cell surface to form an HA coat through continued attachment to the HA synthase.

Further provided is isolated, purified hyaluronan synthase-2 polypeptide. A preferred embodiment of the invention is isolated, purified murine hyaluronan synthase-2 polypeptide. Another preferred embodiment of the invention is isolated, purified hyaluronan synthase-2 polypeptide having SEQ ID NO:2.

Also provided is isolated, purified hyaluronan synthase-3 polypeptide. A preferred embodiment of the invention is isolated, purified murine hyaluronan synthase-3 polypeptide. Another preferred embodiment of the invention is isolated, purified hyaluronan synthase-3 polypeptide having SEQ ID NO:32.

As used herein, the term "Has2" or "hyaluronan synthase-2" is preferably defined to mean a polypeptide comprising SEQ ID NO:2, as well as variants of SEQ ID NO:2 which have at least about 80%, preferably at least about 90%, identity or homology to SEQ ID NO:2, or a biologically active subunit thereof. Biologically active subunits of hyaluronan synthase-2, variant hyaluronan synthase-2 polypeptides and biologically active subunits thereof, falling within the scope of the invention have at least about 50%, preferably at least about 80%, and more preferably at least about 90%, the activity of the hyaluronan synthase-2 polypeptide comprising SEQ ID NO:2. The activity of an hyaluronan synthase-2 polypeptide can be measured by methods well known to the art including, but not limited to, the particle exclusion assay described hereinbelow, an immunoassay which detects HA production, as described by Itano et al. (J. Biol. Chem., 271, 9875 (1996)), HA synthase activity of crude membrane preparations, as described by Itano et al. (*supra*), or HA synthase activity of cell lysate preparations, as described by Meyer et al. (Proc. Natl. Acad. Sci. USA, 93, 4543 (1996)).

As used herein, the term "Has3" or "hyaluronan synthase-3" is preferably defined to mean a polypeptide comprising SEQ ID NO:32, SEQ ID NO:29, or a biologically active subunit thereof, as well as variants of SEQ ID NO:32 or SEQ ID NO:29 and subunits thereof which have at least about 80%, preferably at least about 90%, identity or homology to SEQ ID NO:32 or SEQ ID NO:29,

respectively. Biologically active subunits of hyaluronan synthase-3, variant hyaluronan synthase-3 polypeptides and biologically active subunits thereof, falling within the scope of the invention have at least about 50%, preferably at least about 80%, and more preferably at least about 90%, the activity of the hyaluronan synthase-3 polypeptide comprising SEQ ID NO:32 or SEQ ID NO:29. The activity of an hyaluronan synthase-3 polypeptide can be measured by the methods described above for hyaluronan synthase-2.

The present invention also provides a method to produce hyaluronan synthase-2, comprising: culturing a host cell, preferably a primate host cell, transformed with a nucleic acid molecule comprising a DNA segment encoding hyaluronan synthase-2 operably linked to a promoter, so that said host cell expresses said hyaluronan synthase-2. The method also preferably provides isolated recombinant hyaluronan synthase-2 polypeptide which is recovered from the transformed host cells.

Also provided is a method to produce hyaluronan synthase-3, comprising: culturing a host cell transformed with a nucleic acid molecule comprising a DNA segment encoding hyaluronan synthase-3 operably linked to a promoter, so that said host cell expresses said hyaluronan synthase-3. The method also preferably provides isolated recombinant hyaluronan synthase-3 polypeptide which is recovered from the transformed host cells. Optionally, host cells can be co-transformed with a nucleic acid molecule comprising a DNA segment encoding hyaluronan synthase-3 operably linked to a promoter and a nucleic acid molecule comprising a DNA segment encoding hyaluronan synthase-2 operably linked to a promoter.

Further provided is a method of altering the amount of hyaluronan produced by a cell. The method comprises introducing into a host cell a preselected DNA segment encoding hyaluronan synthase-2 operably linked to a promoter so as to yield a transformed host cell. The preselected DNA segment is expressed as hyaluronan synthase-2 in the transformed host cell in an amount that results in the transformed host cell producing an altered, preferably

increased, amount of hyaluronan relative to the amount of hyaluronan produced by a corresponding untransformed host cell.

Also provided is a method of altering the amount of hyaluronan produced by a cell. The method comprises introducing into a host cell a preselected DNA segment encoding hyaluronan synthase-3 operably linked to a promoter so as to yield a transformed host cell. The preselected DNA segment is expressed as hyaluronan synthase-3 in the transformed host cell in an amount that results in the transformed host cell producing an altered, preferably increased, amount of hyaluronan relative to the amount of hyaluronan produced by a corresponding untransformed host cell.

Once isolated and purified, the genes involved in HA biosynthesis and extracellular accumulation of HA can be employed to synthesize HA *in vitro*. Because *in vitro* synthesized HA is of extremely high purity, is free from bacterial and animal cell contaminants, and can be optimized as to its physicochemical properties, it is a preferred source of HA relative to HA derived from bacterial or animal sources. Thus, the invention provides a method to prepare HA which comprises contacting an amount of hyaluronan synthase-2, an amount of hyaluronan synthase-3, or a combination thereof, with a mixture of components under conditions effective to yield hyaluronan.

Moreover, the identification of genes involved in HA biosynthesis and/or coat formation may also be useful for defining the molecular basis for genetic diseases which are associated with a deficiency in HA biosynthesis, such as cartilage pathologies, for providing a clinically useful diagnostic test or in molecular-based therapeutics. Furthermore, the cloning of these genes will help to elucidate the molecular mechanism giving rise to the alteration of the protein encoded by the gene in patients having a particular disorder, e.g., a cartilage deficiency associated with reduced HA biosynthesis.

Thus, the invention provides a method to prevent or treat a condition associated with an alteration in HA synthesis or extracellular accumulation. The method comprises administering to a mammal afflicted with, or at risk of, said

condition an amount of mammalian hyaluronan synthase-2 effective to alter HA synthesis or extracellular accumulation.

The invention also provides a method to prevent or treat a condition associated with an alteration in HA synthesis or extracellular accumulation, comprising: administering to a mammal afflicted with, or at risk of, said condition an amount of mammalian hyaluronan synthase-3 effective to alter HA synthesis or extracellular accumulation.

Also provided is a method to identify a mammal afflicted with, or at risk of, a condition associated with aberrant HA synthesis or extracellular accumulation. The method comprises contacting an agent that binds to mammalian hyaluronan synthase-2 with a mammalian sample suspected of containing hyaluronan synthase-2 so as to form a complex. Then the presence or amount of complex formation is detected or determined and the presence or amount of complex formation is correlated with the presence or absence of the condition.

The invention also provides a method to identify a mammal afflicted with, or at risk of, a condition associated with aberrant HA synthesis or extracellular accumulation which employs an agent that binds to mammalian hyaluronan synthase-3. The agent is contacted with a mammalian sample suspected of containing hyaluronan synthase-3 so as to form a complex. The presence or amount of complex formation is detected or determined and the presence or amount of complex formation is correlated with the presence or absence of the condition.

Further provided is a method for detecting hyaluronan synthase-2 DNA. The method comprises contacting an amount of DNA obtained by reverse transcription of RNA from a mammalian physiological sample which comprises cells suspected of containing hyaluronan synthase-2 RNA, with an amount of at least two oligonucleotides under conditions effective to amplify the DNA by a polymerase chain reaction so as to yield an amount of amplified hyaluronan synthase-2 DNA. At least one oligonucleotide is an hyaluronan synthase-2-

specific oligonucleotide. The presence or amount of the amplified hyaluronan synthase-2 DNA is then detected.

The invention also provides a method for detecting hyaluronan synthase-3 DNA. The method comprises contacting an amount of DNA obtained by reverse transcription of RNA from a mammalian physiological sample which comprises cells suspected of containing hyaluronan synthase-3 RNA, with an amount of at least two oligonucleotides under conditions effective to amplify the DNA by a polymerase chain reaction so as to yield an amount of amplified hyaluronan synthase-3 DNA. At least one oligonucleotide is an hyaluronan synthase-3-specific oligonucleotide. The presence or amount of the amplified hyaluronan synthase-3 DNA is detected.

As used herein, the term "hyaluronan synthase-2-specific oligonucleotide" or "hyaluronan synthase-3-specific oligonucleotide" means a DNA sequence that has at least about 80%, preferably at least about 90%, and more preferably at least about 95%, sequence identity with SEQ ID NO:1 or SEQ ID NO:23 (has2), or SEQ ID NO:25, SEQ ID NO:29 or SEQ ID NO:32 (has3), respectively. An oligonucleotide or primer of the invention has at least about 7-50, preferably about 10-40, and more preferably about 15-35, nucleotides. Preferably, the oligonucleotide primers of the invention comprise at least 7 nucleotides at their 3′ end which have at least about 85% identity to SEQ ID NO:1, SEQ ID NO:23, SEQ ID NO:25, SEQ ID NO:29 or SEQ ID NO:32. The oligonucleotides of the invention may also include sequences which are unrelated to has sequences.

Further provided is a method for detecting a condition associated with aberrant HA synthesis or extracellular accumulation. The method comprises contacting an amount of DNA obtained by reverse transcription of RNA from a mammalian physiological sample which comprises cells suspected of containing hyaluronan synthase-2 RNA, with an amount of at least two oligonucleotides under conditions effective to amplify the DNA by a polymerase chain reaction so as to yield an amount of amplified hyaluronan synthase-2 DNA. Alternatively, or concurrently, an amount of DNA obtained by reverse transcription of RNA

from a mammalian physiological sample which comprises cells suspected of containing hyaluronan synthase-3 RNA is contacted with an amount of at least two oligonucleotides under conditions effective to amplify the DNA by a polymerase chain reaction so as to yield an amount of amplified hyaluronan synthase-3 DNA. Then the presence or amount of the amplified hyaluronan synthase-2 and/or hyaluronan synthase-3 DNA is detected. The presence or amount of hyaluronan synthase-2 DNA is indicative of the presence of the condition in said mammal and/or hyaluronan synthase-3.

The invention also provides a therapeutic method in which an amount of an agent that alters the activity of native hyaluronan synthase-2, native hyaluronan synthase-3, or a combination thereof, is administered to a mammal.

Brief Description of the Figures

Figure 1. Degenerate RT-PCR analysis. An agarose gel is shown which depicts polymerase chain reaction (PCR) amplified bands characteristic of a typical RT-PCR experiment. RT-PCR was performed on total RNA isolated from 10.5 days post coitum (dpc) (E 10.5) and 14.5 dpc (E 14.5) C57BL/6J mouse embryos. M, indicates 1 kilobase pair ladder (GIBCO-BRL/Life Technologies, Gaithersburg, MD). DEG1/3 indicates degenerate primer pools 1 and 3. DEG 1/5 indicates degenerate primer pools 1 and 5.

Figure 2. cDNA library clones. The extent of overlapping cDNA clones is shown in relation to the mouse Has2 cDNA and to the degenerate RT-PCR mouse Has2 cDNA clone, MHas300. The positions of the translation initiation codon (ATG), the translation termination codon (TGA), and the internal EcoRI restriction endonuclease site (E) are indicated.

Figure 3. Nucleotide sequence encoding, and corresponding amino acid sequence of, mouse Has2 (SEQ ID NO:1 and SEQ ID NO:2, respectively). The 5' and 3' untranslated nucleotide sequences are shown in lowercase, whereas the open reading frame is shown in uppercase. The stop codon, consensus polyadenylation signals, CA repeat and TA repeat are underlined.

Figure 4. Alignment of mouse Has2 with mouse Has1 (Itano et al., J. Biol. Chem., 271, 9875 (1996)) (SEQ ID NO:3), *Xenopus laevis* DG42 (SEQ ID

NO:4), *Streptococcus pyogenes* HasA (SEQ ID NO:5), and *Rhizobium meliloti* NodC (SEQ ID NO:6). Identical residues are boxed. Dashes indicate gaps that have been introduced to maximize the identity. Asterisks below the line indicate positions at which there have been conservative amino acid substitutions.

Figure 5. Alignment of two regions of mouse Has2 (SEQ ID NOs:7 and 8) with equivalent regions of mouse Has1 (Itano et al., *supra*) (SEQ ID NO:9 and SEQ ID NO:40), *X. laevis* DG42 (SEQ ID NO:10 and SEQ ID NO:42), *S. pyogenes* HasA (SEQ ID NO:11 and SEQ ID NO:44), *R. meliloti* NodC (SEQ ID NO:12 and SEQ ID NO:46) and *S. cerevisiae* chitin synthase 2 (Chs2) (SEQ ID NO:13 and SEQ ID NO:45). Dashes represent gaps that have been introduced to maximize homology. Residues highlighted in bold type are those that have been demonstrated to be critical in terms of enzyme activity of Chs2 (see Nagahashi et al., J. Biol. Chem., 270, 13961 (1995)) and that are conserved in all six sequences.

Figure 6. Kyte-Doolittle hydrophilicity plots and linear cartoon representation of mouse Has2 protein. A) Comparison of mouse Has2, mouse Has1 and *Streptococcus pyogenes* HasA by Kyte-Doolittle hydrophilicity plots. The amino acid sequences of mouse Has2, mouse HAS (Has1) and bacterial HasA were analyzed using the Kyte-Doolittle algorithm (MacVector) with a hydrophilicity window size of 15. Strongly hydrophobic areas of the proteins are indicated below the axes. Areas predicted to be potential transmembrane domains or signal peptide are indicated by the black bars below each plot. B) Linear representation of mouse Has2 predicted protein. Hydrophobic areas are indicated by the filled black boxes. Consensus $B(X_7)B$ HA binding motifs (HABM) are indicated by the filled gray boxes and are numbered. These motifs correspond to amino acid residues 100-108, 107-115, 420-428, and 460-468. The predicted intracellular loop of the molecule is indicated.

Figure 7. Northern analyses of mouse Has2 expression. Multiple tissue Northern blots of polyA$^+$ RNA isolated from mouse embryos and adult tissues were hybridized with a mouse Has2 ORF cDNA probe. The relative positions of

RNA molecular weight markers are indicated at the left of each blot. A GAPDH probe was employed as an internal control.

Figure 8. Southern analysis of mouse Has2. Total 129Sv/J mouse genomic DNA was digested with the restriction enzymes, E (EcoRI), B (BamHI), H (HindIII), and S (SacI) and probed with a labeled mouse Has2 ORF cDNA. "M" indicates 1 kilobase pair ladder.

Figure 9. COS-1 cells expressing mouse Has2 hyaluronan coats. HA coats were detected by a particle exclusion assay (see Clarris et al., Exp. Cell Res., 49, 181 (1986)). (A) Mouse 3T6 embryonic fibroblasts. (B) COS-1 cells. (C) COS-1 cells co-transfected with a β-gal expression vector and pCIneo control vector. (D-I) COS-1 cells co-transfected with a vector which expresses mouse Has2 and a vector which expresses β-gal. (E) Co-transfected COS-1 cells which were maintained in starvation-medium. (F and I) Co-transfected COS-1 cells stained for β-gal activity. (H) Co-transfected COS-1 cells which were maintained in starvation-medium containing hyaluronidase.

Figure 10. (A) Partial nucleotide sequence of human hyaluronan synthase-2 (SEQ ID NO:23). (B) Nucleotide sequence alignment of human hyaluronan synthase-2 (SEQ ID NO:23) and mouse hyaluronan synthase-2 (SEQ ID NO:1). (C) Amino acid sequence alignment of human hyaluronan synthase-2 (SEQ ID NO:24) and mouse hyaluronan synthase-2 (SEQ ID NO:2).

Figure 11. (A) Partial nucleotide sequence of human hyaluronan synthase-3 (SEQ ID NO:25). (B) Partial nucleotide sequence of murine hyaluronan synthase-3 (SEQ ID NO:26). (C) Nucleotide sequence alignment of human hyaluronan synthase-3 (SEQ ID NO:25) and mouse hyaluronan synthase-3 (SEQ ID NO:26). (D) Amino acid sequence alignment of human hyaluronan synthase-3 (SEQ ID NO:27) and mouse hyaluronan synthase-3 (SEQ ID NO:28).

Figure 12. (A) Amino acid sequence alignment of a partial sequence for human hyaluronan synthase-3 (Has3) (SEQ ID NO:29) with the equivalent sequence of mouse Has3 (SEQ ID NO:30). Conserved amino acids are indicated by a dash (–). (B) Nucleotide (SEQ ID NO:31) and predicted amino acid (SEQ ID NO:32) sequence of the Has3 open reading frame. Sequences

representing consensus HA binding motifs are underlined. The location of three introns within the gene are indicated by arrowheads. The first intron is located immediately preceding the start codon (ATG).

Figure 13. Northern blot depicting the expression of mouse Has3 at four different stages of mouse embryonic development. A cDNA probe representing the mouse Has3 ORF was radiolabeled and hybridized to a blot containing mouse embryonic polyA+ RNAs (CLONTECH) under conditions recommended by the manufacturer.

Figure 14. (A) Amino acid sequence alignment of mouse Has3 (SEQ ID NO:32) with mouse Has2 (Mhas2) (SEQ ID NO:2), mouse Has1 (Mhas1) (SEQ ID NO:3), *Xenopus laevis* DG42 (DG42) (SEQ ID NO:4) and *Streptococcus pyogenes* HasA (SEQ ID NO:5). Conserved residues are boxed. Gaps have been introduced to maximize the alignment. Asterisks indicate positions at which there have been significant conservative amino acid substitutions. (B) Alignment of two regions of the mouse Has3 protein sequence (SEQ ID NO:35 and SEQ ID NO:36, respectively) with equivalent regions of related glycosyltransferases including mouse Has2 (SEQ ID NO:7 and SEQ ID NO:2, respectively), mouse Has1 (SEQ ID NO:9 and SEQ ID NO:40, respectively), *Xenopus* DG42 (SEQ ID NO:10 and SEQ ID NO:42, respectively), *S. pyogenes* HasA (SEQ ID NO:11 and SEQ ID NO:44, respectively), *Rhizobium meliloti* NodC (SEQ ID NO:12 and SEQ ID NO:46, respectively), *Gossypium hirsutum* putative cellulose synthase A1 (celA1) (SEQ ID NO:47 and SEQ ID NO:48, respectively) and *Saccharomyces cerevisiae* Chitin synthase 2 (Chs2) (SEQ ID NO:15 and SEQ ID NO:45, respectively). Site-directed mutagenesis of the residues highlighted in bold of yeast Chs2 resulted in loss of enzymatic activity (Nagahashi et al., J. Biol. Chem., 270, 13961 (1995)), suggesting that these residues may be critical for $\beta 1 \rightarrow 4$ glycosyltransferase activity. (C) Kyte-Doolittle hydrophilicity plots of mouse Has3, mouse Has2, mouse Has1 and *S. pyogenes* HasA. Hydrophobic areas are represented below the axes. Potential transmembrane domains are indicated by black bars drawn below each plot.

Figure 15. COS-1 cells expressing mouse Has 3 hyaluronan coats. HA coats were detected as described in the legend to Figure 9. (A) COS-1 cells co-transfected with a β-gal expression vector and a vector which expresses mouse Has2. (B) COS-1 cells co-transfected with a β-gal expression vector and pCIneo control vector. (C) COS-1 cells co-transfected with a vector which expresses mouse Has3 and a vector which expresses β-gal before mock treatment with hyaluronidase. (D) COS-1 cells co-transfected with a vector which expresses mouse Has3 and a vector which expresses β-gal after mock treatment with hyaluronidase. (E) COS-1 cells co-transfected with a vector which expresses mouse Has3 and a vector which expresses β-gal before treatment with hyaluronidase. (F) COS-1 cells co-transfected with a vector which expresses mouse Has3 and a vector which expresses β-gal after treatment with hyaluronidase.

Detailed Description of the Invention

Definitions

"Southern analysis" or "Southern blotting" is a method by which the presence of DNA sequences in a restriction endonuclease digest of DNA or DNA-containing composition is confirmed by hybridization to a known, labeled oligonucleotide or DNA fragment. Southern analysis typically involves electrophoretic separation of DNA digests on agarose gels, denaturation of the DNA after electrophoretic separation, and transfer of the DNA to nitrocellulose, nylon, or another suitable membrane support for analysis with a radiolabeled, biotinylated, or enzyme-labeled probe as described in sections 9.37-9.52 of Sambrook et al., Molecular Cloning: A Laboratory Manual, Cold Spring Harbor (1989).

"Northern analysis" or "Northern blotting" is a method used to identify RNA sequences that hybridize to a known probe such as an oligonucleotide, DNA fragment, cDNA or fragment thereof, or RNA fragment. The probe is labeled with a radioisotope such as ^{32}P, by biotinylation or with an enzyme. The RNA to be analyzed can be usually electrophoretically separated on an agarose or polyacrylamide gel, transferred to nitrocellulose, nylon, or other suitable

membrane, and hybridized with the probe, using standard techniques well known in the art such as those described in sections 7.39-7.52 of Sambrook et al., *supra*.

"Polymerase chain reaction" or "PCR" refers to a procedure or technique in which amounts of a preselected fragment of nucleic acid, RNA and/or DNA, are amplified as described in U.S. Patent No. 4,683,195. Generally, sequence information from the ends of the region of interest or beyond is employed to design oligonucleotide primers. These primers will be identical or similar in sequence to opposite strands of the template to be amplified. PCR can be used to amplify specific RNA sequences, specific DNA sequences from total genomic DNA, and cDNA transcribed from total cellular RNA, bacteriophage or plasmid sequences, and the like. See generally Mullis et al., Cold Spring Harbor Symp. Quant. Biol., 51, 263 (1987); Erlich, ed., PCR Technology, (Stockton Press, NY, 1989).

As used herein "stringent conditions" means conditions that detect a nucleic acid molecule with at least 80%, preferably at least 90%, nucleotide sequence homology to the probe or primer sequence. See Sambrook et al., Molecular Cloning: A Laboratory Manual, Cold Spring Harbor Laboratory Press (2nd ed., 1989) for selection of hybridization and washing conditions for DNA:DNA, as well as DNA:RNA (Northern blot), stable and specific duplex formation. Stringent conditions are those that (1) employ low ionic strength and high temperature for washing, for example, 0.015 M NaCl/0.0015 M sodium citrate (SSC); 0.1% sodium lauryl sulfate (SDS) at 50°C, or (2) employ a denaturing agent such as formamide during hybridization, e.g., 50% formamide with 0.1% bovine serum albumin/0.1% Ficoll/0.1% polyvinylpyrrolidone/50 mM sodium phosphate buffer at pH 6.5 with 750 mM NaCl, 75 mM sodium citrate at 42°C. Another example is use of 50% formamide, 5 x SSC (0.75 M NaCl, 0.075 M sodium citrate), 50 mM sodium phosphate (pH 6.8), 0.1% sodium pyrophosphate, 5 x Denhardt's solution, sonicated salmon sperm DNA (50 µg/ml), 0.1% sodium dodecylsulfate (SDS), and 10% dextran sulfate at 42°C, with washes at 42°C in 0.2 x SSC and 0.1% SDS.

Sources of Nucleic Acids Encoding Has2 or Has3

A mouse gene has been recently identified that encodes a putative HA synthase, Has1 (Itano et al., J. Biol. Chem., 271, 9875 (1996)). However, the results of a complementation analysis conducted by Itano et al. during the isolation of the Has1 gene indicated that in the mouse, there are at least three genes that are involved in HA biosynthesis. Sources of nucleotide sequences from which these other genes, i.e., the present DNA molecules encoding Has2 or Has3, can be derived include total or polyA$^+$ RNA from eukaryotic, preferably mammalian, embryonic cells, or mesothelioma and Wilms' tumors or cell lines derived therefrom, as well as RNA isolated from embryonic tissue samples of cartilage, heart, neural tube and the like. Other sources of the DNA molecules of the invention include genomic DNA or cDNA libraries derived from any eukaryotic source including other mammals, e.g., rat, bovine, equine and the like, and other primates, e.g., humans and monkeys.

Isolation of a Gene Encoding Has2 or Has3

A nucleic acid molecule encoding mammalian HA biosynthetic enzymes, such as Has2 or Has3, can be identified and isolated using standard methods, as described by Sambrook et al., Molecular Cloning: A Laboratory Manual, Cold Spring Harbor, NY (1989). For example, degenerate reverse-transcriptase PCR (RT-PCR) can be employed to isolate and clone Has2 or Has3 genes. This approach relies upon conserved sequences deduced from alignments of related gene or protein sequences. Sequence analysis of the *hasA* gene of *S. pyogenes* predicts that the HA synthase is a membrane protein with a large intracellular loop encoding the active site of the enzyme (DeAngelis et al., J. Biol. Chem., 268, *supra*). Similarly, in mammalian cells, the HA synthase has been localized to the plasma membrane, with the active site on the inner face of the membrane (Philipson et al., J. Biol. Chem., 259, 5017 (1984); Prehm, Biochem. J., 220, 597 (1984)). Moreover, database searches have identified the *Rhizobium sp.* nodulation factor C (NodC) proteins, the *Saccharomyces cerevisiae* chitin synthase 2 (Chs2) proteins, and the *Xenopus laevis* DG42 protein as sharing

sequence identity with HasA (DeAngelis, et al., Biochem. Biophys. Res. Commun., 199, 1 (1994)).

At least two degenerate primer pools for RT-PCR are prepared, one of which is predicted to anneal to the antisense strand, and one of which is predicted to anneal to the sense strand of a putative eukaryotic DNA molecule which encodes HA synthase. The oligonucleotides are made to correspond to highly conserved regions of the proteins which were compared to generate the primers.

One degenerate primer pool is then utilized for the first-strand synthesis. RNA is isolated, e.g., using TRIZOL™ reagent (GIBCO-BRL/Life Technologies, Gaithersburg, MD). Reverse transcription reactions are performed on a source of nucleic acid believed to contain the DNA or RNA sequences of interest, e.g., total RNA isolated from mouse embryos.

Resultant first-strand cDNAs are then amplified in separate PCR reactions. The products of each PCR reaction are separated via an agarose gel and all consistently amplified products are gel-purified and cloned directly into a suitable vector, such as a plasmid vector. The resultant plasmids are subjected to restriction endonuclease and dideoxy sequencing of double-stranded plasmid DNAs.

Another approach to identify, isolate and clone genes which encode mammalian HA biosynthetic enzymes is to screen a cDNA library generated from embryonic heart or cartilage tissue. Screening for DNA fragments that encode all or a portion of the gene encoding Has2 or Has3 can be accomplished by probing the library with a probe, which has sequences that are highly conserved between genes believed to be related to Has2 or Has3, e.g., Has1, HasA, DG42 or NodC, or by screening of plaques for binding to antibodies that specifically recognize Has2 or Has3 related proteins. DNA fragments that bind to a probe having sequences which are related to Has2 or Has3, or which are immunoreactive with antibodies to Has2 or Has3 related proteins, can be subcloned into a suitable vector and sequenced and/or used as probes to identify other cDNA or genomic sequences encoding all or a portion of Has2 or Has3.

As used herein, the terms "isolated and/or purified" refer to *in vitro* isolation of a DNA or polypeptide molecule from its natural cellular environment, and from association with other components of the cell, such as nucleic acid or protein, so that it can be sequenced, replicated, and/or expressed. For example, "isolated Has2 nucleic acid" is RNA or DNA containing greater than 7, preferably 15, and more preferably 20 or more, sequential nucleotide bases that encode a biologically active Has2 polypeptide or a fragment thereof, or a biologically active variant Has2 polypeptide or a fragment thereof, that is complementary to the non-coding strand, or complementary to the coding strand, of the native Has2 polypeptide RNA or DNA, or hybridizes to said RNA or DNA and remains stably bound under stringent conditions.

"Isolated Has3 nucleic acid" is RNA or DNA containing greater than 7, preferably 15, and more preferably 20 or more, sequential nucleotide bases that encode a biologically active Has3 polypeptide or a fragment thereof, or a biologically active variant Has3 polypeptide or a fragment thereof, that is complementary to the non-coding strand, or complementary to the coding strand, of the native Has3 polypeptide RNA or DNA, or hybridizes to said RNA or DNA and remains stably bound under stringent conditions. Thus, the RNA or DNA is "isolated" in that it is free from at least one contaminating nucleic acid with which it is normally associated in the natural source of the RNA or DNA and is preferably substantially free of any other mammalian RNA or DNA. The phrase "free from at least one contaminating source nucleic acid with which it is normally associated" includes the case where the nucleic acid is reintroduced into the source or natural cell but is in a different chromosomal location or is otherwise flanked by nucleic acid sequences not normally found in the source cell. An example of isolated Has2 nucleic acid is RNA or DNA that encodes a biologically active Has2 polypeptide sharing at least about 80%, preferably at least about 90%, sequence identity with the Has2 polypeptide of Figure 3. An example of isolated Has3 nucleic acid is RNA or DNA that encodes a biologically active Has3 polypeptide sharing at least about 80%, preferably at least about 90%, sequence identity with the Has3 polypeptide of Figure 12B.

As used herein, the term "recombinant nucleic acid" or "preselected nucleic acid," e.g., "recombinant DNA sequence or segment" or "preselected DNA sequence or segment" refers to a nucleic acid, i.e., to DNA that has been derived or isolated from any appropriate tissue source, that may be subsequently chemically altered *in vitro*, so that its sequence is not naturally occurring, or corresponds to naturally occurring sequences that are not positioned as they would be positioned in a genome which has not been transformed with exogenous DNA. An example of preselected DNA "derived" from a source, would be a DNA sequence that is identified as a useful fragment within a given organism, and which is then chemically synthesized in essentially pure form. An example of such DNA "isolated" from a source would be a useful DNA sequence that is excised or removed from said source by chemical means, e.g., by the use of restriction endonucleases, so that it can be further manipulated, e.g., amplified, for use in the invention, by the methodology of genetic engineering.

Thus, recovery or isolation of a given fragment of DNA from a restriction digest can employ separation of the digest on polyacrylamide or agarose gel by electrophoresis, identification of the fragment of interest by comparison of its mobility versus that of marker DNA fragments of known molecular weight, removal of the gel section containing the desired fragment, and separation of the gel from DNA. See Lawn et al., Nucleic Acids Res., 9, 6103 (1981), and Goeddel et al., Nucleic Acids Res., 8, 4057 (1980). Therefore, "preselected DNA" includes completely synthetic DNA sequences, semi-synthetic DNA sequences, DNA sequences isolated from biological sources, and DNA sequences derived from RNA, as well as mixtures thereof.

As used herein, the term "derived" with respect to a RNA molecule means that the RNA molecule has complementary sequence identity to a particular DNA molecule.

Variants of the DNA Molecules of the Invention

Nucleic acid molecules encoding amino acid sequence variants of Has2 or Has3 are prepared by a variety of methods known in the art. These methods

include, but are not limited to, isolation from a natural source (in the case of naturally occurring amino acid sequence variants) or preparation by oligonucleotide-mediated (or site-directed) mutagenesis, PCR mutagenesis, and cassette mutagenesis of a DNA molecule encoding an earlier prepared variant or a non-variant version of Has2 or Has3 polypeptide.

Oligonucleotide-mediated mutagenesis is a preferred method for preparing amino acid substitution variants of Has2 or Has3. This technique is well known in the art as described by Adelman et al., DNA, 2, 183 (1983). Briefly, Has2 or Has3 DNA is altered by hybridizing an oligonucleotide encoding the desired mutation to a DNA template, where the template is the single-stranded form of a plasmid or bacteriophage containing the unaltered or native DNA sequence of Has2 or Has3. After hybridization, a DNA polymerase is used to synthesize an entire second complementary strand of the template that will thus incorporate the oligonucleotide primer, and will code for the selected alteration in the Has2 or Has3 DNA.

Generally, oligonucleotides of at least 25 nucleotides in length are used. An optimal oligonucleotide will have 12 to 15 nucleotides that are completely complementary to the template on either side of the nucleotide(s) coding for the mutation. This ensures that the oligonucleotide will hybridize properly to the single-stranded DNA template molecule. The oligonucleotides are readily synthesized using techniques known in the art such as that described by Crea et al., Proc. Natl. Acad. Sci. U.S.A., 75, 5765 (1978).

The DNA template can be generated by those vectors that are either derived from bacteriophage M13 vectors (the commercially available M13mp18 and M13mp19 vectors are suitable), or those vectors that contain a single-stranded phage origin of replication as described by Viera et al., Meth. Enzymol., 153, 3 (1987). Thus, the DNA that is to be mutated may be inserted into one of these vectors to generate single-stranded template. Production of the single-stranded template is described in Sections 4.21-4.41 of Sambrook et al., Molecular Cloning: A Laboratory Manual (Cold Spring Harbor Laboratory Press, N.Y. 1989).

Alternatively, single-stranded DNA template may be generated by denaturing double-stranded plasmid (or other) DNA using standard techniques.

For alteration of the native DNA sequence (to generate amino acid sequence variants, for example), the oligonucleotide is hybridized to the single-stranded template under suitable hybridization conditions. A DNA polymerizing enzyme, usually the Klenow fragment of DNA polymerase I, is then added to synthesize the complementary strand of the template using the oligonucleotide as a primer for synthesis. A heteroduplex molecule is thus formed such that one strand of DNA encodes the mutated form of the Has2 or Has3, and the other strand (the original template) encodes the native, unaltered sequence of the Has2 or Has3, respectively. This heteroduplex molecule is then transformed into a suitable host cell, usually a prokaryote such as *E. coli* JM101. After the cells are grown, they are plated onto agarose plates and screened using the oligonucleotide primer radiolabeled with 32-phosphate to identify the bacterial colonies that contain the mutated DNA. The mutated region is then removed and placed in an appropriate vector for protein production, generally an expression vector of the type typically employed for transformation of an appropriate host.

The method described immediately above may be modified such that a homoduplex molecule is created wherein both strands of the plasmid contain the mutations(s). The modifications are as follows: The single-stranded oligonucleotide is annealed to the single-stranded template as described above. A mixture of three deoxyribonucleotides, deoxyriboadenosine (dATP), deoxyriboguanosine (dGTP), and deoxyribothymidine (dTTP), is combined with a modified thiodeoxyribocytosine called dCTP-(aS) (which can be obtained from the Amersham Corporation). This mixture is added to the template-oligonucleotide complex. Upon addition of DNA polymerase to this mixture, a strand of DNA identical to the template except for the mutated bases is generated. In addition, this new strand of DNA will contain dCTP-(aS) instead of dCTP, which serves to protect it from restriction endonuclease digestion.

After the template strand of the double-stranded heteroduplex is nicked with an appropriate restriction enzyme, the template strand can be digested with

ExoIII nuclease or another appropriate nuclease past the region that contains the site(s) to be mutagenized. The reaction is then stopped to leave a molecule that is only partially single-stranded. A complete double-stranded DNA homoduplex is then formed using DNA polymerase in the presence of all four deoxyribonucleotide triphosphates, ATP, and DNA ligase. This homoduplex molecule can then be transformed into a suitable host cell such as *E. coli* JM101.

A preferred embodiment of the invention is an isolated and purified DNA molecule comprising a preselected DNA segment encoding an Has2 polypeptide having SEQ ID NO:2, wherein the DNA segment comprises SEQ ID NO:1, or variants of SEQ ID NO:1 having nucleotide substitutions which are "silent." That is, when nucleotide substitutions are present in a codon, the same amino acid is encoded by the codon with the nucleotide substitution as is encoded by the codon without the substitution. For example, leucine is encoded by the codon CTT, CTC, CTA and CTG. A variant of SEQ ID NO:1 at the seventh codon (CTA in SEQ ID NO:1) includes the substitution of CTT, CTC or CTG for CTA. Other "silent" nucleotide substitutions in SEQ ID NO:1 which can encode a polypeptide having SEQ ID NO:2 can be ascertained by reference to page D1 in Appendix D in Sambrook et al., Molecular Cloning: A Laboratory Manual (1989). Nucleotide substitutions can be introduced into DNA segments by methods well known to the art. See, for example, Sambrook et al., *supra*.

Another preferred embodiment of the invention is an isolated and purified DNA molecule comprising a preselected DNA segment encoding an Has3 polypeptide having SEQ ID NO:32, wherein the DNA segment comprises SEQ ID NO:31, or variants of SEQ ID NO:31 having nucleotide substitutions which are "silent." That is, when nucleotide substitutions are present in a codon, the same amino acid is encoded by the codon with the nucleotide substitution as is encoded by the codon without the substitution. For example, leucine is encoded by the codon CTT, CTC, CTA and CTG. A variant of SEQ ID NO:31 at the fifth codon (CTG in SEQ ID NO:31) includes the substitution of CTT, CTC or CTA for CTG. Other "silent" nucleotide substitutions in SEQ ID NO:31 which can encode a polypeptide having SEQ ID NO:32 can be ascertained by

reference to page D1 in Appendix D in Sambrook et al., Molecular Cloning: A Laboratory Manual (1989). Nucleotide substitutions can be introduced into DNA segments by methods well known to the art. See, for example, Sambrook et al., *supra*.

Chimeric Expression Cassettes

As used herein, "chimeric" means that a vector comprises DNA from at least two different species, or comprises DNA from the same species, which is linked or associated in a manner which does not occur in the "native" or wild type of the species.

The recombinant or preselected DNA sequence or segment, used for transformation herein, may be circular or linear, double-stranded or single-stranded. Generally, the preselected DNA sequence or segment is in the form of chimeric DNA, such as plasmid DNA, that can also contain coding regions flanked by control sequences which promote the expression of the preselected DNA present in the resultant cell line. Aside from preselected DNA sequences that serve as transcription units for Has2, Has3, or portions thereof, a portion of the preselected DNA may be untranscribed, serving a regulatory or a structural function. For example, the preselected DNA may itself comprise a promoter that is active in mammalian cells, or may utilize a promoter already present in the genome that is the transformation target. Such promoters include the CMV promoter, as well as the SV40 late promoter and retroviral LTRs (long terminal repeat elements), although many other promoter elements well known to the art may be employed in the practice of the invention. A preferred promoter useful in the practice of the invention is the CMV promoter.

Other elements functional in the host cells, such as introns, enhancers, polyadenylation sequences and the like, may also be a part of the preselected DNA. Such elements may or may not be necessary for the function of the DNA, but may provide improved expression of the DNA by affecting transcription, stability of the mRNA, or the like. Such elements may be included in the DNA

as desired to obtain the optimal performance of the transforming DNA in the cell.

"Control sequences" is defined to mean DNA sequences necessary for the expression of an operably linked coding sequence in a particular host organism. The control sequences that are suitable for prokaryotic cells, for example, include a promoter, and optionally an operator sequence, and a ribosome binding site. Eukaryotic cells are known to utilize promoters, polyadenylation signals, and enhancers.

"Operably linked" is defined to mean that the nucleic acids are placed in a functional relationship with another nucleic acid sequence. For example, DNA for a presequence or secretory leader is operably linked to DNA for a polypeptide if it is expressed as a preprotein that participates in the secretion of the polypeptide; a promoter or enhancer is operably linked to a coding sequence if it affects the transcription of the sequence; or a ribosome binding site is operably linked to a coding sequence if it is positioned so as to facilitate translation. Generally, "operably linked" means that the DNA sequences being linked are contiguous and, in the case of a secretory leader, contiguous and in reading phase. However, enhancers do not have to be contiguous. Linking is accomplished by ligation at convenient restriction sites. If such sites do not exist, the synthetic oligonucleotide adaptors or linkers are used in accord with conventional practice.

The preselected DNA to be introduced into the cells further will generally contain either a selectable marker gene or a reporter gene or both to facilitate identification and selection of transformed cells from the population of cells sought to be transformed. Alternatively, the selectable marker may be carried on a separate piece of DNA and used in a co-transformation procedure. Both selectable markers and reporter genes may be flanked with appropriate regulatory sequences to enable expression in the host cells. Useful selectable markers are well known in the art and include, for example, antibiotic and herbicide-resistance genes, such as *neo, hpt, dhfr, bar, aroA, dapA* and the like.

See also, the genes listed on Table 1 of Lundquist et al. (U.S. Patent No. 5,848,956).

Reporter genes are used for identifying potentially transformed cells and for evaluating the functionality of regulatory sequences. Reporter genes which encode for easily assayable proteins are well known in the art. In general, a reporter gene is a gene which is not present in or expressed by the recipient organism or tissue and which encodes a protein whose expression is manifested by some easily detectable property, e.g., enzymatic activity. Preferred genes include the chloramphenicol acetyl transferase gene (cat) from Tn9 of *E. coli*, the beta-glucuronidase gene (gus) of the *uidA* locus of *E. coli*, and the luciferase gene from firefly *Photinus pyralis*. Expression of the reporter gene is assayed at a suitable time after the DNA has been introduced into the recipient cells.

The general methods for constructing recombinant DNA which can transform target cells are well known to those skilled in the art, and the same compositions and methods of construction may be utilized to produce the DNA useful herein. For example, J. Sambrook et al., Molecular Cloning: A Laboratory Manual, Cold Spring Harbor Laboratory Press (2d ed., 1989), provides suitable methods of construction.

Transformation into Host Cells

The recombinant DNA can be readily introduced into the host cells by transfection with an expression vector comprising DNA encoding Has2, or an expression vector comprising DNA encoding Has3, by any procedure useful for the introduction into a particular cell, e.g., calcium phosphate precipitation, lipofection, electroporation, and the like.

As used herein, the term "cell line" or "host cell" is intended to refer to well-characterized homogenous, biologically pure populations of cells. These cells may be eukaryotic cells that are neoplastic or which have been "immortalized" *in vitro* by methods known in the art, as well as primary cells, or prokaryotic cells. The cell line or host cell is preferably of mammalian origin, but cell lines or host cells of non-mammalian origin may be employed, including

plant, insect, yeast, fungal or bacterial sources. Generally, the preselected DNA sequence is resident in the genome of the host cell but is not expressed, or not highly expressed.

"Transfected" or "transformed" is used herein to include any host cell or cell line, the genome of which has been altered or augmented by the presence of at least one preselected DNA sequence, which DNA is also referred to in the art of genetic engineering as "heterologous DNA," "recombinant DNA," "exogenous DNA," "genetically engineered," "non-native," or "foreign DNA," wherein said DNA was isolated and introduced into the genome of the host cell or cell line by the process of genetic engineering. The host cells of the present invention are typically produced by transfection with a DNA sequence in a plasmid expression vector, a viral expression vector, or as an isolated linear DNA sequence. Preferably, the transfected DNA is a chromosomally integrated recombinant DNA sequence, which comprises a gene encoding Has2, or which comprises a gene encoding Has3, which host cell may or may not express significant levels of autologous or "native" hyaluronan.

Has2 or Has 3 Polypeptides

The present invention provides an isolated, purified Has2, or an isolated, purified Has3, which can be prepared by recombinant DNA methodologies. The general methods for isolating and purifying a recombinantly expressed protein from a host cell are well known to those in the art. Examples of the isolation and purification of such proteins are given in Sambrook et al., cited *supra*. Moreover, since the present invention provides the complete amino acid sequence of murine Has2 (Figure 3), and murine Has3 (Figure 12B), they or bioactive variants thereof can also be synthesized by the solid phase peptide synthetic method. This established and widely used method, including the experimental procedures, is described in the following references: Stewart et al., Solid Phase Peptide Synthesis, W. H. Freeman Co., San Francisco (1969); Merrifield, J. Am. Chem. Soc., 85 2149 (1963); Meienhofer in "Hormonal Proteins and Peptides," ed.; C.H. Li, Vol. 2 (Academic Press, 1973), pp. 48-267;

and Bavaay and Merrifield, "The Peptides," eds. E. Gross and F. Meienhofer, Vol. 2 (Academic Press, 1980) pp. 3-285.

When Has2 or Has3 polypeptide is expressed in a recombinant cell, preferably a Has2- or Has3- cell, respectively, it is necessary to purify Has2 or Has3 polypeptide from recombinant cell proteins or polypeptides to obtain preparations that are substantially homogenous as to Has2 or Has3 polypeptide. For example, the culture medium or lysate can be centrifuged to remove particulate cell debris. The membrane and soluble protein fractions are then separated. The Has3 polypeptide may then be purified from the soluble protein fraction and, if necessary, from the membrane fraction of the culture lysate. Has3 polypeptide can then be purified from contaminant soluble or membrane proteins and polypeptides by fractionation on immunoaffinity or ion-exchange columns; ethanol precipitation; reverse phase HPLC; chromatography on silica or on an anion-exchange resin such as DEAE; chromatofocusing; SDS-PAGE; ammonium sulfate precipitation; gel filtration using, for example, Sephadex G-75; or ligand affinity chromatography.

Has2 polypeptide, Has3 polypeptide, variant Has2 polypeptides, variant Has3 polypeptides, or biologically active subunits thereof can also be prepared by *in vitro* transcription and translation reactions. For example, a Has3 expression cassette can be employed to generate Has3 transcripts which are subsequently translated *in vitro* so as to result in a preparation of substantially homogenous Has3, variant Has3, or biologically active subunits thereof. The construction of vectors for use *in vitro* transcription/translation reactions, as well as the methodologies for such reactions, are well known to the art.

Once isolated from the resulting transgenic host cells or from *in vitro* transcription/translation reactions, derivatives and chemically derived variants of the Has2 polypeptide or Has 3 polypeptide can be readily prepared. For example, amides of the Has3 polypeptides of the present invention may also be prepared by techniques well known in the art for converting a carboxylic acid group or precursor, to an amide. A preferred method for amide formation at the C-terminal carboxyl group is to cleave the polypeptide from a solid support with

an appropriate amine, or to cleave in the presence of an alcohol, yielding an ester, followed by aminolysis with the desired amine.

Salts of carboxyl groups of the Has2 polypeptide or Has3 polypeptide may be prepared in the usual manner by contacting the peptide with one or more equivalents of a desired base such as, for example, a metallic hydroxide base, e.g., sodium hydroxide; a metal carbonate or bicarbonate base such as, for example, sodium carbonate or sodium bicarbonate; or an amine base such as, for example, triethylamine, triethanolamine, and the like.

N-acyl derivatives of an amino group of the present polypeptides may be prepared by utilizing an N-acyl protected amino acid for the final condensation, or by acylating a protected or unprotected peptide. O-acyl derivatives may be prepared, for example, by acylation of a free hydroxy peptide or peptide resin. Either acylation may be carried out using standard acylating reagents such as acyl halides, anhydrides, acyl imidazoles, and the like. Both N- and O-acylation may be carried out together, if desired. In addition, the internal Has2 or Has3 amino acid sequence of Figure 3 or Figure 12B, respectively, can be modified by substituting one or two conservative amino acid substitutions for the positions specified, including substitutions which utilize the D rather than L form. The invention is also directed to variant or modified forms of the Has2 polypeptide or Has 3 polypeptide. One or more of the residues of the Has 2 polypeptide can be altered, so long as the variant polypeptide has at least about 50% of the biological activity of the protein having SEQ ID NO:2. One or more of the residues of the Has 3 polypeptide can be altered, so long as the variant polypeptide has at least about 50% of the biological activity of the protein having SEQ ID NO:32. Conservative amino acid substitutions are preferred--that is, for example, aspartic-glutamic as acidic amino acids; lysine/arginine/histidine as basic amino acids; leucine/isoleucine, methionine/valine, alanine/valine as hydrophobic amino acids; serine/glycine/alanine/threonine as hydrophilic amino acids.

Acid addition salts of the polypeptides may be prepared by contacting the polypeptide with one or more equivalents of the desired inorganic or organic

acid, such as, for example, hydrochloric acid. Esters of carboxyl groups of the polypeptides may also be prepared by any of the usual methods known in the art.

Has2 or Has 3 Variant Polypeptides

It is envisioned that variant Has2 polypeptides have at least one amino acid substitution relative to SEQ ID NO:2. It is also envisioned that variant Has3 polypeptides have at least one amino acid substitution relative to SEQ ID NO:32. In particular, amino acids are substituted in a relatively conservative manner. Such conservative substitutions are shown in Table 1 under the heading of exemplary substitutions. More preferred substitutions are under the heading of preferred substitutions. After the substitutions are introduced, the products are screened for biological activity.

TABLE 1

Original Residue	Exemplary Substitutions	Preferred Substitutions
Ala (A)	val; leu; ile	val
Arg (R)	lys; gln; asn	lys
Asn (N)	gln; his; lys; arg	gln
Asp (D)	glu	glu
Cys (C)	ser	ser
Gln (Q)	asn	asn
Glu (E)	asp	asp
Gly (G)	pro	pro
His (H)	asn; gln; lys; arg	arg
Ile (I)	leu; val; met; ala; phe norleucine	leu
Leu (L)	norleucine; ile; val; met; ala; phe	ile
Lys (K)	arg; gln; asn	arg
Met (M)	leu; phe; ile	leu
Phe (F)	leu; val; ile; ala	leu
Pro (P)	gly	gly
Ser (S)	thr	thr
Thr (T)	ser	ser
Trp (W)	tyr	tyr
Tyr (Y)	trp; phe; thr; ser	phe
Val (V)	ile; leu; met; phe; ala; norleucine	leu

Amino acid substitutions falling within the scope of the invention, are, in general, accomplished by selecting substitutions that do not differ significantly in their effect on maintaining (a) the structure of the polypeptide backbone in the area of the substitution, for example, as a sheet or helical conformation, (b) the charge or hydrophobicity of the molecule at the target site, or (c) the bulk of the side chain. Naturally occurring residues are divided into groups based on common side-chain properties:

(1) hydrophobic: norleucine, met, ala, val, leu, ile;

(2) neutral hydrophilic: cys, ser, thr;

(3) acidic: asp, glu;

(4) basic: asn, gln, his, lys, arg;

(5) residues that influence chain orientation: gly, pro; and

(6) aromatic; trp, tyr, phe.

The invention also envisions Has2 or Has3 variants with non-conservative substitutions. Non-conservative substitutions entail exchanging a member of one of the classes described above for another. Amino acid substitutions are introduced into the DNA molecules of the invention by methods well known to the art. For example, see the description hereinabove for the introduction of silent mutations into the DNA molecules of the invention.

Uses of Has2 or Has3 Genes and Polypeptides Thereof

The genes involved in HA biosynthesis and extracellular accumulation of HA ("HA coat formation") can be employed to synthesize HA *in vitro*. Because *in vitro* synthesized HA is of extremely high purity, is free from bacterial and animal cell contaminants, and can be optimized as to its physicochemical properties, it is preferred to HA derived by extraction from bacterial or animal sources.

In vitro prepared HA has a similar range of applications as those described above for HA which is derived from animal or bacterial cells, e.g., protecting eye tissue during artificial intraocular lens implantation, as a drug delivery vehicle, and preventing or inhibiting post-operative adhesions. *In vitro* synthesized HA may also be employed to enhance or promote wound healing or tissue repair, e.g., to prevent restenosis following balloon angioplasty, and to repair or replace damaged or absent cartilage present in congenital defects, craniofacial disorders and arthritis. In addition, HA can be derivatized, as described in Balazs et al. (Blood Coag. Fibrinolysis, 2, 173 (1991)), to provide improved mechanical properties and an extended residence time *in vivo*.

Moreover, the identification of genes involved in HA biosynthesis and/or coat formation may also be useful for defining the molecular basis for genetic diseases, such as cartilage pathologies, e.g, rheumatoid arthritis, and for providing a clinically useful diagnostic test or in molecular-based therapeutics.

Once such a gene has been identified, a probe specific for the gene can be made. Patient DNA can be screened with the probe to detect particular genetic variants that correlate with disease, e.g., craniofacial disorders. Patient RNA can be incubated with the probe to determine if the gene is over or under expressed in a patient with a particular disease relative to disease-free patients.

Furthermore, the cloning of genes involved in HA biosynthesis and/or extracellular coat formation will help to elucidate the molecular mechanism giving rise to the alteration of the protein encoded by the gene, or its expression, in patients having a particular disorder, e.g., cartilage deficiency. Once the molecular mechanism underlying the expression of the gene is understood, molecular genetic-based therapies directed to controlling the expression of the gene can then be employed to correct or supplement the expression of the gene in patients with the disorder.

For example, accelerated HA degradation accompanies osteoarthritis and inflammatory arthritides. Thus, the administration of Has2 and/or Has3 polypeptide, expression vectors encoding Has2 and/or Has3 polypeptide or agents that increase the expression or activity of native (i.e., endogenous) Has2 and/or Has3 may be efficacious for diseases which are characterized by decreased levels of HA. Hyperthyroidism (Graves Disease) is associated with excessive accumulation of HA in retro-orbital connective tissues, in the pretibial area and elsewhere. In addition, various ill-characterized skin disorders or mucinosis are also associated with accumulation of HA in the dermis. Thus, the administration of agents that inhibit the expression or activity of native Has2 and/or Has3 or expression vectors comprising has2 and/or has3 antisense sequences, may be useful to prevent or treat these disorders.

In addition, high serum levels of HA are associated rheumatoid arthritis, septic conditions accompanying certain malignancies, e.g., mesothelioma and Wilms' tumor, and edema due to inflammation in the lung and in kidneys post-kidney transplantation. HA has also been implicated in Grave's ophthalmopathy, cirrhosis of the liver and accelerated aging in Werner's syndrome. Thus, the isolation of eukaryotic HA biosynthetic genes can be useful in gene therapies

which employ the cloned genes in antisense expression vectors to inhibit or reduce the overexpression of HA genes in these patient populations. For example, an expression vector containing antisense Has3 can be introduced into joints (for rheumatoid arthritis), or into mesothelioma or Wilms' tumor cells, to inhibit or reduce the overexpression of Has3.

Identification of Agents that Alter Has2 and/or Has3 Expression or Activity

Agents that increase or decrease native Has2 or Has3 activity or expression may be identified using *in vitro* assays. For example, cells with low basal Has2 or Has3 activity, such as Chinese Hamster Ovary (CHO) cells, are stably transfected with recombinant plasmids that express Has2 and/or Has3. The resulting cell lines are then contacted with an agent and the amount of HA synthesized or secreted, and the amount of HA coat formation, in the presence of the agent relative to cells not exposed to the agent, is determined, using methods described herein. To assess coat formation, a bead binding assay may be employed. In this assay, polypeptide fragments with HA binding activity (so-called HA binding domain or HABR) are covalently attached to micro-beads tagged by fluorescent or other means (e.g., biotinylation). Agents that enhance HA coat formation may be useful to decrease the adhesive properties of tissue, e.g., mesothelial, surfaces.

Screening for agents that regulate Has2 and/or Has3 activity may also be accomplished using an assay described in Spicer et al., (J. Biol. Chem., 272, 8957 (1997)). Radiolabeled UDP-sugar substrates (either UDP-N-acetyl-D-glucosamine or UDP-D-glucuronate) in the presence of the other required substrates are incubated with membrane extracts (10 - 25 mg protein) in the presence or absence of the agent for 2 hours at 37°C. The radiolabeled precursor molecules are then separated from the high molecular weight HA product by paper chromatography and agarose gel electrophoresis. Paper chromatography allows accurate quantification of enzyme activity, while agarose gel electrophoresis allows rapid assessment of molecular mass. Filter assays using precipitation with cetylpyridinium chloride or HPLC isolation of reductive

products of HA degradation by *Streptomyces hyaluronidase* may also be employed. Direct interaction of an agent with Has2 and/or Has3 may be determined by binding assays utilizing purified, recombinant Has2 and/or Has3 polypeptide present in liposomes or detergent micelles and labeled agent.

Agents that interact with highly conserved sequences present in enzymes involved in synthesis of β 1→4 linkages may be useful to inhibit native Has2 and/or Has3. *S. cerevisiae* chitin synthase 2 (Chs2) has two highly conserved domains present in all chitin synthases that are critical to enzymatic activity and speculated to be generally conserved in glycosyltransferases that catalyze the synthesis of oligosaccharides with β 1→4 linkages (Nagahasi et al., J. Biol Chem., 270, 13961 (1995)). Sequence alignments of Has1, mHas2, DG42, HasA, NodC, and Chs2 revealed that several amino acid residues required for catalytic activity of Chs2 are conserved in mHas2 and mHas3. In particular, the second region of homology in Chs2 contains the highly conserved motif NMYLA-EDRIL residues (556-565; SEQ ID NO:56). Mutations at residue 562 in Chs2 resulted in complete loss of enzymatic activity. The similarity of mHas2 in this region (NQCSFGDDRH; SEQ ID NO:57) suggests that mutation of the highly conserved D at position 314 may result in loss of enzymatic activity. Expression of a mutant mHas2, having an amino acid substitution (D→A) at this position, in COS-1 cells did not result in coat formation. Similarly, agents that are ligand mimetics, e.g., 5-azido-UDP-glucuronic acid, may be tested for their ability to alter Has2 and/or Has3 activity. Thus, agents that interact with domains which comprise residues required for catalytic activity may be useful *in vivo* inhibitors of Has2 and/or Has3 activity.

Methods to Administer has2 or has3 Genes or Polypeptides to Tissue Surfaces

Delivery of has2 and/or has3 genes (e.g., in viral vectors or liposomes) or purified Has2 and Has3 polypeptide (e.g., in liposomes) to tissue, e.g., mesothelial, surfaces provides an alternative approach to exogenous instillation of HA containing solutions or HA containing films to coat opposing surfaces with HA, to decrease adhesivity. To determine whether has genes or purified

Has polypeptide are useful to alter mesothelial HA synthesis or accumulation, cultured mesothelial cells are transfected with has2 and/or has3 expression vectors and/or contacted with purified Has2 and/or Has3 polypeptide. Sections of serosa stripped off of the underlying mesothelial tissue may also be employed. These sections are maintained in suspended well culture (e.g., Becton-Dickson Transwells) which allows access of nutrients to epithelial sheets. Radiolabeled precursors (e.g., ^{3}H or ^{14}C labeled N-acetyl-D-glucosamine) can be added to the culture medium of cultured cells or serosa, and secretion of HA analyzed by removing the culture medium, and determining the incorporation of radiolabeled precursor into a high molecular weight form (e.g., > 1 x 10^{6} Daltons) which is sensitive to degradation by *Streptomyces hyaluronylticus*. HA coat formation can also be determined by fixation of the cells in the presence of cetyltrimethylammonium bromine (CTAB), followed by immunohistochemical staining with purified HA binding domain conjugated to biotin.

These *in vitro* tests can be extended to *in vivo* models in small animals (e.g., rats, mice), in which viral vectors containing cDNAs encoding Has2 and/or Has3, or purified, recombinant Has2 and/or Has3 polypeptide are introduced into the peritoneal cavity. To assess optimal dosing, two approaches are envisioned. First, to optimize the production of HA by the peritoneal surface, extensive peritoneal lavage to remove free HA is performed. The HA can be quantified, using methods outlined herein. Then, fixation *in situ* using CTAB containing fixative, followed by staining for HA with biotinylated HA binding domain is employed to show cell surface HA. Optimal dosages of viral vectors and/or recombinant polypeptide depend upon the specific application (e.g., operative site, specific surgery) and desired outcome (persistence of HA secretion and anti-adhesive properties). The presence or amount of HA on mucosal or serosal surfaces *in vivo* can be determined using labeled proteins containing HA binding domains (Ripellino et al., J. Histochem. & Cytochem., 33, 1060 (1985); Fenderson et al., Different., 54, 85 (1993)). Likewise, small molecules, identified on the basis of their ability to stimulate or inhibit HA secretion *in vitro* can be tested in similar models.

The invention will be further described by the following examples.

Example 1

cDNA Cloning and Characterization of Mouse Hyaluronan Synthase-2

The aligned amino acid sequences of HasA, DG42 and NodC were utilized to prepare primers for a degenerate PCR strategy to identify a HasA/DG42 related cDNA in the mouse. Three degenerate primer pools for RT-PCR were prepared, two of which were predicted to anneal to the antisense strand, and one of which was predicted to anneal to the sense strand of a putative eukaryotic DNA molecule which encodes HA synthase. The oligonucleotides were made corresponding to the peptide sequences AFNVERACQ (SEQ ID NO:14), GDDRHLTN (SEQ ID NO:15), and QQTRWTKSYF (SEQ ID NO:16), and had the following degenerate nucleotide sequences: DEG 1 primer, 5'-GCN TTY AAY GTN GAR MGN GCN TGY CA 3' (SEQ ID NO:17, sense strand), DEG 3 primer, 5'-RTT NGT NAR RTG NCK RTC RTC NCC-3' (SEQ ID NO:18, antisense strand), and DEG 5 primer, 5'-RAA RTA NSW YTT NGT CCA NCK NGT YTG YTG-3' (SEQ ID NO:19, antisense strand).

A degenerate primer pool made to the peptide sequence QQTRWTKSYF (SEQ ID NO:16, DEG 5) was utilized for the first-strand synthesis. RNA was isolated using TRIZOL™ reagent (GIBCO-BRL/Life Technologies, Gaithersburg, MD) according to the manufacturer's directions. Reverse transcription reactions were performed on total RNA isolated from 10.5 and 14.5 days post coitum (dpc) C57BL/6J mouse embryos. Briefly, 5 µg of total RNA were heat-denatured at 95°C then split into two separate reactions. One reaction served as a control and amplified a fragment of 28S ribosomal RNA. The second reaction received one of two degenerate primer pools at a final concentration of 2 µM. Reverse-transcription was carried out at 42°C using 10 units M-MuLV reverse transcriptase (Boehringer Mannheim, Indianapolis, IN) in a total volume of 25 µl.

Five microliters of each resultant first-strand cDNA were amplified in separate 100 µl PCR reactions using combinations of degenerate primer pools

1 and 3 (DEG 1/3) or 1 and 5 (DEG 1/5). Amplification conditions were as follows: 35 cycles of 94°C for 1 minute, 50°C for 1 minute, 72°C for 1 minute, followed by a final extension of 72°C for 10 minutes. Primer pools were used at a final concentration of 1 μM. Twenty microliters of each PCR reaction was separated through a 2.0% agarose gel (Figure 1). All consistently amplified products (see arrows in Figure 1) were gel-purified and cloned directly into a pBluescript KSII+ (Stratagene Cloning Systems, La Jolla, CA) T-vector prepared as described by Marchuk et al. (Nucleic Acids Res., 19, 1154 (1991)). The resultant plasmids were subjected to restriction endonuclease and dideoxy sequencing of double-stranded plasmid DNAs using a Sequenase Version 2.0 sequencing kit (United States Biochemical Corp, Cleveland, OH).

The 300 bp DEG 1/5 product (MHas300) and the 180 bp DEG 1/3 product were related by a common internal site for the restriction endonuclease EcoRI, as shown below the gel image in Figure 1. Sequence analysis of the other consistently amplified PCR products indicated that they were unrelated to mouse HAS (Itano et al., J. Biol. Chem., 271, 9875 (1996)) *hasA*, DG42, *nodC*, and the 180 bp and 300 bp PCR products.

The 300 bp cDNA fragment, MHas300 was utilized as a probe to screen a primary λgt10 cDNA library constructed from 8.5 dpc C57BL/6J polyA+ RNA (kindly provided by Dr. J. J. Lee, Mayo Clinic Scottsdale). The probe was labeled to high specific activity using random-priming in the presence of [α^{32}P]dCTP (Feinberg et al., Anal. Biochem., 132, 6 (1984)). Approximately 1.5 x 10^6 plaque-forming units (pfus) were screened using standard procedures (Sambrook et al., Molecular Cloning: A Laboratory Manual, Cold Spring Harbor (1989)). Double positive plaques were identified and taken through two additional rounds of plaque-purification. In addition, a portion of each primary plaque was screened by PCR, employing a combination of primers that flanked the λgt10 cloning site and MHas2 specific primers, to determine insert size relative to the MHas300 cDNA fragment. Fourteen positive clones were obtained and analyzed. The mouse λ cDNA library yielded multiple overlapping clones, which collectively spanned approximately 3 kb (Figure 2). EcoRI restriction

fragments were then subcloned into pBluescript KSII+ for sequence analysis. The nucleotide sequence of both strands was determined using synthetic oligonucleotide primers made to the mouse Has2 sequence and to the vector.

Sequence analyses identified an open reading frame (ORF) of 1656 bps, flanked by 5' and 3' untranslated regions (UTRs) of 507 and 772 bps, respectively (Figure 3, SEQ ID NO:1). The open reading frame predicted a 63 kDa protein with several transmembrane sequences, multiple consensus phosphorylation sites, and four putative hyaluronan binding motifs. The predicted translation initiation site conformed to the Kozak consensus for initiation (Kozak, Nucleic Acids Res., 12, 857 (1984)). Although there were four additional upstream ATGs within the 5' UTR, none of these fitted the Kozak consensus and all were followed closely by in-frame stop codons. The presence of several upstream ATGs has, however, been more commonly described in oncogenic sequences (Kozak, Nucleic Acids Res., 15, 8125 (1987)). The 3' UTR contained two consensus sequences for polyadenylation, a CA repeat and a TA repeat (Figure 3).

Database searches indicated that the predicted amino acid sequence of mouse Has2 (SEQ ID NO:2) aligned most significantly with *Xenopus* DG42 (SEQ ID NO:10; 56% identity, 70% similarity; Rosa et al., Dev. Biol., 129, 114 (1987)), Streptococcal HasA (SEQ ID NO:11; 21% identity, 28% similarity; DeAngelis et al., J. Biol. Chem., 268, 19181 (1993)), *Rhizobium sp.* NodC (SEQ ID NO:12; Jacobs et al., J. Bacteriol., 162, 469 (1985); Collins-Emerson et al., Nucleic Acids Res., 18, 6690 (1990)), and *Saccharomyces cerevisiae* chitin synthase 2 (Chs2) (SEQ ID NO:13; Bulawa, Mol. Cell. Biol., 12, 1764 (1992)) (Figure 5). In addition, mouse Has2 displayed 55% identity and 73% similarity to the recently reported mouse Has1 gene (SEQ ID NO:11, Itano et al., J. Biol. Chem., 271, 9875 (1996)), and the human homologue of this gene (Yang et al., EMBO J., 13, 286 (1994)). Surprisingly, the deduced amino acid sequence of the cDNA of Itano et al. is distinct from the Has2 cDNA described hereinbelow, although the sequences are clearly related.

Recently isolated clones for a second human Has gene, which shares greater than 90% amino acid identity to mouse Has2 and thus is predicted to represent the human Has2 gene have also been obtained (SEQ ID NO:23). This suggests that there are at least two related Has genes in both mouse and humans.

Investigation of the primary amino acid sequence of mouse Has2 identified several potential transmembrane sequences (Figure 4), four potential HA binding motifs fitting the $B(X_7)B$ consensus (Yang et al., EMBO J, 13, 286 (1994)), and numerous consensus sequences for phosphorylation by protein kinase C (PKC) and cyclic-AMP dependent kinases, such as protein kinase A (PKA) (Person et al., In: Protein Phosphorylation: A Practical Approach (Hardie, D. G., ed), IRL Press at Oxford University Press, Oxford (1993)). Has2 is predicted to be a multiple membrane-spanning protein with a large cytoplasmic loop, similar to the predicted structure of *Streptococcus* HasA and mouse HAS (Has1) (Figure 6B). Sequence alignment of Has2 with *Saccharomyces cerevisiae* Chitin synthase2 (Chs2; SEQ ID NO:13) (Figure 5) demonstrated that the residues recently shown to be required for catalytic activity in Chs2 (Nagahashi et al., J. Biol. Chem., 270, 13961 (1995)) are conserved within the large predicted cytoplasmic loop of mouse Has2 (Figure 6B). It has been suggested that these catalytic residues may be generally conserved within glycosyltransferases that catalyze the synthesis of oligosaccharides with β 1→4 linkages (Nagahashi et al., *supra*). Significantly, the predicted cytoplasmic loop of the Has2 molecule is the most highly conserved across species, and thus this part of the protein may form the catalytic domain.

Example 2

Molecular Biochemical Characterization of Mouse Has2

Northern and Southern Analysis. Mouse multiple tissue Northern (MTN) Blots (CLONTECH, Palo Alto, CA) were hybridized to a [α^{32}P]dCTP-labeled cDNA probe corresponding to the 1.65 kb open-reading-frame (ORF) of the mouse Has2 gene. Blots were hybridized at 42°C and washed to high stringency according to the manufacturer's recommendations. The mouse embryo blot was exposed overnight at -70°C to BioMax MR film (Eastman Kodak Company,

New Haven, CT) with two intensifying screens, whereas the adult tissue blot was exposed for six days at -70°C with two screens. To control for variation in loading, both blots were stripped, and rehybridized with a mouse glyceraldehyde-3-phosphate dehydrogenase (GAPDH) probe. Both GAPDH hybridized blots were exposed for one hour at -70°C with two screens.

Northern analyses detected two transcripts of approximately 3.2 kb and 4.8 kb, respectively, in embryonic samples (Figure 7). Only the 4.8 kb message was observed in RNA from adult tissues. The 4.8 kb transcript was expressed at levels approximately 20 fold higher than the 3.2 kb transcript. High levels of expression were observed in the developing mouse embryo, in addition to lower levels in adult mouse heart, brain, spleen, lung and skeletal muscle (Figure 6). All of the isolated cDNA clones were predicted to form an identical ORF. Thus, rather than being the result of alternate splicing, the 4.8 kb transcript most probably corresponds to a mouse Has2 mRNA with an alternate polyA signal, generating a 3' UTR with approximately 1.8 kb of sequence, in addition to that reported herein.

Moreover, the observed expression pattern of mouse Has2, i.e., Has2 expression was detected in the primitive streak stage embryo (7.5 dpc) and an increase in Has2 expression in the later embryo, correlates well with the previously described expression pattern of HA. HA has previously been observed at significant levels starting as early as the egg cylinder stage (5.5 dpc), when it is secreted into the expanding yolk cavity. Thus, HA may play a role in the formation and expansion of embryonic cavities. From 9.5 dpc, synthesis increases, and the HA assumes more of a pericellular distribution, rather than being primarily associated with fluid-filled spaces. HA is present at high levels within the developing vertebral column, the neural crest-derived mesenchyme of the craniofacial region, and the heart and smooth muscle throughout the mid-gestation embryo.

In the adult, Has2 expression was detected in heart, brain, spleen, lung and skeletal muscle, but not in liver or kidney (Figure 7). The level of

expression of Has2 was markedly reduced in adult tissues as compared to the embryo.

Mouse 129Sv/J genomic DNA was prepared from tail snips using standard procedures. Approximately 15 µg samples of genomic DNA were digested overnight with restriction endonucleases, size-separated through 0.8% agarose gels, and transferred to Hybond N+ nylon membranes (Amersham, Arlington Heights, IL). Membranes were hybridized to a [$\propto^{32}$P]dCTP-labeled cDNA probe corresponding to the 1.65 kb ORF of mouse Has2. Hybridization conditions were performed as recommended by the manufacturer. Membranes were washed to low (1 X SSC + 0.1% SDS at 37°C) and high (0.1 X SSC + 0.1% SDS at 55°C) stringency (1 X SSC (saline sodium citrate) is 150 mM NaCl, 15 mM Na citrate) and autoradiography was performed as described above.

The pattern of hybridizing restriction fragments that was observed through Southern analyses was consistent with mouse Has2 being a single copy gene within the mouse genome (Figure 8). In addition, the pattern observed in digests of total mouse genomic DNA was identical to that observed in equivalent digests of recently isolated mouse Has2 genomic clones. Low stringency wash conditions failed to identify any further hybridizing fragments including those fragments corresponding to the related mouse Has1 (Itano et al., *supra*) gene. This suggests that the level of sequence identity (55%) between mouse Has2 and mouse Has1, and possibly other Has-related genes, is not sufficient to permit detection through Southern hybridization even at low stringency. Thus, while these results preclude the existence of a mouse Has2 pseudogene, they do not preclude the existence of other genes related to mouse Has2 and mouse Has1.

Transfection Studies. To investigate the potential role of mouse Has2 in HA biosynthesis, expression constructs were created in the mammalian expression vector, pCIneo (Promega Corporation, Madison, WI). Mouse Has2 ORFs were amplified by PCR, from a template of mouse Has cDNA clone λ11.1 (Figure 2). PCR primers were designed to create a mouse Has2 cDNA with an optimized Kozak consensus A--ATGG, and to contain SmaI/XmaI sites at each

end suitable for cloning. Primers were as follows: 5'-CCCGGGCAAG ATG GAT TGT GAG AGG TTT CTA TGT GTC CTG -3' (SEQ ID NO:21, bps 504 to 537, Figure 3) and 5'-CCCGGG TCA TAC ATC AAG CAC CAT GTC ATA CTG -3' (SEQ ID NO:22, bps 2163 to 2137, Figure 3). Gel-purified PCR products were cloned directly into a pBluescript KSII+ T-vector for sequence verification, prior to subcloning into the XmaI site of pCIneo.

The mouse Has2 expression vector was co-transfected with a cytomegalovirus promoter (CMV) driven β-gal expression vector into COS-1 (SV40-transformed African green monkey kidney) cells (Gluzman, Cell, 23, 175 (1981)) using Lipofectamine™ (GIBCO-BRL/Life Technologies, Gaithersburg, MD), according to the manufacturer's instructions. The β-gal expression plasmid was used in all transfections to permit the visual identification of cells that had been successfully transfected. Control co-transfections were pCIneo (vector control) and LacZ vector. Cells were analyzed 36 hours after lipofection (transient transfection). The COS-1 cell line and the mouse 3T6 (Swiss embryonic fibroblast) cell line were routinely maintained at 37°C in Dulbecco's modified Eagle's medium (DMEM) supplemented with 10% fetal bovine serum (FBS) and 2 mM L-glutamine, in a humidified chamber at 5% CO_2.

HA Coat Assays. Glutaraldehyde fixed horse erythrocytes (Sigma Chemical Company, St. Louis, MO) were reconstituted in phosphate-buffered saline (PBS), washed several times to remove traces of sodium azide, and finally resuspended in PBS plus 1 mg/ml BSA to a density of 5×10^8 cells/ml. HA coats were visualized around live cells growing in individual wells of a 24-well plate or 6-well plate by adding 1×10^7 or 5×10^7 red blood cells, respectively, to the growth medium. Red cells were allowed to settle for 15 minutes before HA coats were scored. To confirm the coats as being composed of HA, red cells were removed by extensive washing with PBS, and one well of each experimental sample was treated with 10 units/ml bovine testicular hyaluronidase (CALBIOCHEM, San Diego, CA) or 5 units/ml *Streptomyces* hyaluronidase (CALBIOCHEM, San Diego, CA) in DMEM plus 0.5% FBS for 1 hour at 37°C. Equivalent wells were incubated under the same conditions in

the absence of hyaluronidase. After incubation, red cells were added to the wells, as previously described, and coats were again scored. HA coats were imaged at 200x magnification. After imaging, red cells were removed by extensive washing with PBS. Cells were stained to detect β-galactosidase (LacZ) activity and imaged as described by Sanes et al. EMBO J., 5, 3133 (1986).

Parental, untransfected COS-1 cells had no detectable coat-forming ability in HA pericellular coat-forming assays (Figure 9B). In contrast, untransfected 3T6 mouse embryonic fibroblast cells had well-developed HA coats (Figure 9A). Transient co-transfection of mouse Has2 and LacZ expression constructs into COS-1 cells resulted in the production of large HA coats (Figure 9D-I). Cells acquiring an HA coat also stained positively for β-gal activity (Figure 9D-I), confirming that cells that had generated HA coats had successfully taken up DNA. HA coats were destroyed by treatment with *Streptomyces* hyaluronidase (Figure 9H) or bovine testicular hyaluronidase. Control pCIneo transfected cells produced no coats (Figure 9C), and were indistinguishable from parental untransfected COS-1 cells. Equivalent numbers of LacZ positive cells were observed in experimental and control transfections.

These results indicate that parental COS-1 cells express all other factors required for HA biosynthesis and pericellular coat formation, but most likely lack HA synthase activity. Thus, expression of Has2 in COS-1 cells is sufficient for HA coat formation.

Discussion

Residues demonstrated to be critical in terms of the β1→4 glycosyltransferase activity of yeast Chs2 were conserved in mouse Has2, mouse Has1, Streptococcal HasA, *Xenopus* DG42 and *Rhizobium* NodC. Thus, it is likely that mouse Has proteins have β 1→4 glycosyltransferase activity. Furthermore, although overall sequence identity between mouse Has2 and *Streptococcus pyogenes* HasA was only 21%, a 180 amino acid region within the predicted intracellular loop (residues 182 to 361) was highly conserved. This region exhibited 54% similarity between mouse Has2 and bacterial HasA, and

greater than 80% similarity between mouse Has2, mouse Has1, and *Xenopus* DG42. This level of sequence conservation suggests that these proteins are functionally related.

Sequence analyses predicted that mouse Has2 and Has3 encode a membrane protein with multiple transmembrane domains, similar in structure to the bacterial HasA protein and mouse Has1. Significantly, four consensus binding sites for HA were identified in Has2, three of which were predicted to be intracellular. These sites may thus represent areas of potential binding of HA chains during elongation, and/or may represent sites at which the newly synthesized HA polymer remains attached prior to release from the cell. In addition to putative HA binding sites, numerous consensus sequences for phosphorylation by PKC and cAMP-dependent kinases were identified within the predicted intracellular loop of the molecule. This is significant, as mammalian HA biosynthesis has been shown to be dependent on activation by PKC, and suggests that the PKC dependence may partly involve direct activation of Has2 through phosphorylation.

HA-dependent pericellular coats have been proposed to form through two alternate mechanisms. The first mechanism is HA receptor-dependent and HA synthesis independent. This type of coat can form through association of HA with cell surface HA receptors, and stabilization of the coat by association of HA binding proteoglycans, such as aggrecan and link protein (Lee et al., J. Cell Biol., 123, 1899 (1993); Knudson et al., Proc. Natl. Acad. Sci. USA, 90, 4003 (1993)). Presumably, this permits cells expressing HA receptors to enter an environment rich in HA, and to organize an HA matrix around themselves that is independent of the ability to synthesize HA.

The second mechanism is HA receptor independent, and requires the synthesis and extrusion of HA through the plasma membrane. It has been proposed that the extruded HA associates with the membrane through continued attachment to the synthase, and that this coat is stabilized by HA-HA and HA-protein bridges (Heldin et al., Exp. Cell Res., 208, 422 (1993)).

Expression of mouse Has2 by COS-1 cells resulted in the formation of large well-pronounced HA coats, as determined by a particle exclusion assay (Figure 9). Previous studies in COS cells have shown that transfection of the HA receptor, CD44, and the addition of exogenous HA (15 μg/ml) and proteoglycans to the medium was required for HA-dependent pericellular matrix formation (Knudson et al., Proc. Natl. Acad. Sci. USA, 90, 4003 (1993)). In contrast, the studies described hereinabove demonstrate that expression of mouse Has2 in COS cells, in the absence of HA receptor expression, exogenously added HA, or proteoglycans, was sufficient for HA coat formation. This suggests that Has2 expression leads to the synthesis of HA, which is extruded through the plasma membrane and may associate with the cell surface to form an HA coat through continued attachment to the synthase. In this respect, the consensus HA binding motifs predicted within mouse Has2 may play an important role.

HA biosynthesis requires two enzyme activities; the transfer of UDP-N-acetylglucosamine (UDP-GlcNAc) and UDP-glucuronic acid (UDP-GlcUA), respectively, to the growing HA chain (Philipson et al., Biochemistry 24, 7899 (1985)). In *S. pyogenes*, a single enzyme, HasA, carries out both activities. In contrast, recombinant *Xenopus* DG42 protein can synthesize short chitin oligomers from UDP-GlcNAc *in vitro*, but cannot synthesize a hyaluronan chain in the presence of UDP-GlcNAc and UDP-GlcUA (Semino et al., Proc. Natl. Acad. Sci. USA, 92, 3498 (1995)). This suggests that eukaryotic HA synthesis requires DG42-like activity and a second enzyme activity provided by a separate protein.

Example 3

cDNA Cloning and Characterization of Human Hyaluronan Synthase-2 and Mouse and Human Hyaluronan Synthase-3

Using degenerate PCR primer pair DEG 1 and DEG 5, described in Example 1, PCR products of approximately 300 bp were amplified from human and mouse total genomic DNA. The templates for PCR were 100 ng of human T47D mammary carcinoma cell line genomic DNA, and 100 ng of mouse 129 Sv/J genomic DNA. Cycling parameters were as follows: 35 cycles of 94°C for 10 seconds, 50°C for 30 seconds, and 72°C for 1 minute, followed by a final

extension step at 72°C for 10 minutes. Amplified fragments of the expected size were identified through agarose gel electrophoresis, gel-purified, and cloned directly as described in Example 1.

Two additional degenerate oligonucleotide primer pools (DEG 10 and DEG 11) were designed, based upon the conserved amino acid sequences GWGTSGRK (SEQ ID NO:20) and RWLNQQTRW (SEQ ID NO:33) (see Figure 14). Similar PCR conditions were used to amplify fragments of the expected size from human and mouse genomic DNA using these degenerate primers. Amplified PCR products were gel-purified and ligated directly into a cloning vector for sequence analyses.

Sequences obtained from the clones fell into two groups in both the mouse and human. One group of human clones, represented by SEQ ID NO:23, shared 88% sequence identity with the equivalent region of mouse Has2 (SEQ ID NO:1) (Figure 10C), and was 100% identical at the amino acid level to SEQ ID NO:2 (Figure 10D). Thus, SEQ ID NO:23 represents a partial nucleotide sequence of human Has2. A human fetal lung expressed sequence tag (EST) (Genbank Accession No. W21505) shares approximately 90% nucleotide sequence identity with SEQ ID NO:1, and close to 100% amino acid identity to the predicted carboxy-terminal end of SEQ ID NO:2.

The second group of clones obtained through degenerate PCR, although clearly related to Has2 and Has1, were unique. The genes present in these clones has been designated Has3 (Figure 11). The mouse and human Has3 genes share 93% nucleotide identity (SEQ ID Nos. 26 and 25, respectively) and 99% amino acid identity (SEQ ID Nos. 28 and 27, respectively).

Based upon the sequence of these partial fragments, a single pair of oligonucleotide primers, forward 5′-TAC TGG ATG GCT TTC AAC GTG GAG-3′ (corresponding to nucleotides 790 to 813, SEQ ID NO:34, Figure 12B), and reverse 5′-GTC ATC CAG AGG TGG TGC TTA TGG-3′ (corresponding to antisense complement of nucleotides 1142 to 1119, SEQ ID NO:37, Figure 12B) were employed to facilitate PCR screening of a mouse 129Sv P1 genomic library (Genome Systems, St. Louis, MO). Three positive P1 clones were obtained.

The restriction fragments spanning the entire mouse Has3 gene were identified, the inserts comprising the fragments subcloned into pBluescript (Stratagene, La Jolla, CA) based vectors and the inserts sequenced.

To confirm the sequence obtained from the analysis of genomic clones, the Has 3 cDNA was obtained. The cDNA was cloned by reverse-transcriptase polymerase chain reaction (RT-PCR) amplification. The template for the reaction was total RNA from late gestation (17.5 days post-coitum) mouse C57BL/6J embryos. First-strand cDNA synthesis was performed as described in Example 1 using the mouse Has3 reverse oligonucleotide primer.

First-strand cDNAs were PCR amplified using standard PCR buffer conditions supplemented with 2% deionized formamide, through 35 cycles of 94°C for 10 seconds, 65°C for 30 seconds, and 72°C for 2 minutes, followed by a final extension step of 72°C for 10 minutes. Oligonucleotide primers possessed EcoRI restriction endonuclease sites (underlined) at their 5′ termini to facilitate subsequent cloning steps. These oligonucleotides included: forward, 5′-CCGAATTCAAG ATG GCG GTG CAG CTG ACT ACA GCC-3′(corresponding to nucleotides 1 to 24, SEQ ID NO:38, Figure 12B), and reverse, 5′ CCGAATTC TCA CAC CTC CGC AAA AGC CAG GC-3′(corresponding to the antisense complement of nucleotides 1665 to 1643, SEQ ID NO:39, Figure 12B). Amplified cDNAs of the expected size were gel-purified and cloned. All sequence analyses were performed using the Genetics Computer Group (GCG) package, and MacVector programs.

The open reading frame (ORF) encoding mouse Has3 is 1662 bp (SEQ ID NO:31) (Figure 12B). This ORF encodes a polypeptide of 554 amino acids (SEQ ID NO:32) with a predicted molecular mass of 63.3 kDa. This polypeptide is only 2 amino acids longer than the mouse Has2 polypeptide. Sequence alignments indicated that mouse Has3 is 71%, 57%, 56%, and 28% identical to mouse Has2, mouse Has1 (HAS protein), *Xenopus* DG42, and *Streptococcus pyogenes* HasA, respectively (Figure 13A). Like Has1 and Has2, residues demonstrated to be critical for N-acetylglucosaminyltransferase activity of yeast chitin synthase 2 are completely conserved. In addition, these residues are

conserved with members of a recently identified putative plant cellulose synthase family (Pear et al., Proc. Natl. Acad. Sci. USA, 93, 12637 (1996)) (Figure 13B).

Alignment of the partial sequence of human has3 (HAS3 hereinafter) and mouse Has3 (Has3 hereinafter) indicated a very high level of sequence conservation (99%) (Figure 12A). This is similar to the high level of conservation observed for human and mouse HAS1 (96%) and HAS2 (99%).

Hydrophilicity plots suggested that Has3 is very similar in structure to Has2 and Has1, and predicted the presence of multiple transmembrane domains, with two at the N-terminus and a cluster at the C-terminus (Figure 14C). Significantly, like Has2 and Has1, the Has3 sequence predicts the presence of several potential HA binding motifs defined by the consensus B $(X_7)B$ (underlined in Figure 12B). Furthermore, these motifs are located at similar positions within the Has3 polypeptide.

Example 4

Molecular Biochemical Characterization of Mouse Has3

Northern Analysis. To determine the temporal expression pattern of mouse Has3 in the developing mouse embryo, Northern blot analysis was employed. The mouse Has3 ORF cDNA was labeled with [α^{32}P]dCTP by random priming (Feinberg and Vogelstein, Anal. Biochem., 132, 6 (1984)) and hybridized to a Northern blot of mouse embryo messenger RNA (CLONTECH, Palo Alto, CA) under conditions recommended by the manufacturer. The results showed that, in contrast to mouse Has2 which is highly expressed from as early as day 7.5 post-coitum through late gestation in the developing mouse embryo, mouse Has3 is expressed predominantly in the late gestation embryo (Figure 13). One major transcript of approximately 6.0-6.5 kb and a minor transcript of approximately 4.0 kb were observed (Figure 13).

Transfection Studies. The mouse Has3 ORF was cloned into the EcoRI site of the expression vector pCIneo (Promega, Madison, WI). To test the enzyme activity of mouse Has3, the mouse Has3 expression vector was co-transfected with a pCMV β-gal vector into COS-1 (SV40-transformed African green monkey kidney) cells using LipofectAMINE™ (Life Technologies Inc.,

Gaithersburg, MD), according to the manufacturer's instructions. Positive control transfections utilized the mouse Has2 expression vector described above. HA coat assays and detection of β-galactosidase activity were performed as described in Example 2.

pCIneo (vector only control) transfected cells failed to produce coats (Figure 15B). Mouse Has3 transfected cells produced pericellular coats that were destroyed by treatment with a specific hyaluronidase from *Streptomyces* (5 TRU/ml for 1 hour at 37°C) (compare panels E, before hyaluronidase treatment, and F, after hyaluronidase treatment, in Figure 15). In contrast, pericellular coats remained on mock hyaluronidase treated cells (compare panels C, before, and D, after mock hyaluronidase treatment in Figure 15). Thus, the data showed that expression of mouse Has3 in COS-1 cells resulted in the generation of well-pronounced HA-dependent pericellular coats, as previously observed for Has 2.

To confirm the HA biosynthetic capability of Has3 transfected cells, HA synthase assays were performed on crude membranes prepared from these cells. Crude cell membrane preparations were isolated as described by Becq et al. (Proc. Natl. Acad. Sci. USA, 91, 9160 (1994)), except the final membrane pellets were resuspended in 50 µl of lysis buffer (LB) consisting of 10 mM KCl, 1.5 mM $MgCl_2$, and 10 mM Tris-HCl pH 7.4 plus protease inhibitors (aprotinin, leupeptin and phenylmethylsulfonyl fluoride) (LB+). Protein content of crude membrane preparations was determined by a BCA assay (Pierce, Rockford, IL). To detect HA synthase activity, duplicate samples of approximately 100 µg crude membrane protein were incubated overnight at 37°C in a total reaction volume of 200 µl under the following conditions: 5 mM dithiothreitol, 15 mM $MgCl_2$, 25 mM HEPES pH 7.1, 1 mM UDP-GlcNAc, 0.05 mM UDP-GlcUA, 0.4 µg aprotinin, 0.4 µg leupeptin, 0.5 µCi UDP-[^{14}C]GlcUA (ICN, Costa Mesa, CA). An additional specificity control reaction was set up in which UDP-GlcNAc was omitted. After overnight incubation, samples were boiled for 10 minutes, and subsequently divided in two equal portions. *Streptomyces* hyaluronidase (1 turbidity reducing unit (TRU)) was added to one half and

incubated for an additional hour at 37°C. SDS was added to a final concentration of 1%, samples were boiled and analyzed by descending paper chromatography essentially as described in DeAngelis and Weegel, Biochemistry, 33, 9033 (1994).

These assays indicated that crude membranes prepared from either Has3 or Has2 transfected COS-1 cells were capable of converting UDP-[^{14}C]GlcUA into significant amounts of a high molecular weight product only in the presence of UDP-GlcNAc (Table 2). Furthermore, this product could be specifically degraded by *Streptomyces* hyaluronidase (Table 2). Thus, in COS-1 cells, Has2 and Has3 appear to possess similar enzymatic activities.

TABLE 2

Hyaluronan Synthase Activity of Transfected COS-1 Cells

Vector	+ UDP-GlcNAc[a]	- UDP-GlcNAc	Hyaluronidase[b]
Mouse Has3	204.2[c]	1.9[d]	-
pCIneo	65.0	2.2	+
Mouse Has2	26.9	2.5	-
pCIneo	10.5	2.0	+
pCIneo (control)	11.0	ND[e]	-
	10.3	ND	+

[a] Plus and minus symbols indicate whether or not UDP-GlcNAc was included in these reactions.

[b] Plus and minus symbols indicate whether or not a reaction was subsequently treated for 1 hour at 37°C with 1 TRU *Streptomyces* hyaluronidase prior to paper chromatography.

[c] Numbers represent picomoles radiolabeled product formed and were calculated taking into account the specific activity of the UDP[^{14}C]-GlcUA used, the amount of cold UDP-GlcUA per reaction, and assumed a scintillation counting efficiency of >95%. Based upon these calculations, 1 picomole of radiolabeled product is represented by 384 disintegrations per minute (dpm), i.e., 204.2 picomoles product was calculated from 78, 413 dpm. Numbers represent the mean calculated from duplicate reactions.

[d] Number represents the result of a single reaction in each instance.

[e] Not determined.

Discussion. The three Has proteins are encoded by three separate but related genes, which constitute a mammalian HAS gene family. Sequence comparisons and structural predictions suggest that the mammalian HAS proteins are very similar in structure. They are predicted to have one or two N-terminal transmembrane domains and a cluster of C-terminal transmembrane domains separated by a large cytoplasmic loop. This topology is extraordinarily similar to that predicted for the bacterial HA synthase, HasA (Helderman et al., Glycobiology, 6, 741 (1996)), and to that recently reported for the *Rhizobium meliloti* nodulation factor, NodC (Barny et al., Molec. Microbiol., 19, 443 (1996)). In addition, the mammalian HAS sequences, the *Xenopus* DG42 sequence, HasA sequence, NodC sequence, and the recently reported putative plant cellulose synthases share critical residues shown to be required for N-acetylglucosaminyltransferase activity of yeast chitin synthase 2, making it highly likely that all these proteins are functionally related processive β-glycosyltransferases. The highly conserved aspartate residues may represent sites such as cation binding sites that in turn may coordinate nucleotide-sugar interaction with the enzyme.

While Semino and Robbins have postulated that DG42 and its related mammalian homologs, rather than being bona fide HA synthases, may stimulate HA production through synthesizing chitin oligosaccharide primers, which are required for and rate limiting for eukaryotic HA biosynthesis (Proc. Natl. Acad. Sci. USA, 93, 4548 (1996)), cell membranes isolated from baker's yeast, *Saccharomyces cerevisiae*, engineered to express DG42 have HA synthesis activity *in vitro* when supplied with the required UDP-precursors (DeAngelis and Achyuthan, J. Biol. Chem., 271, 23657 (1996)) since *S. cerevisiae* is deficient in UDP-glucuronic acid production, *S. cerevisiae* is incapable of HA biosynthesis.

Expression of any one of the mammalian HAS proteins in transfected mammalian cells leads to a dramatic increase in HA biosynthesis. This would suggest that the proteins have similar activities. However, the high degree of sequence conservation (96-99% identity) between human and mouse HA

synthases contrasts with the lower level of identity between synthases within a species (Has1/Has2, 55% identity; Has1/Has3, 57% identity; Has2/Has3, 71% identity), arguing for evolutionary conservation of functionally important residues, and for some differences in the mode of action of the three proteins. Potential differences in function of the proteins could relate to the length of the HA chain synthesized, the rate of HA synthesis, the ability to interact with cell-type specific accessory proteins, and whether or not the HA is preferentially secreted by the cell or alternatively retained by the cell in the form of a pericellular coat.

Example 5

Identification of the Chromosomal Location of the Has Genes

To determine the chromosomal location of the mouse Has genes, a panel of DNA samples, from an interspecific cross that has been characterized for over 2,000 genetic markers throughout the mouse genome, was analyzed. The genetic markers included in this genetic map span between 50 and 80 centi-Morgans (cM) on each mouse autosome and the X chromosome (Chr), and the mapping of the reference loci in this interspecific cross are indicated with citations in an online database (data can be accessed through the internet as follows: http://www.informatics.jax.org/crossdata.html to enter the DNA Mapping Panel Data Sets from the Mouse Genome Database (MGD), then select the Seldin cross and Chromosome).

Initially, DNAs from two parental mice [C3H/HeJ-*gld* and (C3H/HeJ-*gld* x *Mus spretus*)F1] were digested with various restriction endonucleases and hybridized with probes specific to mouse *Has1, Has2* and *Has3* to determine restriction fragment length variants (RFLVs) to allow haplotype analyses. The 223 bp mouse Has1 probe was generated through PCR amplification of a full-length mouse Has1 cDNA template using oligonucleotide primers, 5'GTCAGAGCTACTTCCACTGTG3' (SEQ ID NO:53) and 5'AAGGAGGAGGGCGTCTCCGAG3' (SEQ ID NO:54) (nt positions 947-967 and 1169-1149, respectively). The mouse Has2 probe was the MHas300 partial cDNA (Figure 2), and the mouse Has3 probe was an equivalent fragment of the

mouse Has3 gene, generated using degenerate PCR primers as described above (Example 1). For each gene, informative RFLVs were detected: *Has1* using BamHI restriction endonuclease, C2H/HeJ-*gld*, 18.0 kb, 6.8 kb; *Mus spretus*, 2.1 kb; *Has2* using TaqI restriction endonuclease, C3H/HeJ-*gld*, 3.7 kb; *Mus spretus*, 3.9 kb; *Has3* using MspI restriction endonuclease, C3H/HeJ-*gld*, 1.3 kb, 4.2 kb; *Mus spretus*, 3.2 kb.

Comparison of the hapotype distribution of the *Has* RFLVs indicated that these genes segregated to three different mouse autosomes; *Has1* to mouse Chr 17, *Has2* to mouse Chr 15, and *Has3* to mouse Chr 8. The best gene order ± the standard deviation (Green, In: Genetics and Probability in Animal Breeding Experiments (E. Green, ed.), MacMillan, NY, pp. 77-113 (1981)) indicated the following gene orders: on mouse Chr 17 (centromere) *Thbs2* - 0.9 cM ± 0.9 cM - *Has1* - 3.5 cM ± 1.7 cM - *Hsp84-1*; on mouse Chr 15 (centromere) *Dhfr-rs1* - 14.0 cM ± 3.3 cM - *Has2* - 0.9 cM ± 0.9 cM - *Myc*; and on mouse Chr 8 (centromere) *Mt1* - 5.3 cM ± 2.1 cM - *D8Mit242* - 0.9 cM ± 0.9 cM - *Has3/D8Mit12* - 11.4 cM ± 3.0 cM - *D8Mit154*.

Pairwise sequence alignments of mouse Has cDNAs with human HAS cDNAs permitted the design of oligonucleotide primer pairs specific for the respective human HAS genes. Human HAS1: HAS1F 5′GTGCTTCTGTCGCTCTACGCG3′ (SEQ ID NO:49) and Human HAS1R 5′CCAGTCCCAATATAGTCCAGACTG3′ (SEQ ID NO:50) (nt positions 1410-1431 and 1940-1917, respectively, (Shyjan et al., J. Biol. Chem., 271, 23395 (1996)) which amplified a 520 bp fragment. Human HAS2: HAS2F 5′GGTGTGTTCAGTGCATTAGTGGA3′ (SEQ ID NO:51) and HAS2R 5′TAGCCATCTGAGATATTCTATAGGT3′(SEQ ID NO:52) (nt positions 1359-1382 and 1579-1555, respectively, Watanabe and Yamaguchi, J. Biol. Chem., 271, 22945 (1996)) which amplified a 220 bp fragment. Human HAS3: HAS3F 5′TGTGCAGTGTATTAGTGGGCCCT3′ (SEQ ID NO:41) and HAS3R 5′GTTGAGCCACCGGAGGTACTTAG3′ (SEQ ID NO:43) which amplified a 220 bp fragment. Conditions used in all PCR reactions were: 0.2 mM each dNTP, 50 mM KCl, 10 mM Tris-HCl pH 8.3, 1.5 mM $MgCl_2$, 2%

deionized formamide, 0.25 U Taq polymerase (Boehringer Mannheim), primers at 0.4 μM, 100 μl reactions. Cycling parameters for each primer pair were as follows: 35 cycles of 94°C for 10 seconds, 67°C (HAS1), 63°C (HAS2), or 65°C (HAS3) for 30 seconds, and 72°C for 1 minute, followed by a final extension step at 72°C for 10 minutes.

The oligonucleotide primers were used to screen two somatic cell hybrid mapping panels (Coriell Institute, Camden, NJ) segregating human chromosomes on a mouse or hamster background. Using this approach, the human HAS genes were unequivocally assigned to human Chr 19 (*HAS1*), Chr 8 (*HAS2*), and Chr 16 (*HAS3*).

To refine the location of human *HAS1* on Chr 19, the PCR fragment described above was used as a probe to screen colony filters of a Chr 19 cosmid library (Olsen et al., Genomics, 23, 659 (1994)). Two positive clones, R30674 and F21560, were identified, neither of which had been incorporated into any of the previously assembled contigs constituting the Chr 19 map (Ashworth et al., Nat. Genet., 11, 422 (1965)). Alu-PCR products (Parrish et al., Am. J. Hum. Genet., 57(5), 267 (1995)) from clone F21560 were hybridized to the cosmid library and to a genomic Bacterial Artificial Chromosome (BAC) library (Shizuya et al., Proc. Natl. Acad. Sci. USA, 89, 8794 (1992)) to form a contig around the *HAS1* gene. The probe identified several additional cosmids that were members of a previously assembled contig (CT1665), which had been *in situ* mapped to 19q13.3, as well as two BACs (BC79672 and BC56224) which extended the HAS1 contig in the opposite direction from CT1665. Alu-PCR products from BC56224 were hybridized to cosmids and identified the HAS1 cosmids in addition to numerous clones from another previously assembled contig (CT1031). Clone D1852 from this contig has been incorporated into the high resolution pronuclear FISH map of human 19q, placing *HAS1* at the q13.3-13.4 boundary, within the approximately 400 kb region between *ETFB* (Electron-Transferring-Flavoprotein, Beta polypeptide) and *FPR1* (Formyl Peptide Receptor 1). EcoRI mapping confirmed the clone overlaps detected by hybridization and indicated a size of 286 kb for the extended HAS 1 contig. In

addition to the above mapping results, the localization of HAS1 to Chr 19q13.3-13.4 was confirmed using a 2.1 kb human HAS1 cDNA (Itano et al., BBRC, 222, 816 (1996)) and FISH analysis, as described in Inazawa et al. (Genomes, 17, 153 (1993)). The mapping results for mouse *Has1* and human *HAS1* reinforce the recently reported relationship between a small region of human 19q and mouse Chr 17.

The position of *Has2* on proximal mouse Chr 15 suggested that the human homolog, *HAS2*, is located on the long arm of human Chr 8 at band q24.1 (DeBry and Seldin, Genomics, 33, 337 (1996) and online database: http://www3.ncbi.nlm.nih.gov/Homology/). This location corresponds to the region predicted to contain the gene for the human Langer-Giedion syndrome (LGS) (Chen et al., Genomics, 32, 117 (1996)), a contiguous genetic syndrome characterized by craniofacial deformities, multiple exostoses, mental retardation, microcephaly, and redundant skin (Bauermeister and Letts, Ortho. Rev., 21, 31 (1962)). To refine the location of human *HAS2* on Chr 8, the human HAS2 primers were used to PCR screen the following human-hamster somatic cell hybrids: CL-17, 3;8/4-1, MC2F, 21q+, and TL/UC (Parrish et al., Som. Cell Molec. Genet., 20, 143 (1994); Wagner et al., Genomics, 10, 114 (1991)). Positive PCR signals were observed for CL-17, 21q+ and 3;8/4-1 in addition to total human DNA, sublocalizing the *HAS2* gene to the q arm in interval I-8 (Spurr et al., Cytogenet. Cell Genet., 68, 147 (1995)). Human HAS2 primers were further screened against YACs within the distal portion of a large YAC contig (Chen et al., *supra*). This contig extends from interval I-1 into interval I-9. Only three of the YACs tested were positive, narrowing the location of *HAS2* to the overlapping region between these YACs. This places the human *HAS2* gene at human Chr 8q24.12, close to the *DAP-A1* gene, and between the defined critical region for the Langer-Giedion syndrome (LGS) and the *MYC* gene. Thus, *HAS2* can be excluded as a candidate gene for LGS.

The localization of the mouse *Has3* gene to mouse Chr 8 near the *D8Mit12* locus implicated human Chr 16q as the most likely location for the human homolog of this gene. To confirm and refine this localization YAC DNA

pools from a YAC map of human Chr 16 (Daggett et al., Nature, 377(5), 335 (1995)) were screened with DNA primers that were specific for the human *HAS3* gene, as described above. Three YACs (My782G9, My703C5, and My878A4) were identified which produced an amplimer of the correct size with these primers. These results place the *HAS3* gene in band 16q22.1 between the somatic cell hybrid breakpoints CY127(D) and CY6, and near the E-cadherin gene (*CDH1*) gene and the *D16S496* marker.

All publications and patents are incorporated by reference herein, as though individually incorporated by reference. The invention is not limited to the exact details shown and described, for it should be understood that many variations and modifications may be made while remaining within the spirit and scope of the invention defined by the claims.

SEQUENCE LISTING

(1) GENERAL INFORMATION

(i) APPLICANT: Mayo Foundation for Medical Education and Research

(ii) TITLE OF THE INVENTION: GENE ENCODING HYALNURONAN SYNTHASE

(iii) NUMBER OF SEQUENCES: 57

(iv) CORRESPONDENCE ADDRESS:
(A) ADDRESSEE: Schwegman, Lundberg, Woessner & Kluth, P.A.
(B) STREET: P.O. Box 2938
(C) CITY: Minneapolis
(D) STATE: MN
(E) COUNTRY: U.S.A
(F) ZIP: 55402

(v) COMPUTER READABLE FORM:
(A) MEDIUM TYPE: Diskette
(B) COMPUTER: IBM Compatible
(C) OPERATING SYSTEM: DOS
(D) SOFTWARE: FastSEQ Version 2.0

(vi) CURRENT APPLICATION DATA:
(A) APPLICATION NUMBER: 08/812,008
(B) FILING DATE: 05-MAR-1997
(C) CLASSIFICATION:

(vii) PRIOR APPLICATION DATA:
(A) APPLICATION NUMBER: 08/812,008
(B) FILING DATE: 05-MAR-1997

(A) APPLICATION NUMBER: 08/675,499
(B) FILING DATE: 03-JUL-1996

(viii) ATTORNEY/AGENT INFORMATION:
(A) NAME: Embretson, Janet E
(B) REGISTRATION NUMBER: 39,665
(C) REFERENCE/DOCKET NUMBER: 150.183US1

(ix) TELECOMMUNICATION INFORMATION:
(A) TELEPHONE: 612-373-6900
(B) TELEFAX: 612-339-3061
(C) TELEX:

(2) INFORMATION FOR SEQ ID NO:1:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 2947 base pairs

(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:1:

ACATGTAAGA AGAAGGAGAA GTCAAGGCGT CTGGAAAGAA TTACCCAGTC CTGGCTTCGA 60
GCAGCCCATT GAACGGGGGA CTTGAACCAG CCAAAGACTT CTTCATTCTG CTCTTGCTAG 120
ACTCTGCTGA GTCTTGACCC GGCTTGTAGG TTGATGTGAA AAGAGATTTT GTGTCGTCGG 180
AGGGAAGGGG ATTGGAGCAA ATAGCAAAAC AGGGGGAAAA GTTAATTTAT CTTTAAAGCA 240
GATATAACAA AGAATTAGAA GACTTAAGTG CAGCGGAAAT ATAAAGAGAA TATTAGTGAA 300
ATTTCTTCTC AAAGAGGGGA GAACCAAGCA TTTAAGGCTC CCCCATCTTT TTTTTAAAAT 360
GTTGTTTTTA AATTTCTTAT TTTTTTTGGC CGGTCGTCTC AAATTCATCT GATTTCTTAT 420
TACCTCAATT TTGGAAACTT CCTTCCACGA CCCTCCGGGA CCACACAGAC AGGCGGAGGA 480
CGAGTCTATG AGCAGGAGCT GAACAAGATG CATTGTGAGA GGTTTCTATG TGTCCTGAGA 540
ATAATTGGAA CTACACTTTT TGGAGTGTCT CTCCTCCTCG GAATCACAGC TGCTTATATT 600
GTTGGCTACC AGTTTATCCA AACAGATAAT TACTACTTCT CATTTGGACT GTACGGTGCC 660
TTTTTAGCCT CGCCATCTCAT CATCCAAAGC CTCTTTGCCT TTTTGGAACA CCGGAAAATG 720
AAGAAGTCCC TTGAAACCCC GATTAAATTG AACAAAACGG TAGCACTCTG CATCGCTGCG 780
TACCAAGAGG ACCCTGACTA CTTACGGAAA TGTTTGCAAT CTGTGAAAAG GCTGACCTAC 840
CCTGGGATTA AAGTCGTGAT GGTCATCGAT GGGAACTCAG ACGACGACCT TTACATGATG 900
GACATATTCA GCGAAGTTAT TGGCAGGGAC AAATCGGCCA CGTACATCTG GAAGAACAAC 960
TTTCATGAAA AGGGACCTGG TGAGACAGAA GAGTCCCATA AAGAAAGTTC ACAACATGTC 1020
ACCCAATTGG TCTTGTCTAA CAAAAGTATT TGCATCATGC AAAAATGGGG TGGAAAGAGA 1080
GAAGTCATGT ACACAGCCTT CAGAGCACTG GGGCGAAGCG TGGATTATGT ACAGGTGTGT 1140
GACTCAGATA CTATGCTTGA CCCTGCCTCA TCTGTGGAGA TGGTGAAGGT CTTAGAGGAA 1200
GACCCTATGG TTGGAGGTGT TGGAGGAGAT GTCCAGATTT TAAACAAGTA TGATTCCTGG 1260
ATCTCCTTCC TCAGCAGCGT GAGATACTGG ATGGCTTTTA ATATAGAAAG GGCCTGCCAG 1320
TCTTATTTTG GCTGTGTCCA GTGCATAAGC GGTCCTCTGG GAATGTACAG AAACTCCTTG 1380
CTGCATGAAT TTGTGGAAGA CTGGTACAAT CAGGAATTCA TGGGTAACCA ATGCAGTTTT 1440
GGTGACGACA GGCACCTTAC CAACAGGGTG TTGAGTCTGG GCTATGCAAC TAAATACACG 1500
GCTCGGTCCA AGTGCCTTAC TGAAACTCCC ATAGAATATC TGAGATGGCT GAACCAGCAG 1560
ACCCGATGGA GCAAGTCCTA CTTCCGAGAG TGGCTGTACA ATGCCATGTG GTTTCACAAG 1620
CATCACCTGT GGATGACCTA TGAAGCTGTT ATCACTGGAT TCTTTCCTTT CTTTCTCATT 1680
GCCACAGTCA TCCAGCTCTT CTACAGGGGT AAAATCTGGA ACATCCTCCT CTTCCTGTTA 1740
ACTGTCCAGC TAGTGGGTCT CATCAAGTCA TCTTTTGCCA GCTGCCTTAG AGGAAATATC 1800
GTCATGGTAT TCATGTCTCT GTATTCAGTG TTATACATGT CAAGTCTACT TCCTGCCAAG 1860
ATGTTTGCAA TTGCAACCAT AAACAAAGCT GGGTGGGGCA CATCTGGAAG GAAGACCATT 1920
GTTGTTAATT TCATAGGACT TATTCCAGTG TCCGTGTGGT TTACAATCCT TCTAGGTGGT 1980
GTAATTTTCA CCATTTATAA GGAATCTAAA AAGCCATTTT CCGAATCCAA ACAGACTGTT 2040
CTCATCGTGG GAACTTTGAT CTATGCATGC TACTGGGTCA TGCTTTTGAC TCTCTATGTG 2100
GTTCTCATCA ATAAGTGTGG CAGGCGGAAG AAGGGACAAC AGTATGACAT GGTGCTTGAT 2160
GTATGATGAT GTTTGTAGTC ACACCTGGAG ACACACACAC ACACACATCA CACACACACA 2220
CACCTTAGCT CCTCAAGGGG CTATACAGTA TTGTGGCACC GCACCCTGCC ACCACAGGAG 2280
ACATATCACT GCTGCTGGGA CTTGAACAAA GACATTCAAT GGGGGTTGGT TTCTTTTTTA 2340
TTCTGCCAAA GCAAATTGAT ACATCAGTGA GAAGAAAGTC CGATTAAATC TGACAGTTTT 2400
AGGACGGTGG GATGATGTCT TGGCTTATGC ACTTTTCCCT TACTGTGCAT CTGCCTGACA 2460
GTGTTTGTTC TAAATACCTC ACTTGCCATG CTTTGTGTGG GTGATCATGG AAGAAAAGGA 2520
TTCTGAAAAC TCAAGGGAAC GTTCTTTCAA CCTACACATC CTAACTTATG GACTCTTTTG 2580
ATAGCTGATG ATTTTCTTTC TATTTTTTGT TTTTAAGGAA AATTGTTCAT CTTTACCAAA 2640
TGAAATGCCA AAGGAAAGTT GGAAAGCCAC TGGCTATGCT GTATTTTGAT ATAATAATTG 2700
TACTGTGTTT TAAATTTTGT ATCCGGATTT TTAAAAACAA AATTTCACAC CATAGTCTAT 2760
ATTTTACTTC TCTGGCAAAA TACACTTTTG TTCTTTTATA TATATATATA TATATATATA 2820

```
ATAAAATAGG TTCTAAAAAA ATCCATACTA TAAAAAAAAA TTAACCTGCC CAAAATGTGA   2880
AACGTGGTTG ACTGATGTTC ATGAAAGAAT AAAATGTTTC TCTCTTTCTC TACATTTTAA   2940
AAAAAAA                                                             2947
```

(2) INFORMATION FOR SEQ ID NO:2:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 552 amino acids
(B) TYPE: amino acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:2:

```
Met His Cys Glu Arg Phe Leu Cys Val Leu Arg Ile Ile Gly Thr Thr
 1               5                  10                  15
Leu Phe Gly Val Ser Leu Leu Leu Gly Ile Thr Ala Ala Tyr Ile Val
            20                  25                  30
Gly Tyr Gln Phe Ile Gln Thr Asp Asn Tyr Tyr Phe Ser Phe Gly Leu
        35                  40                  45
Tyr Gly Ala Phe Leu Ala Ser His Leu Ile Ile Gln Ser Leu Phe Ala
    50                  55                  60
Phe Leu Glu His Arg Lys Met Lys Lys Ser Leu Glu Thr Pro Ile Lys
65                  70                  75                  80
Leu Asn Lys Thr Val Ala Leu Cys Ile Ala Ala Tyr Gln Glu Asp Pro
                85                  90                  95
Asp Tyr Leu Arg Lys Cys Leu Gln Ser Val Lys Arg Leu Thr Tyr Pro
            100                 105                 110
Gly Ile Lys Val Val Met Val Ile Asp Gly Asn Ser Asp Asp Asp Leu
        115                 120                 125
Tyr Met Met Asp Ile Phe Ser Glu Val Ile Gly Arg Asp Lys Ser Ala
    130                 135                 140
Thr Tyr Ile Trp Lys Asn Asn Phe His Glu Lys Gly Pro Gly Glu Thr
145                 150                 155                 160
Glu Glu Ser His Lys Glu Ser Ser Gln His Val Thr Gln Leu Val Leu
                165                 170                 175
Ser Asn Lys Ser Ile Cys Ile Met Gln Lys Trp Gly Gly Lys Arg Glu
            180                 185                 190
Val Met Tyr Thr Ala Phe Arg Ala Leu Gly Arg Ser Val Asp Tyr Val
        195                 200                 205
Gln Val Cys Asp Ser Asp Thr Met Leu Asp Pro Ala Ser Ser Val Glu
    210                 215                 220
Met Val Lys Val Leu Glu Glu Asp Pro Met Val Gly Gly Val Gly Gly
225                 230                 235                 240
Asp Val Gln Ile Leu Asn Lys Tyr Asp Ser Trp Ile Ser Phe Leu Ser
                245                 250                 255
Ser Val Arg Tyr Trp Met Ala Phe Asn Ile Glu Arg Ala Cys Gln Ser
            260                 265                 270
Tyr Phe Gly Cys Val Gln Cys Ile Ser Gly Pro Leu Gly Met Tyr Arg
        275                 280                 285
Asn Ser Leu Leu His Glu Phe Val Glu Asp Trp Tyr Asn Gln Glu Phe
    290                 295                 300
Met Gly Asn Gln Cys Ser Phe Gly Asp Asp Arg His Leu Thr Asn Arg
```

```
305                 310                 315                 320
Val Leu Ser Leu Gly Tyr Ala Thr Lys Tyr Thr Ala Arg Ser Lys Cys
                325                 330                 335
Leu Thr Glu Thr Pro Ile Glu Tyr Leu Arg Trp Leu Asn Gln Gln Thr
            340                 345                 350
Arg Trp Ser Lys Ser Tyr Phe Arg Glu Trp Leu Tyr Asn Ala Met Trp
        355                 360                 365
Phe His Lys His His Leu Trp Met Thr Tyr Glu Ala Val Ile Thr Gly
    370                 375                 380
Phe Phe Pro Phe Phe Leu Ile Ala Thr Val Ile Gln Leu Phe Tyr Arg
385                 390                 395                 400
Gly Lys Ile Trp Asn Ile Leu Leu Phe Leu Leu Thr Val Gln Leu Val
                405                 410                 415
Gly Leu Ile Lys Ser Ser Phe Ala Ser Cys Leu Arg Gly Asn Ile Val
            420                 425                 430
Met Val Phe Met Ser Leu Tyr Ser Val Leu Tyr Met Ser Ser Leu Leu
        435                 440                 445
Pro Ala Lys Met Phe Ala Ile Ala Thr Ile Asn Lys Ala Gly Trp Gly
    450                 455                 460
Thr Ser Gly Arg Lys Thr Ile Val Val Asn Phe Ile Gly Leu Ile Pro
465                 470                 475                 480
Val Ser Val Trp Phe Thr Ile Leu Leu Gly Gly Val Ile Phe Thr Ile
                485                 490                 495
Tyr Lys Glu Ser Lys Lys Pro Phe Ser Glu Ser Lys Gln Thr Val Leu
            500                 505                 510
Ile Val Gly Thr Leu Ile Tyr Ala Cys Tyr Trp Val Met Leu Leu Thr
        515                 520                 525
Leu Tyr Val Val Leu Ile Asn Lys Cys Gly Arg Arg Lys Lys Gly Gln
    530                 535                 540
Gln Tyr Asp Met Val Leu Asp Val
545                 550
```

(2) INFORMATION FOR SEQ ID NO:3:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 583 amino acids
(B) TYPE: amino acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:3:

```
Met Arg Gln Asp Met Pro Lys Pro Ser Glu Ala Ala Arg Cys Cys Ser
 1               5                  10                  15
Gly Leu Ala Arg Arg Ala Leu Thr Ile Ile Phe Ala Leu Leu Ile Leu
            20                  25                  30
Gly Leu Met Thr Trp Ala Tyr Ala Ala Gly Val Pro Leu Ala Ser Asp
        35                  40                  45
Arg Tyr Gly Leu Leu Ala Phe Gly Leu Tyr Gly Ala Phe Leu Ser Ala
    50                  55                  60
His Leu Val Ala Gln Ser Leu Phe Ala Tyr Leu Glu His Arg Arg Val
65                  70                  75                  80
Ala Ala Ala Ala Arg Arg Ser Leu Ala Lys Gly Pro Leu Asp Ala Ala
```

```
                  85                  90                  95
Thr Ala Arg Ser Val Ala Leu Thr Ile Ser Ala Tyr Gln Glu Asp Pro
             100                 105                 110
Ala Tyr Leu Arg Gln Cys Leu Thr Ser Ala Arg Ala Leu Leu Tyr Pro
         115                 120                 125
His Thr Arg Leu Arg Val Leu Met Val Val Asp Gly Asn Arg Ala Glu
     130                 135                 140
Asp Leu Tyr Met Val Asp Met Phe Arg Glu Val Phe Ala Asp Glu Asp
145                 150                 155                 160
Pro Ala Thr Tyr Val Trp Asp Gly Asn Tyr His Gln Pro Trp Glu Pro
                165                 170                 175
Ala Glu Ala Thr Gly Ala Val Gly Glu Gly Ala Tyr Arg Glu Val Glu
            180                 185                 190
Ala Glu Asp Pro Gly Arg Leu Ala Val Glu Ala Leu Val Arg Thr Arg
        195                 200                 205
Arg Cys Val Cys Val Ala Gln Arg Trp Gly Gly Lys Arg Glu Val Met
    210                 215                 220
Tyr Thr Ala Phe Lys Ala Leu Gly Asp Ser Val Asp Tyr Val Gln Val
225                 230                 235                 240
Cys Asp Ser Asp Thr Arg Leu Asp Pro Met Ala Leu Leu Glu Leu Val
                245                 250                 255
Arg Val Leu Asp Glu Asp Pro Arg Val Gly Ala Val Gly Gly Asp Val
            260                 265                 270
Arg Ile Leu Asn Pro Leu Asp Ser Trp Val Ser Phe Leu Ser Ser Leu
        275                 280                 285
Arg Tyr Trp Val Ala Phe Asn Val Glu Arg Ala Cys Gln Ser Tyr Phe
    290                 295                 300
His Cys Val Ser Cys Ile Ser Gly Pro Leu Gly Leu Tyr Arg Asn Asn
305                 310                 315                 320
Leu Leu Gln Gln Phe Leu Glu Ala Trp Tyr Asn Gln Lys Phe Leu Gly
                325                 330                 335
Thr His Cys Thr Phe Gly Asp Asp Arg His Leu Thr Asn Arg Met Leu
            340                 345                 350
Ser Met Gly Tyr Ala Thr Lys Tyr Thr Ser Arg Ser Arg Cys Tyr Ser
        355                 360                 365
Glu Thr Pro Ser Ser Phe Leu Arg Trp Leu Ser Gln Gln Thr Arg Trp
    370                 375                 380
Ser Lys Ser Tyr Phe Arg Glu Trp Leu Tyr Asn Ala Leu Trp Trp His
385                 390                 395                 400
Arg His His Ala Trp Met Thr Tyr Glu Ala Val Val Ser Gly Leu Phe
                405                 410                 415
Pro Phe Phe Val Ala Ala Thr Val Leu Arg Leu Phe Tyr Ala Gly Arg
            420                 425                 430
Pro Trp Ala Leu Leu Trp Val Leu Leu Cys Val Gln Gly Val Ala Leu
        435                 440                 445
Ala Lys Ala Ala Phe Ala Ala Trp Leu Arg Gly Cys Val Arg Met Val
    450                 455                 460
Leu Leu Ser Leu Tyr Ala Pro Leu Tyr Met Cys Gly Leu Leu Pro Ala
465                 470                 475                 480
Lys Phe Leu Ala Leu Val Thr Met Asn Gln Ser Gly Trp Gly Thr Ser
                485                 490                 495
Gly Arg Lys Lys Leu Ala Ala Asn Tyr Val Pro Val Leu Pro Leu Ala
            500                 505                 510
Leu Trp Ala Leu Leu Leu Leu Gly Gly Leu Ala Arg Ser Val Ala Gln
        515                 520                 525
```

```
Glu Ala Arg Ala Asp Trp Ser Gly Pro Ser Arg Ala Ala Glu Ala Tyr
    530                 535                 540
His Leu Ala Ala Gly Ala Gly Ala Tyr Val Ala Tyr Trp Val Val Met
545                 550                 555                 560
Leu Thr Ile Tyr Trp Val Gly Val Arg Arg Leu Cys Arg Arg Arg Ser
                565                 570                 575
Gly Gly Tyr Arg Val Gln Val
            580
```

(2) INFORMATION FOR SEQ ID NO:4:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 587 amino acids
(B) TYPE: amino acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:4:

```
Met Lys Glu Lys Ala Ala Glu Thr Met Glu Ile Pro Glu Gly Ile Pro
 1               5                  10                  15
Lys Asp Leu Glu Pro Lys His Pro Thr Leu Trp Arg Ile Ile Tyr Tyr
            20                  25                  30
Ser Phe Gly Val Val Leu Leu Ala Thr Ile Thr Ala Ala Tyr Val Ala
        35                  40                  45
Glu Phe Gln Val Leu Lys His Glu Ala Ile Leu Phe Ser Leu Gly Leu
    50                  55                  60
Tyr Gly Leu Ala Met Leu Leu His Leu Met Met Gln Ser Leu Phe Ala
65                  70                  75                  80
Phe Leu Glu Ile Arg Arg Val Asn Lys Ser Glu Leu Pro Cys Ser Phe
                85                  90                  95
Lys Lys Thr Val Ala Leu Thr Ile Ala Gly Tyr Gln Glu Asn Pro Glu
            100                 105                 110
Tyr Leu Ile Lys Cys Leu Glu Ser Cys Lys Tyr Val Lys Tyr Pro Lys
        115                 120                 125
Asp Lys Leu Lys Ile Ile Leu Val Ile Asp Gly Asn Thr Glu Asp Asp
    130                 135                 140
Ala Tyr Met Met Glu Met Phe Lys Asp Val Phe His Gly Glu Asp Val
145                 150                 155                 160
Gly Thr Tyr Val Trp Lys Gly Asn Tyr His Thr Val Lys Lys Pro Glu
                165                 170                 175
Glu Thr Asn Lys Gly Ser Cys Pro Glu Val Ser Lys Pro Leu Asn Glu
            180                 185                 190
Asp Glu Gly Ile Asn Met Val Glu Glu Leu Val Arg Asn Lys Arg Cys
        195                 200                 205
Val Cys Ile Met Gln Gln Trp Gly Lys Arg Glu Val Met Tyr Thr Ala
    210                 215                 220
Phe Gln Ala Ile Gly Thr Ser Val Asp Tyr Val Gln Val Cys Asp Ser
225                 230                 235                 240
Asp Thr Lys Leu Asp Glu Leu Ala Thr Val Glu Met Val Lys Val Leu
                245                 250                 255
Glu Ser Asn Asp Met Tyr Gly Ala Val Gly Gly Asp Val Arg Ile Leu
            260                 265                 270
```

```
Asn Pro Tyr Asp Ser Phe Ile Ser Phe Met Ser Ser Leu Arg Tyr Trp
        275                 280                 285
Met Ala Phe Asn Val Glu Arg Ala Cys Gln Ser Tyr Phe Asp Cys Val
    290                 295                 300
Ser Cys Ile Ser Gly Pro Leu Gly Met Tyr Arg Asn Asn Ile Leu Gln
305                 310                 315                 320
Val Phe Leu Glu Ala Trp Tyr Arg Gln Lys Phe Leu Gly Thr Tyr Cys
                325                 330                 335
Thr Leu Gly Asp Asp Arg His Leu Thr Asn Arg Val Leu Ser Met Gly
            340                 345                 350
Tyr Arg Thr Lys Tyr Thr His Lys Ser Arg Ala Phe Ser Glu Thr Pro
        355                 360                 365
Ser Leu Tyr Leu Arg Trp Leu Asn Gln Gln Thr Arg Trp Thr Lys Ser
    370                 375                 380
Tyr Phe Arg Glu Trp Leu Tyr Asn Ala Gln Trp Trp His Lys His His
385                 390                 395                 400
Ile Trp Met Thr Tyr Glu Ser Val Val Ser Phe Ile Phe Pro Phe Phe
                405                 410                 415
Ile Thr Ala Thr Val Ile Arg Leu Ile Tyr Ala Gly Thr Ile Trp Asn
            420                 425                 430
Val Val Trp Leu Leu Leu Cys Ile Gln Ile Met Ser Leu Phe Lys Ser
        435                 440                 445
Ile Tyr Ala Cys Trp Leu Arg Gly Asn Phe Ile Met Leu Leu Met Ser
    450                 455                 460
Leu Tyr Ser Met Leu Tyr Met Thr Gly Leu Leu Pro Ser Lys Tyr Phe
465                 470                 475                 480
Ala Leu Leu Thr Leu Asn Lys Thr Gly Trp Gly Thr Ser Gly Arg Lys
                485                 490                 495
Lys Ile Val Gly Asn Tyr Met Pro Ile Leu Pro Leu Ser Ile Trp Ala
            500                 505                 510
Ala Val Leu Cys Gly Gly Val Gly Tyr Ser Ile Tyr Met Asp Cys Gln
        515                 520                 525
Asn Asp Trp Ser Thr Pro Glu Lys Gln Lys Glu Met Tyr His Leu Leu
    530                 535                 540
Tyr Gly Cys Val Gly Tyr Val Met Tyr Met Val Ile Met Ala Val Met
545                 550                 555                 560
Tyr Trp Val Trp Val Lys Arg Cys Cys Arg Lys Arg Ser Gln Thr Val
                565                 570                 575
Thr Leu Val His Asp Ile Pro Asp Met Cys Val
            580                 585
```

(2) INFORMATION FOR SEQ ID NO:5:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 419 amino acids
(B) TYPE: amino acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:5:

```
Met Pro Ile Phe Lys Lys Thr Leu Ile Val Leu Ser Phe Ile Phe Leu
 1               5                  10                  15
```

```
Ile Ser Ile Leu Ile Tyr Leu Asn Met Tyr Leu Phe Gly Thr Ser Thr
            20                  25                  30
Val Gly Ile Tyr Gly Val Ile Leu Ile Thr Tyr Leu Val Ile Lys Leu
        35                  40                  45
Gly Leu Ser Phe Leu Tyr Glu Pro Phe Lys Gly Asn Pro His Asp Tyr
    50                  55                  60
Lys Val Ala Ala Val Ile Pro Ser Tyr Asn Glu Asp Ala Glu Ser Leu
65                  70                  75                  80
Leu Glu Thr Leu Lys Ser Val Leu Ala Gln Thr Tyr Pro Leu Ser Glu
                85                  90                  95
Ile Tyr Ile Val Asp Asp Gly Ser Ser Asn Thr Asp Ala Ile Gln Leu
            100                 105                 110
Ile Glu Glu Tyr Val Asn Arg Glu Val Asp Ile Cys Arg Asn Val Ile
        115                 120                 125
Val His Arg Ser Leu Val Asn Lys Gly Lys Arg His Ala Gln Ala Trp
    130                 135                 140
Ala Phe Glu Arg Ser Asp Ala Asp Val Phe Leu Thr Val Asp Ser Asp
145                 150                 155                 160
Thr Tyr Ile Tyr Pro Asn Ala Leu Glu Glu Leu Leu Lys Ser Phe Asn
                165                 170                 175
Asp Glu Thr Val Tyr Ala Ala Thr Gly His Leu Asn Ala Arg Asn Arg
            180                 185                 190
Gln Thr Asn Leu Leu Thr Arg Leu Thr Asp Ile Arg Tyr Asp Asn Ala
        195                 200                 205
Phe Gly Val Glu Arg Ala Ala Gln Ser Leu Thr Gly Asn Ile Leu Val
    210                 215                 220
Cys Ser Gly Pro Leu Ser Ile Tyr Arg Arg Glu Val Ile Ile Pro Asn
225                 230                 235                 240
Leu Glu Arg Tyr Lys Asn Gln Thr Phe Leu Gly Leu Pro Val Ser Ile
                245                 250                 255
Gly Asp Asp Arg Cys Leu Thr Asn Tyr Ala Ile Asp Leu Gly Arg Thr
            260                 265                 270
Val Tyr Gln Ser Thr Ala Arg Cys Asp Thr Asp Val Pro Phe Gln Leu
        275                 280                 285
Lys Ser Tyr Leu Lys Gln Gln Asn Arg Trp Asn Lys Ser Phe Phe Arg
    290                 295                 300
Glu Ser Ile Ile Ser Val Lys Lys Ile Leu Ser Asn Pro Ile Val Ala
305                 310                 315                 320
Leu Trp Thr Ile Phe Glu Val Val Met Phe Met Met Leu Ile Val Ala
                325                 330                 335
Ile Gly Asn Leu Leu Phe Asn Gln Ala Ile Gln Leu Asp Leu Ile Lys
            340                 345                 350
Leu Phe Ala Phe Leu Ser Ile Ile Phe Ile Val Ala Leu Cys Arg Asn
        355                 360                 365
Val His Tyr Met Val Lys His Pro Ala Ser Phe Leu Leu Ser Pro Leu
    370                 375                 380
Tyr Gly Ile Leu His Leu Phe Val Leu Gln Pro Leu Lys Leu Tyr Ser
385                 390                 395                 400
Leu Cys Thr Ile Lys Asn Thr Glu Trp Gly Thr Arg Lys Lys Val Thr
                405                 410                 415
Ile Phe Lys
```

(2) INFORMATION FOR SEQ ID NO:6:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 426 amino acids
(B) TYPE: amino acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:6:

```
Met Tyr Leu Leu Asp Thr Thr Ser Thr Ala Ala Ile Ser Ile Tyr Ala
 1               5                  10                  15
Leu Leu Leu Thr Ala Tyr Arg Ser Met Gln Val Leu Tyr Ala Arg Pro
            20                  25                  30
Ile Asp Gly Leu Ala Val Ala Ala Glu Pro Val Glu Thr Arg Pro Leu
        35                  40                  45
Pro Ala Val Asp Val Ile Val Pro Ser Phe Asn Glu Asp Pro Gly Ile
    50                  55                  60
Leu Ser Ala Cys Leu Ala Ser Ile Ala Asp Gln Asp Tyr Pro Gly Glu
65                  70                  75                  80
Leu Arg Val Tyr Val Val Asp Asp Gly Ser Arg Asn Arg Glu Ala Ile
                85                  90                  95
Val Arg Val Arg Ala Phe Tyr Ser Arg Asp Pro Arg Phe Ser Phe Ile
            100                 105                 110
Leu Leu Pro Glu Asn Val Gly Lys Arg Lys Ala Gln Ile Ala Ala Ile
        115                 120                 125
Gly Gln Ser Ser Gly Asp Leu Val Leu Asn Val Asp Ser Asp Ser Thr
    130                 135                 140
Ile Ala Phe Asp Val Val Ser Lys Leu Ala Ser Lys Met Arg Asp Pro
145                 150                 155                 160
Glu Val Gly Ala Val Met Gly Gln Leu Thr Ala Ser Asn Ser Gly Asp
                165                 170                 175
Thr Trp Leu Thr Lys Leu Ile Asp Met Glu Tyr Trp Leu Ala Cys Asn
            180                 185                 190
Glu Glu Arg Ala Ala Gln Ser Arg Phe Gly Ala Val Met Cys Cys Cys
        195                 200                 205
Gly Pro Cys Ala Met Tyr Arg Arg Ser Ala Leu Ala Ser Leu Leu Asp
    210                 215                 220
Gln Tyr Glu Thr Gln Leu Phe Arg Gly Lys Pro Ser Asp Phe Gly Glu
225                 230                 235                 240
Asp Arg His Leu Thr Ile Leu Met Leu Lys Ala Gly Phe Arg Thr Glu
                245                 250                 255
Tyr Val Pro Asp Ala Ile Val Ala Thr Val Val Pro Asp Thr Leu Lys
            260                 265                 270
Pro Tyr Leu Arg Gln Gln Leu Arg Trp Ala Arg Ser Thr Phe Arg Asp
        275                 280                 285
Thr Phe Leu Ala Leu Pro Leu Leu Arg Gly Leu Ser Pro Phe Leu Ala
    290                 295                 300
Phe Asp Ala Val Gly Gln Asn Ile Gly Gln Leu Leu Leu Ala Leu Ser
305                 310                 315                 320
Val Val Thr Gly Leu Ala His Leu Ile Met Thr Ala Thr Val Pro Trp
                325                 330                 335
Trp Thr Ile Leu Ile Ile Ala Cys Met Thr Ile Ile Arg Cys Ser Val
            340                 345                 350
Val Ala Leu His Ala Arg Gln Leu Arg Phe Leu Gly Phe Val Leu His
```

```
        355                 360                 365
Thr Pro Ile Asn Leu Phe Leu Ile Leu Pro Leu Lys Ala Tyr Ala Leu
    370                 375                 380
Cys Thr Leu Ser Asn Ser Asp Trp Leu Ser Arg Tyr Ser Ala Pro Glu
385                 390                 395                 400
Val Pro Val Ser Gly Gly Lys Gln Thr Pro Ile Gln Thr Ser Gly Arg
                405                 410                 415
Val Thr Pro Asp Cys Thr Cys Ser Gly Glu
            420                 425
```

(2) INFORMATION FOR SEQ ID NO:7:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 43 amino acids
(B) TYPE: amino acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:7:

```
Lys Arg Glu Val Met Tyr Thr Ala Phe Arg Ala Leu Gly Arg Ser Val
 1               5                  10                  15
Asp Tyr Val Gln Val Cys Asp Ser Asp Thr Met Leu Asp Pro Ala Ser
            20                  25                  30
Ser Val Glu Met Val Lys Val Leu Glu Glu Asp
        35                  40
```

(2) INFORMATION FOR SEQ ID NO:8:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 55 amino acids
(B) TYPE: amino acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:8:

```
Gln Cys Ser Phe Gly Asp Asp Arg His Leu Thr Asn Arg Val Leu Ser
 1               5                  10                  15
Leu Gly Tyr Ala Thr Lys Tyr Thr Ala Arg Ser Lys Cys Leu Thr Glu
            20                  25                  30
Thr Pro Ile Glu Tyr Leu Arg Trp Leu Asn Gln Gln Thr Arg Trp Ser
        35                  40                  45
Lys Ser Tyr Phe Arg Glu Trp
    50                  55
```

(2) INFORMATION FOR SEQ ID NO:9:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 43 amino acids
(B) TYPE: amino acid

(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:9:

```
Lys Arg Glu Val Met Tyr Thr Ala Phe Lys Ala Leu Gly Asp Ser Val
 1               5                  10                  15
Asp Tyr Val Gln Val Cys Asp Ser Asp Thr Arg Leu Asp Pro Met Ala
            20                  25                  30
Leu Leu Glu Leu Val Arg Val Leu Asp Glu Asp
        35                  40
```

(2) INFORMATION FOR SEQ ID NO:10:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 43 amino acids
(B) TYPE: amino acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:10:

```
Lys Arg Glu Val Met Tyr Thr Ala Phe Gln Ala Ile Gly Thr Ser Val
 1               5                  10                  15
Asp Tyr Val Gln Val Cys Asp Ser Asp Thr Lys Leu Asp Glu Leu Ala
            20                  25                  30
Thr Val Glu Met Val Lys Val Leu Glu Ser Asn
        35                  40
```

(2) INFORMATION FOR SEQ ID NO:11:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 41 amino acids
(B) TYPE: amino acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:11:

```
Lys Arg His Ala Gln Ala Trp Ala Phe Glu Arg Ser Asp Ala Asp Val
 1               5                  10                  15
Phe Leu Thr Val Asp Ser Asp Thr Tyr Ile Tyr Pro Asn Ala Leu Glu
            20                  25                  30
Glu Leu Leu Lys Ser Phe Asn Asp Glu
        35                  40
```

(2) INFORMATION FOR SEQ ID NO:12:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 41 amino acids
(B) TYPE: amino acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:12:

```
Lys Arg Lys Ala Gln Ile Ala Ala Ile Gly Gln Ser Ser Gly Asp Leu
 1               5                  10                  15
Val Leu Asn Val Asp Ser Asp Ser Thr Ile Ala Phe Asp Val Val Ser
            20                  25                  30
Lys Leu Ala Ser Lys Met Arg Asp Pro
        35                  40
```

(2) INFORMATION FOR SEQ ID NO:13:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 47 amino acids
(B) TYPE: amino acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:13:

```
Lys Lys Lys Ile Asn Ser His Arg Trp Leu Phe Asn Ala Phe Cys Pro
 1               5                  10                  15
Val Leu Gln Pro Thr Val Val Thr Leu Val Asp Val Gly Thr Arg Leu
            20                  25                  30
Asn Asn Thr Ala Ile Tyr Arg Leu Trp Lys Val Phe Asp Met Asp
        35                  40                  45
```

(2) INFORMATION FOR SEQ ID NO:14:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 9 amino acids
(B) TYPE: amino acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:14:

```
Ala Phe Asn Val Glu Arg Ala Cys Gln
 1               5
```

(2) INFORMATION FOR SEQ ID NO:15:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 8 amino acids
(B) TYPE: amino acid

(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:15:

Gly Asp Asp Arg His Leu Thr Asn
1 5

(2) INFORMATION FOR SEQ ID NO:16:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 amino acids
(B) TYPE: amino acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:16:

Gln Gln Thr Arg Trp Thr Lys Ser Tyr Phe
1 5 10

(2) INFORMATION FOR SEQ ID NO:17:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 26 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: unknown
(D) TOPOLOGY: unknown

(ii) MOLECULE TYPE: cDNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:17:

GCNTTYAAYG TNGARMGNGC NTGYCA 26

(2) INFORMATION FOR SEQ ID NO:18:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 24 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: unknown
(D) TOPOLOGY: unknown

(ii) MOLECULE TYPE: cDNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:18:

RTTNGTNARR TGNCKRTCRT CNCC 24

(2) INFORMATION FOR SEQ ID NO:19:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 30 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: unknown
(D) TOPOLOGY: unknown

(ii) MOLECULE TYPE: cDNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:19:

RAARTANSWY TTNGTCCANC KNGTYTGYTG 30

(2) INFORMATION FOR SEQ ID NO:20:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 8 amino acids
(B) TYPE: amino acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:20:

Gly Trp Gly Thr Ser Gly Arg Lys
1 5

(2) INFORMATION FOR SEQ ID NO:21:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 40 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: unknown
(D) TOPOLOGY: unknown

(ii) MOLECULE TYPE: cDNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:21:

CCCGGGCAAG ATGGATTGTG AGAGGTTTCT ATGTGTCCTG 40

(2) INFORMATION FOR SEQ ID NO:22:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 33 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: unknown
(D) TOPOLOGY: unknown

(ii) MOLECULE TYPE: cDNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:22:

CCCGGGTCAT ACATCAAGCA CCATGTCATA CTG 33

(2) INFORMATION FOR SEQ ID NO:23:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 235 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: unknown
(D) TOPOLOGY: unknown

(ii) MOLECULE TYPE: cDNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:23:

```
GTCTTATTTT GGGTGTGTTC AGTGCATTAG TGGACCTCTG GGAATGTACA GAAACTCCTT     60
GTTGCATGAG TTTGTGGAAG ATTGGTACAA TCAAGAATTT ATGGGCAACC AATGTAGCTT    120
TGGTGATGAC AGGCATCTCA CGAACCGGGT GCTGAGCCTG GGCTATGCAA CAAAATACAC    180
AGCTCGATCT AAGTGCCTTA CTGAAACACC TATAGAATAT CTCAGATGGC TAAAC         235
```

(2) INFORMATION FOR SEQ ID NO:24:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 78 amino acids
(B) TYPE: amino acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:24:

```
Ser Tyr Phe Gly Cys Val Gln Cys Ile Ser Gly Pro Leu Gly Met Tyr
 1               5                  10                  15
Arg Asn Ser Leu Leu Gln Gln Phe Leu Glu Asp Trp Tyr His Gln Lys
            20                  25                  30
Phe Leu Gly Ser Lys Cys Ser Phe Gly Asp Asp Arg His Leu Thr Asn
        35                  40                  45
Arg Val Leu Ser Leu Gly Tyr Arg Thr Lys Tyr Thr Ala Arg Ser Lys
    50                  55                  60
Cys Leu Thr Glu Thr Pro Thr Lys Tyr Leu Arg Trp Leu Asn
65                  70                  75
```

(2) INFORMATION FOR SEQ ID NO:25:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 235 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: unknown
(D) TOPOLOGY: unknown

(ii) MOLECULE TYPE: cDNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:25:

```
GTCCTACTTT GGCTGTGTGC AGTGTATTAG TGGGCCCTTG GGCATGTACC GCAACAGCCT     60
CCTCCAGCAG TTCCTGGAGG ACTGGTACCA TCAGAAGTTC CTAGGCAGCA AGTGCAGCTT    120
CGGGGATGAC CGGCACCTCA CCAACCGAGT CCTGAGCCTT GGCTACCGAA CTAAGTATAC    180
```

CGCGCGCTCC AAGTGCCTCA CAGAGACCCC CACTAAGTAC CTCCGGTGGC TCAAC 235

(2) INFORMATION FOR SEQ ID NO:26:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 235 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: unknown
(D) TOPOLOGY: unknown

(ii) MOLECULE TYPE: cDNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:26:

GTCCTACTTT GGCTGTGTGC AATGTATTAG TGGGCCTTTG GGCATGTACC GCAACAGCCT 60
CCTTCAGCAG TTCCTGGAGG ATTGGTACCA TCAGAAGTTC CTAGGCAGCA AGTGCAGCTT 120
TGGGGATGAT CGGCACCTTA CCAACCGAGT CCTGAGTCTT GGCTACCGGA CTAAGTATAC 180
AGCACGCTCT AAGTGCCTCA CAGAGACCCC CACTAGGTAC CTTCGATGGC TCAAT 235

(2) INFORMATION FOR SEQ ID NO:27:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 78 amino acids
(B) TYPE: amino acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:27:

Ser Tyr Phe Gly Cys Val Gln Cys Ile Ser Gly Pro Leu Gly Met Tyr
1 5 10 15
Arg Asn Ser Leu Leu Gln Gln Phe Leu Glu Asp Trp Tyr His Gln Lys
20 25 30
Phe Leu Gly Ser Lys Cys Ser Phe Gly Asp Asp Arg His Leu Thr Asn
35 40 45
Arg Val Leu Ser Leu Gly Tyr Arg Thr Lys Tyr Thr Ala Arg Ser Lys
50 55 60
Cys Leu Thr Glu Thr Pro Thr Lys Tyr Leu Arg Trp Leu Asn
65 70 75

(2) INFORMATION FOR SEQ ID NO:28:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 78 amino acids
(B) TYPE: amino acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:28:

Ser Tyr Phe Gly Cys Val Gln Cys Ile Ser Gly Pro Leu Gly Met Tyr

```
 1               5                  10                  15
Arg Asn Ser Leu Leu Gln Gln Phe Leu Glu Asp Trp Tyr His Gln Lys
            20                  25                  30
Phe Leu Gly Ser Lys Cys Ser Phe Gly Asp Asp Arg His Leu Thr Asn
        35                  40                  45
Arg Val Leu Ser Leu Gly Tyr Arg Thr Lys Tyr Thr Ala Arg Ser Lys
    50                  55                  60
Cys Leu Thr Glu Thr Pro Thr Arg Tyr Leu Arg Trp Leu Asn
65                  70                  75
```

(2) INFORMATION FOR SEQ ID NO:29:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 190 amino acids
(B) TYPE: amino acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:29:

```
Ser Tyr Phe Gly Cys Val Gln Cys Ile Ser Gly Pro Leu Gly Met Tyr
 1               5                  10                  15
Arg Asn Ser Leu Leu Gln Gln Phe Leu Glu Asp Trp Tyr His Gln Lys
            20                  25                  30
Phe Leu Gly Ser Lys Cys Ser Phe Gly Asp Asp Arg His Leu Thr Asn
        35                  40                  45
Arg Val Leu Ser Leu Gly Tyr Arg Thr Lys Tyr Thr Ala Arg Ser Lys
    50                  55                  60
Cys Leu Thr Glu Thr Pro Thr Lys Tyr Leu Arg Trp Leu Asn Gln Gln
65                  70                  75                  80
Thr Arg Trp Ser Lys Ser Tyr Phe Arg Glu Trp Leu Tyr Asn Ser Leu
                85                  90                  95
Trp Phe His Lys His His Leu Trp Met Thr Tyr Glu Ser Val Val Thr
            100                 105                 110
Gly Phe Phe Pro Phe Phe Leu Ile Ala Thr Val Ile Gln Leu Phe Tyr
        115                 120                 125
Arg Gly Arg Ile Trp Asn Ile Leu Leu Phe Leu Leu Thr Val Gln Leu
    130                 135                 140
Val Gly Ile Ile Lys Ala Thr Tyr Ala Cys Phe Leu Arg Gly Asn Ala
145                 150                 155                 160
Glu Met Ile Phe Met Ser Tyr Leu Ser Leu Leu Tyr Met Ser Ser Leu
                165                 170                 175
Leu Pro Ala Lys Ile Phe Ala Ile Ala Thr Ile Asn Lys Ser
            180                 185                 190
```

(2) INFORMATION FOR SEQ ID NO:30:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 190 amino acids
(B) TYPE: amino acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:30:

```
Ser Tyr Phe Gly Cys Val Gln Cys Ile Ser Gly Pro Leu Gly Met Tyr
 1               5                  10                  15
Arg Asn Ser Leu Leu Gln Gln Phe Leu Glu Asp Trp Tyr His Gln Lys
            20                  25                  30
Phe Leu Gly Ser Lys Cys Ser Phe Gly Asp Asp Arg His Leu Thr Asn
        35                  40                  45
Arg Val Leu Ser Leu Gly Tyr Arg Thr Lys Tyr Thr Ala Arg Ser Lys
    50                  55                  60
Cys Leu Thr Glu Thr Pro Thr Arg Tyr Leu Arg Trp Leu Asn Gln Gln
65                  70                  75                  80
Thr Arg Trp Ser Lys Ser Tyr Phe Arg Glu Trp Leu Tyr Asn Ser Leu
                85                  90                  95
Trp Phe His Lys His His Leu Trp Met Thr Tyr Glu Ser Val Val Thr
            100                 105                 110
Gly Phe Phe Pro Phe Phe Leu Ile Ala Thr Val Ile Gln Leu Phe Tyr
        115                 120                 125
Arg Gly Arg Ile Trp Asn Ile Leu Leu Phe Leu Leu Thr Val Gln Leu
    130                 135                 140
Val Gly Ile Ile Lys Ala Thr Tyr Ala Cys Phe Leu Arg Gly Asn Ala
145                 150                 155                 160
Glu Met Ile Phe Met Ser Tyr Leu Ser Leu Leu Tyr Met Ser Ser Leu
                165                 170                 175
Leu Pro Ala Lys Ile Phe Ala Ile Ala Thr Ile Asn Lys Ser
            180                 185                 190
```

(2) INFORMATION FOR SEQ ID NO:31:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 1665 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: unknown
(D) TOPOLOGY: unknown

(ii) MOLECULE TYPE: cDNA
(ix) FEATURE:

(A) NAME/KEY: Coding Sequence
(B) LOCATION: 1...1662
(D) OTHER INFORMATION:

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:31:

```
ATG CCG GTG CAG CTG ACT ACA GCC CTG CGT GTG GTG GGC ACC AGT CTG      48
Met Pro Val Gln Leu Thr Thr Ala Leu Arg Val Val Gly Thr Ser Leu
 1               5                  10                  15

TTT GCC CTG GTA GTG CTG GGA GGC ATC CTG GCG GCC TAT GTG ACA GGC      96
Phe Ala Leu Val Val Leu Gly Gly Ile Leu Ala Ala Tyr Val Thr Gly
            20                  25                  30
```

```
TAC CAG TTT ATC CAC ACA GAA AAG CAC TAC CTG TCC TTT GGC CTC TAC     144
Tyr Gln Phe Ile His Thr Glu Lys His Tyr Leu Ser Phe Gly Leu Tyr
        35                  40                  45

GGT GCC ATC CTG GGT CTA CAT CTG CTC ATC CAG AGC CTG TTT GCC TTC     192
Gly Ala Ile Leu Gly Leu His Leu Leu Ile Gln Ser Leu Phe Ala Phe
    50                  55                  60

CTG GAG CAC CGT CGA ATG CGC AGG GCA GGG CGC CCC CTC AAG CTG CAC     240
Leu Glu His Arg Arg Met Arg Arg Ala Gly Arg Pro Leu Lys Leu His
65                  70                  75                  80

TGC TCC CAG AGG TCG CGT TCA GTG GCA CTC TGC ATT GCT GCC TAC CAA     288
Cys Ser Gln Arg Ser Arg Ser Val Ala Leu Cys Ile Ala Ala Tyr Gln
                85                  90                  95

GAG GAC CCC GAA TAC CTG CGC AAG TGC CTT CGC TCA GCT CAG CGC ATT     336
Glu Asp Pro Glu Tyr Leu Arg Lys Cys Leu Arg Ser Ala Gln Arg Ile
            100                 105                 110

GCC TTT CCA AAC CTC AAG GTG GTC ATG GTA GTG GAT GGC AAT CGC CAG     384
Ala Phe Pro Asn Leu Lys Val Val Met Val Val Asp Gly Asn Arg Gln
        115                 120                 125

GAA GAT ACC TAC ATG TTG GAC ATC TTC CAT GAG GTG CTG GGT GGC ACT     432
Glu Asp Thr Tyr Met Leu Asp Ile Phe His Glu Val Leu Gly Gly Thr
    130                 135                 140

GAG CAA GCT GGC TTC TTT GTG TGG CGT AGC AAT TTC CAT GAG GCG GGT     480
Glu Gln Ala Gly Phe Phe Val Trp Arg Ser Asn Phe His Glu Ala Gly
145                 150                 155                 160

GAA GGA GAG ACA GAG GCC AGC CTG CAG GAA GGC ATG GAG CGT GTG CGA     528
Glu Gly Glu Thr Glu Ala Ser Leu Gln Glu Gly Met Glu Arg Val Arg
                165                 170                 175

GCT GTG GTG TGG GCC AGC ACC TTC TCA TGC ATC ATG CAG AAG TGG GGG     576
Ala Val Val Trp Ala Ser Thr Phe Ser Cys Ile Met Gln Lys Trp Gly
            180                 185                 190

GGC AAG CGT GAG GTC ATG TAC ACT GCC TTC AAG GCC CTT GGC AAC TCA     624
Gly Lys Arg Glu Val Met Tyr Thr Ala Phe Lys Ala Leu Gly Asn Ser
        195                 200                 205

GTG GAC TAC ATC CAG GTG TGT GAC TCT GAC ACT GTG CTG GAC CCA GCC     672
Val Asp Tyr Ile Gln Val Cys Asp Ser Asp Thr Val Leu Asp Pro Ala
    210                 215                 220

TGC ACC ATT GAG ATG CTT CGA GTC TTG GAA GAA GAT CCC CAA GTA GGA     720
Cys Thr Ile Glu Met Leu Arg Val Leu Glu Glu Asp Pro Gln Val Gly
225                 230                 235                 240

GGT GTT GGA GGA GAT GTC CAA ATC CTC AAC AAG TAT GAT TCA TGG ATC     768
Gly Val Gly Gly Asp Val Gln Ile Leu Asn Lys Tyr Asp Ser Trp Ile
                245                 250                 255
```

```
TCC TTC CTG AGC AGT GTG AGG TAC TGG ATG GCT TTC AAC GTG GAG CGG      816
Ser Phe Leu Ser Ser Val Arg Tyr Trp Met Ala Phe Asn Val Glu Arg
            260                 265                 270

GCC TGC CAG TCC TAC TTT GGC TGT GTG CAA TGT ATT AGT GGG CCT TTG      864
Ala Cys Gln Ser Tyr Phe Gly Cys Val Gln Cys Ile Ser Gly Pro Leu
        275                 280                 285

GGC ATG TAC CGC AAC AGC CTC CTT CAG CAG TTC CTG GAG GAT TGG TAC      912
Gly Met Tyr Arg Asn Ser Leu Leu Gln Gln Phe Leu Glu Asp Trp Tyr
    290                 295                 300

CAT CAG AAG TTC CTA GGC AGC AAG TGC AGC TTT GGG GAT GAT CGG CAC      960
His Gln Lys Phe Leu Gly Ser Lys Cys Ser Phe Gly Asp Asp Arg His
305                 310                 315                 320

CTT ACC AAC CGA GTC CTG AGT CTT GGC TAC CGG ACT AAG TAT ACA GCA     1008
Leu Thr Asn Arg Val Leu Ser Leu Gly Tyr Arg Thr Lys Tyr Thr Ala
                325                 330                 335

CGC TCT AAG TGC CTC ACA GAG ACC CCC ACT AGG TAC CTT CGA TGG CTC     1056
Arg Ser Lys Cys Leu Thr Glu Thr Pro Thr Arg Tyr Leu Arg Trp Leu
            340                 345                 350

AAT CAG CAA ACC CGC TGG AGC AAG TCT TAC TTT CGG GAA TGG CTC TAC     1104
Asn Gln Gln Thr Arg Trp Ser Lys Ser Tyr Phe Arg Glu Trp Leu Tyr
        355                 360                 365

AAT TCT CTG TGG TTC CAT AAG CAC CAC CTC TGG ATG ACC TAT GAA TCA     1152
Asn Ser Leu Trp Phe His Lys His His Leu Trp Met Thr Tyr Glu Ser
    370                 375                 380

GTG GTC ACA GGT TTC TTC CCA TTC TTC CTC ATT GCT ACA GTC ATA CAA     1200
Val Val Thr Gly Phe Phe Pro Phe Phe Leu Ile Ala Thr Val Ile Gln
385                 390                 395                 400

CTT TTC TAC CGT GGC CGC ATC TGG AAC ATT CTC CTC TTC CTG CTA ACA     1248
Leu Phe Tyr Arg Gly Arg Ile Trp Asn Ile Leu Leu Phe Leu Leu Thr
                405                 410                 415

GTG CAG CTG GTG GGC ATT ATC AAG GCT ACC TAT GCC TGC TTC CTT CGA     1296
Val Gln Leu Val Gly Ile Ile Lys Ala Thr Tyr Ala Cys Phe Leu Arg
            420                 425                 430

GGC AAT GCA GAG ATG ATC TTC ATG TCC CTC TAC TCC CTT CTC TAT ATG     1344
Gly Asn Ala Glu Met Ile Phe Met Ser Leu Tyr Ser Leu Leu Tyr Met
        435                 440                 445

TCC AGC CTC TTG CCA GCC AAG ATC TTT GCT ATT GCT ACC ATC AAC AAG     1392
Ser Ser Leu Leu Pro Ala Lys Ile Phe Ala Ile Ala Thr Ile Asn Lys
    450                 455                 460

TCT GGC TGG GGC ACT TCT GGC AGG AAA ACC ATT GTC GTG AAC TTC ATT     1440
Ser Gly Trp Gly Thr Ser Gly Arg Lys Thr Ile Val Val Asn Phe Ile
465                 470                 475                 480
```

```
GGC CTA ATC CCC GTG TCC ATC TGG GTG GCA GTT CTT CTA GGG GGG TTA    1488
Gly Leu Ile Pro Val Ser Ile Trp Val Ala Val Leu Leu Gly Gly Leu
                485                 490                 495

GCC TAC ACA GCT TAT TGC CAG GAC CTG TTC AGT GAG ACC GAG CTA GCC    1536
Ala Tyr Thr Ala Tyr Cys Gln Asp Leu Phe Ser Glu Thr Glu Leu Ala
            500                 505                 510

TTC CTA GTC TCT GGG GCC ATC CTG TAT GGC TGC TAC TGG GTG GCC CTC    1584
Phe Leu Val Ser Gly Ala Ile Leu Tyr Gly Cys Tyr Trp Val Ala Leu
        515                 520                 525

CTC ATG CTG TAT CTG GCC ATT ATT GCC CGG AGG TGT GGG AAG AAG CCA    1632
Leu Met Leu Tyr Leu Ala Ile Ile Ala Arg Arg Cys Gly Lys Lys Pro
    530                 535                 540

GAA CAG TAT AGC CTG GCT TTT GCG GAG GTG TGA                        1665
Glu Gln Tyr Ser Leu Ala Phe Ala Glu Val
545                 550
```

(2) INFORMATION FOR SEQ ID NO:32:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 554 amino acids
(B) TYPE: amino acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein
(v) FRAGMENT TYPE: internal

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:32:

```
Met Pro Val Gln Leu Thr Thr Ala Leu Arg Val Val Gly Thr Ser Leu
 1               5                  10                  15
Phe Ala Leu Val Val Leu Gly Gly Ile Leu Ala Ala Tyr Val Thr Gly
            20                  25                  30
Tyr Gln Phe Ile His Thr Glu Lys His Tyr Leu Ser Phe Gly Leu Tyr
        35                  40                  45
Gly Ala Ile Leu Gly Leu His Leu Leu Ile Gln Ser Leu Phe Ala Phe
    50                  55                  60
Leu Glu His Arg Arg Met Arg Arg Ala Gly Arg Pro Leu Lys Leu His
65                  70                  75                  80
Cys Ser Gln Arg Ser Arg Ser Val Ala Leu Cys Ile Ala Ala Tyr Gln
                85                  90                  95
Glu Asp Pro Glu Tyr Leu Arg Lys Cys Leu Arg Ser Ala Gln Arg Ile
            100                 105                 110
Ala Phe Pro Asn Leu Lys Val Val Met Val Val Asp Gly Asn Arg Gln
        115                 120                 125
Glu Asp Thr Tyr Met Leu Asp Ile Phe His Glu Val Leu Gly Gly Thr
    130                 135                 140
Glu Gln Ala Gly Phe Phe Val Trp Arg Ser Asn Phe His Glu Ala Gly
145                 150                 155                 160
Glu Gly Glu Thr Glu Ala Ser Leu Gln Glu Gly Met Glu Arg Val Arg
```

```
                165                 170                 175
Ala Val Val Trp Ala Ser Thr Phe Ser Cys Ile Met Gln Lys Trp Gly
            180                 185                 190
Gly Lys Arg Glu Val Met Tyr Thr Ala Phe Lys Ala Leu Gly Asn Ser
        195                 200                 205
Val Asp Tyr Ile Gln Val Cys Asp Ser Asp Thr Val Leu Asp Pro Ala
    210                 215                 220
Cys Thr Ile Glu Met Leu Arg Val Leu Glu Glu Asp Pro Gln Val Gly
225                 230                 235                 240
Gly Val Gly Gly Asp Val Gln Ile Leu Asn Lys Tyr Asp Ser Trp Ile
                245                 250                 255
Ser Phe Leu Ser Ser Val Arg Tyr Trp Met Ala Phe Asn Val Glu Arg
            260                 265                 270
Ala Cys Gln Ser Tyr Phe Gly Cys Val Gln Cys Ile Ser Gly Pro Leu
        275                 280                 285
Gly Met Tyr Arg Asn Ser Leu Leu Gln Gln Phe Leu Glu Asp Trp Tyr
    290                 295                 300
His Gln Lys Phe Leu Gly Ser Lys Cys Ser Phe Gly Asp Asp Arg His
305                 310                 315                 320
Leu Thr Asn Arg Val Leu Ser Leu Gly Tyr Arg Thr Lys Tyr Thr Ala
                325                 330                 335
Arg Ser Lys Cys Leu Thr Glu Thr Pro Thr Arg Tyr Leu Arg Trp Leu
            340                 345                 350
Asn Gln Gln Thr Arg Trp Ser Lys Ser Tyr Phe Arg Glu Trp Leu Tyr
        355                 360                 365
Asn Ser Leu Trp Phe His Lys His His Leu Trp Met Thr Tyr Glu Ser
    370                 375                 380
Val Val Thr Gly Phe Phe Pro Phe Phe Leu Ile Ala Thr Val Ile Gln
385                 390                 395                 400
Leu Phe Tyr Arg Gly Arg Ile Trp Asn Ile Leu Leu Phe Leu Leu Thr
                405                 410                 415
Val Gln Leu Val Gly Ile Ile Lys Ala Thr Tyr Ala Cys Phe Leu Arg
            420                 425                 430
Gly Asn Ala Glu Met Ile Phe Met Ser Leu Tyr Ser Leu Leu Tyr Met
        435                 440                 445
Ser Ser Leu Leu Pro Ala Lys Ile Phe Ala Ile Ala Thr Ile Asn Lys
    450                 455                 460
Ser Gly Trp Gly Thr Ser Gly Arg Lys Thr Ile Val Val Asn Phe Ile
465                 470                 475                 480
Gly Leu Ile Pro Val Ser Ile Trp Val Ala Val Leu Leu Gly Gly Leu
                485                 490                 495
Ala Tyr Thr Ala Tyr Cys Gln Asp Leu Phe Ser Glu Thr Glu Leu Ala
            500                 505                 510
Phe Leu Val Ser Gly Ala Ile Leu Tyr Gly Cys Tyr Trp Val Ala Leu
        515                 520                 525
Leu Met Leu Tyr Leu Ala Ile Ile Ala Arg Arg Cys Gly Lys Lys Pro
    530                 535                 540
Glu Gln Tyr Ser Leu Ala Phe Ala Glu Val
545                 550
```

(2) INFORMATION FOR SEQ ID NO:33:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 9 amino acids
(B) TYPE: amino acid

(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:33:

```
Arg Trp Leu Asn Gln Gln Thr Arg Trp
 1               5
```

(2) INFORMATION FOR SEQ ID NO:34:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 24 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: unknown
(D) TOPOLOGY: unknown

(ii) MOLECULE TYPE: cDNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:34:

```
TACTGGATGG CTTTCAACGT GGAG                                          24
```

(2) INFORMATION FOR SEQ ID NO:35:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 43 amino acids
(B) TYPE: amino acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:35:

```
Lys Arg Glu Val Met Tyr Thr Ala Phe Lys Ala Leu Gly Asn Ser Val
 1               5                  10                  15
Asp Tyr Ile Gln Val Cys Asp Ser Asp Thr Val Leu Asp Pro Ala Cys
            20                  25                  30
Thr Ile Glu Met Leu Arg Val Leu Glu Glu Asp
        35                  40
```

(2) INFORMATION FOR SEQ ID NO:36:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 55 amino acids
(B) TYPE: amino acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:36:

```
Lys Cys Ser Phe Gly Asp Asp Arg His Leu Thr Asn Arg Val Leu Ser
 1               5                  10                  15
Leu Gly Tyr Arg Thr Lys Tyr Thr Ala Arg Ser Lys Cys Leu Thr Glu
            20                  25                  30
Thr Pro Thr Arg Tyr Leu Arg Trp Leu Asn Gln Gln Thr Arg Trp Ser
        35                  40                  45
Lys Ser Tyr Phe Arg Glu Trp
    50                  55
```

(2) INFORMATION FOR SEQ ID NO:37:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 24 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: unknown
(D) TOPOLOGY: unknown

(ii) MOLECULE TYPE: cDNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:37:

GTCATCCAGA GGTGGTGCTT ATGG 24

(2) INFORMATION FOR SEQ ID NO:38:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 35 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: unknown
(D) TOPOLOGY: unknown

(ii) MOLECULE TYPE: cDNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:38:

CCGAATTCAA GATGGCGGTG CAGCTGACTA CAGCC 35

(2) INFORMATION FOR SEQ ID NO:39:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 31 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:39:

CCGAATTCTC ACACCTCCGC AAAAGCCAGG C 31

(2) INFORMATION FOR SEQ ID NO:40:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 55 amino acids

(B) TYPE: amino acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:40:

```
His Cys Thr Phe Gly Asp Asp Arg His Leu Thr Asn Arg Met Leu Ser
 1               5                  10                  15
Met Gly Tyr Ala Thr Lys Tyr Thr Ser Arg Ser Arg Cys Tyr Ser Glu
            20                  25                  30
Thr Pro Ser Ser Phe Leu Arg Trp Leu Ser Gln Gln Thr Arg Trp Ser
        35                  40                  45
Lys Ser Tyr Phe Arg Glu Trp
    50                  55
```

(2) INFORMATION FOR SEQ ID NO:41:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 24 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: unknown
(D) TOPOLOGY: unknown

(ii) MOLECULE TYPE: cDNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:41:

```
TGTGCAGTGT AATTAGTGGG CCCT                                          24
```

(2) INFORMATION FOR SEQ ID NO:42:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 55 amino acids
(B) TYPE: amino acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:42:

```
Tyr Cys Thr Leu Gly Asp Asp Arg His Leu Thr Asn Arg Val Leu Ser
 1               5                  10                  15
Met Gly Tyr Arg Thr Lys Tyr Thr His Lys Ser Arg Ala Phe Ser Glu
            20                  25                  30
Thr Pro Ser Leu Tyr Leu Arg Trp Leu Asn Gln Gln Thr Arg Trp Thr
        35                  40                  45
Lys Ser Tyr Phe Arg Glu Trp
    50                  55
```

(2) INFORMATION FOR SEQ ID NO:43:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 23 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: unknown
(D) TOPOLOGY: unknown

(ii) MOLECULE TYPE: cDNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:43:

GTTGAGCCAC CGGAGGTACT TAG 23

(2) INFORMATION FOR SEQ ID NO:44:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 54 amino acids
(B) TYPE: amino acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:44:

```
Pro Val Ser Ile Gly Asp Asp Arg Cys Leu Thr Asn Tyr Ala Ile Asp
 1               5                  10                  15
Leu Gly Arg Thr Val Tyr Gln Ser Thr Ala Arg Cys Asp Thr Asp Val
            20                  25                  30
Pro Phe Gln Leu Lys Ser Tyr Leu Lys Gln Gln Asn Arg Trp Asn Lys
        35                  40                  45
Ser Phe Phe Arg Glu Ser
    50
```

(2) INFORMATION FOR SEQ ID NO:45:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 58 amino acids
(B) TYPE: amino acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:45:

```
Asn Met Tyr Leu Ala Glu Asp Arg Ile Leu Cys Trp Glu Leu Val Ala
 1               5                  10                  15
Lys Arg Asp Ala Lys Trp Val Leu Lys Tyr Val Lys Glu Ala Thr Gly
            20                  25                  30
Glu Thr Asp Val Pro Glu Asp Val Ser Glu Phe Ile Ser Gln Arg Arg
        35                  40                  45
Arg Trp Leu Asn Cys Ala Met Phe Ala Ala
    50                  55
```

(2) INFORMATION FOR SEQ ID NO:46:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 55 amino acids
(B) TYPE: amino acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:46:

```
Pro Ser Asp Phe Gly Glu Asp Arg His Leu Thr Ile Leu Met Leu Lys
 1               5                  10                  15
Ala Gly Phe Arg Thr Glu Tyr Val Pro Asp Ala Ile Val Ala Thr Val
            20                  25                  30
Val Pro Asp Thr Leu Lys Pro Tyr Leu Arg Gln Gln Leu Arg Trp Ala
        35                  40                  45
Arg Ser Thr Phe Arg Asp Thr
    50                  55
```

(2) INFORMATION FOR SEQ ID NO:47:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 45 amino acids
(B) TYPE: amino acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:47:

```
Lys Ala Gly Ala Glu Asn Ala Leu Val Arg Val Ser Ala Val Leu Thr
 1               5                  10                  15
Asn Ala Pro Phe Ile Leu Asn Leu Asp Cys Asp His Tyr Val Asn Asn
            20                  25                  30
Ser Lys Ala Val Arg Glu Ala Met Cys Phe Leu Met Asp
        35                  40                  45
```

(2) INFORMATION FOR SEQ ID NO:48:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 57 amino acids
(B) TYPE: amino acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:48:

```
Tyr Gly Ser Val Thr Glu Asp Ile Leu Thr Gly Phe Lys Met His Cys
 1               5                  10                  15
Arg Gly Trp Arg Ser Ile Tyr Cys Met Pro Leu Arg Pro Ala Phe Lys
            20                  25                  30
Gly Ser Ala Pro Ile Asn Leu Ser Asp Arg Leu His Gln Val Leu Arg
```

35 40 45
Trp Ala Leu Gly Ser Val Glu Ile Phe
50 55

(2) INFORMATION FOR SEQ ID NO:49:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 21 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:49:

GTGCTTCTGT CTCTCTACGC G 21

(2) INFORMATION FOR SEQ ID NO:50:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 24 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:50:

CCAGTCCCAA TATAGTCCAG ACTG 24

(2) INFORMATION FOR SEQ ID NO:51:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 23 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:51:

GGTGTGTTCA GTGCATTAGT GGA 23

(2) INFORMATION FOR SEQ ID NO:52:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 25 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:52:

TAGCCATCTG AGATATTCTA TAGGT 25

(2) INFORMATION FOR SEQ ID NO:53:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 21 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:53:

GTCAGAGCTA CTTCCACTGT G 21

(2) INFORMATION FOR SEQ ID NO:54:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 21 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:54:

AAGGAGGAGG GCGTCTCCGA G 21

(2) INFORMATION FOR SEQ ID NO:55:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 2108 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: mRNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:55:

GAATTCCGGG CGCCCGGGAC TCACGCCCCT TCCTTTCCCC TCTCGCTCCC AGCAGGACGC 60
GCCCAAGCCC ACTCCTGCAG CCCGCCGCTG CTCCGGCCTG GCCCGGAGGG TGCTGACCAT 120
CGCCTTCGCC CTGCTCATCC TGGCCCTCAT GACCTGGGCC TACGCCGCCG GGGTGCCGCT 180
GGCCTCCGAT CGCTACGGCC TCCTGGCCTT CGGCCTCTAC GGGGCCTTCC TTTCAGCGCA 240
CCTGGTGGCG CAGAGCCTCT TCGCGTACCT GGAGCACCGG CGGGTGGCGG CGGCGGCGCG 300
GGGGCCGCTG GATGCAGCCA CCGCGCGCAG TGTGGCGCTG ACCATCTCCG CCTACCAGGA 360
GGACCCCGCG TACCTGCGCC AGTGCCTGGC GTCCGCCCGC GCCCTGCTGT ACCCGCGCGC 420
GCGCGTGCGC GTCCTCATGG TGGTGGATGG CAACCGCGCC GAGGACCTCT ACATGGTCGA 480
CATGTTCCGC GAGGTCTTCG CTGACGAGGA CCCCGCCACG TACGTGTGGG ACGGCAACTA 540
CCACCAGCCC TGGGAACCCG CGGCGGCGGG CGCGGTGGGC GCCGGAGCCT ATCGGGAGGT 600
GGAGGCGGAG GATCCTGGGC GGCTGGCAGT GGAGGCGCTG GTGAGGACTC GCAGGTGCGT 660

```
GTGCGTGGCG CAGCGCTGGG GCGGCAAGCG CGAGGTCATG TACACAGCCT TCAAGGCGCT    720
CGGAGATTCG GTGGACTACG TGCAGGTCTG TGACTCGGAC ACAAGGTTGG ACCCCATGGC    780
ACTGCTGGAG CTCGTGCGGG TACTGGACGA GGACCCCCGG GTAGGGGCTG TTGGTGGGGA    840
TGTGCGGATC CTTAACCCTC TGGACTCCTG GGTCAGCTTC CTAAGCAGCC TGCGATACTG    900
GGTAGCCTTC AATGTGGAGC GGGCTTGTCA GAGCTACTTC CACTGTGTAT CCTGCATCAG    960
CGGTCCTCTA GGCCTATATA GGAATAACCT CTTGCAGCAG TTTCTTGAGG CCTGGTACAA   1020
CCAGAAGTTC CTGGGTACCC ACTGTACTTT TGGGGATGAC CGGCACCTCA CCAACCGCAT   1080
GCTCAGCATG GGTTATGCTA CCAAGTACAC CTCCAGGTCC CGCTGCTACT CAGAGACGCC   1140
CTCGTCCTTC CTGCGGTGGC TGAGCCAGCA GACACGCTGG TCCAAGTCGT ACTTCCGTGA   1200
GTGGCTGTAC AACGCGCTCT GGTGGCACCG GCACCATGCG TGGATGACCT ACGAGGCGGT   1260
GGTCTCCGGC CTGTTCCCCT TCTTCGTGGC GGCCACTGTG CTGCGTCTGT TCTACGCGGG   1320
CCGCCCTTGG GCGCTGCTGT GGGTGCTGCT GTGCGTGCAG GGCGTGGCAC TGGCCAAGGC   1380
GGCCTTCGCG GCCTGGCTGC GGGGCTGCCT GCGCATGGTG CTTCTGTCGC TCTACGCGCC   1440
CCTCTACATG TGTGGCCTCC TGCCTGCCAA GTTCCTGGCG CTAGTCACCA TGAACCAGAG   1500
TGGCTGGGGC ACCTCGGGCC GGCGGAAGCT GGCCGCTAAC TACGTCCCTC TGCTGCCCCT   1560
GGCGCTCTGG GCGCTGCTGC TGCTTGGGGG CCTGGTCCGC AGCGTAGCAC ACGAGGCCAG   1620
GGCCGACTGG AGCGGCCCTT CCCGCGCAGC CGAGGCCTAC CACTTGGCCG CGGGGGCCGG   1680
CGCCTACGTG GGCTACTGGG TGGCCATGTT GACGCTGTAC TGGGTGGGCG TGCGGAGGCT   1740
TTGCCGGCGG CGGACCGGGG GCTACCGCGT CCAGGTGTGA GTCCAGCCAC GCGGATGCCG   1800
CCTCAAGGGT CTTCAGGGGA GGCCAGAGGA GAGCTGCTGG GCCCCGAGCC ACGAACTTGC   1860
TGGGTGGTTC TCTGGGCCTC AGTTTCCCTC CTCTGCCAAA CGAGGGGGTC AGCCCAAGAT   1920
TCTTCAGTCT GGACTATATT GGGACTGGGA CTTCTGGGTC TCCAGGGAGG GTATTTATTG   1980
GTCAGGATGT GGGATTTGAG GAGTGGAGGG GAAGGGTCC TGCTTTCTCC TCGTTCTTAT   2040
TTAATCTCCA TTTCTACTGT GTGATCAGGA TGTAATAAAG AATTTTATTT ATTTTCAAAA   2100
AAAAAAAA                                                           2108
```

(2) INFORMATION FOR SEQ ID NO:56:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 amino acids
(B) TYPE: amino acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:56:

```
Asn Met Tyr Leu Ala Glu Asp Arg Ile Leu
 1               5                  10
```

(2) INFORMATION FOR SEQ ID NO:57:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 amino acids
(B) TYPE: amino acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:57:

```
Asn Gln Cys Ser Phe Gly Asp Asp Arg His
 1               5                  10
```

WHAT IS CLAIMED IS:

1. An isolated and purified DNA molecule comprising a preselected DNA segment encoding hyaluronan synthase-2, a biologically active variant thereof or a biologically active subunit of the variant.

2. The DNA molecule of claim 1 wherein the preselected DNA segment encodes murine hyaluronan synthase-2.

3. The DNA molecule of claim 1 or 2 wherein the preselected DNA segment encodes a hyaluronan synthase-2 having SEQ ID NO:2.

4. The DNA molecule of claim 1 wherein the preselected DNA segment comprises SEQ ID NO:1.

5. The DNA molecule of claim 1 wherein the preselected DNA segment encodes human hyaluronan synthase-2.

6. The DNA molecule of claim 1 or 5 wherein the preselected DNA segment comprises SEQ ID NO:23.

7. An isolated and purified DNA molecule comprising SEQ ID NO:1.

8. An isolated and purified DNA molecule comprising a preselected DNA segment encoding hyaluronan synthase-3, or a biologically active subunit or variant thereof.

9. The DNA molecule of claim 8 wherein the preselected DNA segment encodes murine hyaluronan synthase-3.

10. The DNA molecule of claim 8 wherein the preselected DNA segment encodes a hyaluronan synthase-3 having SEQ ID NO:32.

11. The DNA molecule of claim 8 wherein the preselected DNA segment comprises SEQ ID NO:31.

12. The DNA molecule of claim 8 wherein the preselected DNA segment encodes human hyaluronan synthase-3.

13. The DNA molecule of claim 8 wherein the preselected DNA segment comprises SEQ ID NO:25.

14. The DNA molecule of claim 8 wherein the preselected DNA segment encodes a polypeptide comprising SEQ ID NO:29.

15. A primer or a probe, having at least about 15 nucleotides, wherein the primer or probe has at least about 80% identity to the DNA molecule of claim 8.

16. An expression cassette comprising a promoter operably linked to a preselected DNA segment encoding hyaluronan synthase-2.

17. An expression cassette comprising a promoter operably linked to a preselected DNA segment encoding hyaluronan synthase-3.

18. A host cell, the genome of which is augmented by a preselected DNA segment encoding hyaluronan synthase-2.

19. A host cell, the genome of which is augmented by a preselected DNA segment encoding hyaluronan synthase-3.

20. A method to produce hyaluronan synthase-2, comprising: culturing a host cell transformed with a nucleic acid molecule comprising a DNA segment encoding hyaluronan synthase-2 operably linked to a promoter, so that said host cell expresses said hyaluronan synthase-2.

21. The method of claim 20 further comprising isolating hyaluronan synthase-2 from the host cell.

22. A method to produce hyaluronan synthase-3, comprising: culturing a host cell transformed with a nucleic acid molecule comprising a DNA segment encoding hyaluronan synthase-3 operably linked to a promoter, so that said host cell expresses said hyaluronan synthase-3.

23. The method of claim 22 further comprising isolating hyaluronan synthase-3 from the host cell.

24. A method of altering the amount of hyaluronan produced by a cell, comprising:
    (a) introducing into a host cell a preselected DNA segment encoding hyaluronan synthase-2 operably linked to a promoter functional in the host cell so as to yield a transformed host cell; and
    (b) expressing the preselected DNA segment in the transformed host cell in an amount that alters the amount of hyaluronan produced by the transformed cell relative to the amount of hyaluronan produced by a corresponding untransformed cell.

25. A method of altering the amount of hyaluronan produced by a cell, comprising:
    (a) introducing into a host cell a preselected DNA segment encoding hyaluronan synthase-3 operably linked to a promoter functional in the host cell so as to yield a transformed host cell; and

(b) expressing the preselected DNA segment in the transformed host cell in an amount that alters the amount of hyaluronan produced by the transformed cell relative to the amount of hyaluronan produced by a corresponding untransformed cell.

26. The method of claim 24 or 25 wherein the amount of hyaluronan produced by the transformed host cell is increased relative to the amount of hyaluronan produced by the corresponding untransformed host cell.

27. The method of claim 24 or 25 wherein the amount of hyaluronan produced by the transformed host cell is decreased relative to the amount of hyaluronan produced by the corresponding untransformed host cell.

28. Isolated, purified hyaluronan synthase-2 polypeptide, or a biologically active subunit or variant thereof.

29. The hyaluronan synthase-2 polypeptide of claim 28 having SEQ ID NO:2.

30. Isolated, purified hyaluronan synthase-3 polypeptide, or a biologically active subunit or variant thereof.

31. The hyaluronan synthase-3 polypeptide of claim 31 having SEQ ID NO:32.

32. A method to prevent or treat a condition associated with an alteration in hyaluronan synthesis or extracellular accumulation, comprising: administering to a mammal afflicted with, or at risk of, said condition an amount of mammalian hyaluronan synthase-2 effective to alter hyaluronan synthesis or extracellular accumulation.

33. A method to prevent or treat a condition associated with an alteration in hyaluronan synthesis or extracellular accumulation, comprising: administering to a mammal afflicted with, or at risk of, said condition an amount of mammalian hyaluronan synthase-3 effective to alter hyaluronan synthesis or extracellular accumulation.

34. A method to identify a mammal afflicted with, or at risk of, a condition associated with aberrant hyaluronan synthesis or extracellular accumulation, comprising:

(a) contacting an agent that binds to mammalian hyaluronan synthase-2 with a mammalian sample suspected of containing hyaluronan synthase-2 so as to form a complex; and

(b) detecting or determining the presence or amount of complex formation and correlating the presence or amount of complex formation with the presence or absence of the condition.

35. A method to identify a mammal afflicted with, or at risk of, a condition associated with aberrant hyaluronan synthesis or extracellular accumulation, comprising:

(a) contacting an agent that binds to mammalian hyaluronan synthase-3 with a mammalian sample suspected of containing hyaluronan synthase-3 so as to form a complex; and

(b) detecting or determining the presence or amount of complex formation and correlating the presence or amount of complex formation with the presence or absence of the condition.

36. A method for detecting hyaluronan synthase-2 DNA, comprising:

(a) contacting an amount of DNA obtained by reverse transcription of RNA from a mammalian physiological sample which comprises cells suspected of containing hyaluronan synthase-2 RNA, with an amount of at least two oligonucleotides under

conditions effective to amplify the DNA by a polymerase chain reaction so as to yield an amount of amplified hyaluronan synthase-2 DNA, wherein at least one oligonucleotide is an hyaluronan synthase-2-specific oligonucleotide; and

(b) detecting the presence or amount of the amplified hyaluronan synthase-2 DNA.

37. A method for detecting hyaluronan synthase-3 DNA, comprising:

(a) contacting an amount of DNA obtained by reverse transcription of RNA from a mammalian physiological sample which comprises cells suspected of containing hyaluronan synthase-3 RNA, with an amount of at least two oligonucleotides under conditions effective to amplify the DNA by a polymerase chain reaction so as to yield an amount of amplified hyaluronan synthase-3 DNA, wherein at least one oligonucleotide is an hyaluronan synthase-3-specific oligonucleotide; and

(b) detecting the presence or amount of the amplified hyaluronan synthase-3 DNA.

38. A method for detecting a condition associated with aberrant hyaluronan synthesis or extracellular accumulation, comprising:

(a) contacting an amount of DNA obtained by reverse transcription of RNA from a mammalian physiological sample which comprises cells suspected of containing hyaluronan synthase-2 RNA, with an amount of at least two oligonucleotides under conditions effective to amplify the DNA by a polymerase chain reaction so as to yield an amount of amplified hyaluronan synthase-2 DNA, wherein at least one oligonucleotide is an hyaluronan synthase-2-specific oligonucleotide; and

(b) detecting the presence or amount of the amplified hyaluronan synthase-2 DNA, wherein the presence or amount of hyaluronan

synthase-2 DNA is indicative of the presence of the condition in said mammal.

39. A method for detecting a condition associated with aberrant hyaluronan synthesis or extracellular accumulation, comprising:

(a) contacting an amount of DNA obtained by reverse transcription of RNA from a mammalian physiological sample which comprises cells suspected of containing hyaluronan synthase-3 RNA, with an amount of at least two oligonucleotides under conditions effective to amplify the DNA by a polymerase chain reaction so as to yield an amount of amplified hyaluronan synthase-3 DNA, wherein at least one oligonucleotide is an hyaluronan synthase-3-specific oligonucleotide; and

(b) detecting the presence or amount of the amplified hyaluronan synthase-3 DNA, wherein the presence or amount of hyaluronan synthase-3 DNA is indicative of the presence of the condition in said mammal.

40. The method of claim 36, 37, 38 or 39 wherein the physiological sample is a tissue sample.

41. The method of claim 36, 37, 38 or 39 wherein the physiological sample is a fluid.

42. A therapeutic method, comprising: administering to a mammal an amount of an agent effective to alter native hyaluronan synthase-2 activity in said mammal.

43. A therapeutic method, comprising: administering to a mammal an amount of an agent effective to alter native hyaluronan synthase-3 activity in said mammal.

44. A method to prepare hyaluronan, comprising: contacting an amount of isolated hyaluronan synthase-2 with a mixture of components under conditions effective to yield hyaluronan.

45. The method of claim 44 wherein the hyaluronan synthase-2 is obtained by the method of claim 20.

46. A method to prepare hyaluronan, comprising: contacting an amount of isolated hyaluronan synthase-3 with a mixture of components under conditions effective to yield hyaluronan.

47. The method of claim 44 wherein the hyaluronan synthase-3 is obtained by the method of claim 22.


E 10.5
E14.5
M
1/3
1/5
1/3
1/5
DEG1
EcoRI
DEG3
DEG 1/3 180 bp
DEG5
DEG 1/5 300 bp

FIG. 1


ATG
MHas300
E
TGA
AAAAA
λ5
λ7
λ8.1
λ9.2
λ11.1
λ11.2
λ11.3
λ18
λ20.2
100 bp

FIG. 2

```
1     acatgtaagaagaaggagaagtcaaggcgtctggaaagaattacccagtcctggcttcgagcagcccattga
73    acgggggacttgaaccagccaaagacttcttcattctgctcttgctagactctgctgagtcttgacccggct
145   tgtaggttgatgtgaaaagagattttgtgtcgtcggagggaaggggattggagcaaatagcaaaacaggggg
217   aaaagttaatttatctttaaagcagatataacaaagaattagaagacttaagtgcagcggaaatataaagag
289   aatattagtgaaatttcttctcaaagaggggagaaccaagcatttaaggctcccccatcttttttttttaaat
361   gttgtttttaaatttcttatttttttggccggtcgtctcaaattcatctgatttcttattacctcaatttt
433   ggaaacttccttccacgaccctccgggaccacacagacaggcggaggacgagtctatgagcaggagctgaac
505   aagATGCATTGTGAGAGGTTTCTATGTGTCCTGAGAATAATTGGAACTACACTTTTTGGAGTGTCTCTCCTC
         M  H  C  E  R  F  L  C  V  L  R  I  I  G  T  T  L  F  G  V  S  L  L     23
577   CTCGGAATCACAGCTGCTTATATTGTTGGCTACCAGTTTATCCAAACAGATAATTACTACTTCTCATTTGGA
       L  G  I  T  A  A  Y  I  V  G  Y  Q  F  I  Q  T  D  N  Y  Y  F  S  F  G    47
649   CTGTACGGTGCCTTTTTAGCCTCGCATCTCATCATCCAAAGCCTCTTTGCCTTTTTGGAACACCGGAAAATG
       L  Y  G  A  F  L  A  S  H  L  I  I  Q  S  L  F  A  F  L  E  H  R  K  M    71
721   AAGAAGTCCCTTGAAACCCCGATTAAATTGAACAAAACGGTAGCACTCTGCATCGCTGCGTACCAAGAGGAC
       K  K  S  L  E  T  P  I  K  L  N  K  T  V  A  L  C  I  A  A  Y  Q  E  D    95
793   CCTGACTACTTACGGAAATGTTTGCAATCTGTGAAAAGGCTGACCTACCCTGGGATTAAAGTCGTGATGGTC
       P  D  Y  L  R  K  C  L  Q  S  V  K  R  L  T  Y  P  G  I  K  V  V  M  V    119
865   ATCGATGGGAACTCAGACGACGACCTTTACATGATGGACATATTCAGCGAAGTTATTGGCAGGGACAAATCG
       I  D  G  N  S  D  D  D  L  Y  M  M  D  I  F  S  E  V  I  G  R  D  K  S    143
937   GCCACGTACATCTGGAAGAACAACTTTCATGAAAAGGGACCTGGTGAGACAGAAGAGTCCCATAAAGAAAGT
       A  T  Y  I  W  K  N  N  F  H  E  K  G  P  G  E  T  E  E  S  H  K  E  S    167
1009  TCACAACATGTCACCCAATTGGTCTTGTCTAACAAAAGTATTTGCATCATGCAAAAATGGGGTGGAAAGAGA
       S  Q  H  V  T  Q  L  V  L  S  N  K  S  I  C  I  M  Q  K  W  G  G  K  R    191
1081  GAAGTCATGTACACAGCCTTCAGAGCACTGGGGCGAAGCGTGGATTATGTACAGGTGTGTGACTCAGATACT
       E  V  M  Y  T  A  F  R  A  L  G  R  S  V  D  Y  V  Q  V  C  D  S  D  T    215
1153  ATGCTTGACCCTGCCTCATCTGTGGAGATGGTGAAGGTCTTAGAGGAAGACCCTATGGTTGGAGGTGTTGGA
       M  L  D  P  A  S  S  V  E  M  V  K  V  L  E  E  D  P  M  V  G  G  V  G    239
1225  GGAGATGTCCAGATTTTAAACAAGTATGATTCCTGGATCTCCTTCCTCAGCAGCGTGAGATACTGGATGGCT
       G  D  V  Q  I  L  N  K  Y  D  S  W  I  S  F  L  S  S  V  R  Y  W  M  A    263
1297  TTTAATATAGAAAGGGCCTGCCAGTCTTATTTTGGCTGTGTCCAGTGCATAAGCGGTCCTCTGGGAATGTAC
       F  N  I  E  R  A  C  Q  S  Y  F  G  C  V  Q  C  I  S  G  P  L  G  M  Y    287
1369  AGAAACTCCTTGCTGCATGAATTTGTGGAAGACTGGTACAATCAGGAATTCATGGGTAACCAATGCAGTTTT
       R  N  S  L  L  H  E  F  V  E  D  W  Y  N  Q  E  F  M  G  N  Q  C  S  F    311
1441  GGTGACGACAGGCACCTTACCAACAGGGTGTTGAGTCTGGGCTATGCAACTAAATACACGGCTCGGTCCAAG
       G  D  D  R  H  L  T  N  R  V  L  S  L  G  Y  A  T  K  Y  T  A  R  S  K    335
1513  TGCCTTACTGAAACTCCCATAGAATATCTGAGATGGCTGAACCAGCAGACCCGATGGAGCAAGTCCTACTTC
       C  L  T  E  T  P  I  E  Y  L  R  W  L  N  Q  Q  T  R  W  S  K  S  Y  F    359
1585  CGAGAGTGGCTGTACAATGCCATGTGGTTTCACAAGCATCACCTGTGGATGACCTATGAAGCTGTTATCACT
       R  E  W  L  Y  N  A  M  W  F  H  K  H  H  L  W  M  T  Y  E  A  V  I  T    383
1657  GGATTCTTTCCTTTCTTTCTCATTGCCACAGTCATCCAGCTCTTCTACAGGGGTAAAATCTGGAACATCCTC
       G  F  F  P  F  F  L  I  A  T  V  I  Q  L  F  Y  R  G  K  I  W  N  I  L    407
1729  CTCTTCCTGTTAACTGTCCAGCTAGTGGGTCTCATCAAGTCATCTTTTGCCAGCTGCCTTAGAGGAAATATC
       L  F  L  L  T  V  Q  L  V  G  L  I  K  S  S  F  A  S  C  L  R  G  N  I    431
1801  GTCATGGTATTCATGTCTCTGTATTCAGTGTTATACATGTCAAGTCTACTTCCTGCCAAGATGTTTGCAATT
       V  M  V  F  M  S  L  Y  S  V  L  Y  M  S  S  L  L  P  A  K  M  F  A  I    455
1873  GCAACCATAAACAAAGCTGGGTGGGGCACATCTGGAAGGAAGACCATTGTTGTTAATTTCATAGGACTTATT
       A  T  I  N  K  A  G  W  G  T  S  G  R  K  T  I  V  V  N  F  I  G  L  I    479
1945  CCAGTGTCCGTGTGGTTTACAATCCTTCTAGGTGGTGTAATTTTCACCATTTATAAGGAATCTAAAAAGCCA
       P  V  S  V  W  F  T  I  L  L  G  G  V  I  F  T  I  Y  K  E  S  K  K  P    503
2017  TTTTCCGAATCCAAACAGACTGTTCTCATCGTGGGAACTTTGATCTATGCATGCTACTGGGTCATGCTTTTG
       F  S  E  S  K  Q  T  V  L  I  V  G  T  L  I  Y  A  C  Y  W  V  M  L  L    527
2089  ACTCTCTATGTGGTTCTCATCAATAAGTGTGGCAGGCGGAAGAAGGGACAACAGTATGACATGGTGCTTGAT
       T  L  Y  V  V  L  I  N  K  C  G  R  R  K  K  G  Q  Q  Y  D  M  V  L  D    551
2161  GTA TGAtgatgtttgtagtcacacctggagacacacacacacacacatcacacacacacacacccttagctc
       V  .                                                                      552
2232  ctcaaggggctatacagtattgtggcaccgcaccctgccaccacaggagacatatcactgctgctgggactt
2304  gaacaaagacattcaatgggggttggtttctttttttattctgccaaagcaaattgatacatcagtgagaaga
2376  aagtccgattaaatctgacagttttaggacggtgggatgatgtcttggcttatgcacttttcccttactgtg
2448  catctgcctgacagtgtttgttctaaatacctcacttgccatgctttgtgtgggtgatcatggaagaaaagg
2520  attctgaaaactcaagggaacgttctttcaacctacacatcctaacttatggactcttttgatagctgatga
2592  ttttctttctatttttgtttttaaggaaaattgttcatctttaccaaatgaaatgccaaaggaaagttgga
2664  aagccactggctatgctgtattttgatataataattgtactgtgttttaaattttgtatccggatttttaaa
2736  aacaaaatttcacaccatagtctatatttacttctctggcaaaatacacttttgttctttttatatatatat
2808  atatatatatataataaaataggttctaaaaaaatccatactataaaaaaaaattaacctgcccaaaatgtg
2880  aaacgtggttgactgatgttcatgaaagaataaaatgtttctctctttctctacattttaaaaaaaaa
```

FIG. 3



FIG. 4

SUBSTITUTE SHEET (RULE 26)

```
MHas2     190 KREVMY--TAFRALGRSVD--YVQVCDSDTMLDPASSVEMVKVLEED 232
MHas1     220 KREVMY--TAFKALGDSVD--YVQVCDSDTKLDPMALLELVRVLDED 262
DG42 207  KREVMY--TAFQAIGTSVD--YVQVCDSDTKLDELATVEMVKVLESN 249
HasA 138  KRHAQA--WAFERSDADV----FLTV-DSDTYIYPNALELLKSFNDE 178
NodC 120  KRKAQI--AAIGQSSGDL----VLNV-DSDSTIAFDVVSKLASKMRDP 160
Chs2 415  KKKINSHRWLFNAFCPVLQPTVVTLVDVGTRLANNTAIYRLWKVFDMD 461

MHas2     270 QCSFGDDRHLTN-RVLS--LGYATKYTARSKCLTETPIEYLRWLNQQTRWSKSYFREW 362
MHas1     338 HCTFGDDRHLTN-RMLS--MGYATKYTSRSRCYSETPSSFLRWLSQQTRWSKSYFREW 392
DG42 337  YCTLGDDRHLTN-RVLS--MGYRTKYTHKSRAFSETPSLYLRWLNQQTRWTKSYFREW 390
HasA 253  PVSIGDDRCLTN-YAID--LG-RTVYQSTARCDTDVPFQLKSYLKQQNRWNKSPFRES 306
NodC 236  PSDFGEDRHLTI-LMLK--AGFRTEYVPDAIVATVVPDTLKPYLRQQLRWARSTFRDT 288
Chs2 557  NMYLAEDRIILGWELVAKRDAKWLKYVKEATGETDVPEDVSEFISQRRRWNLNCAMFAA 613
```

FIG. 5

FIG. 6A


Hydrophilicity Window Size = 15 Scale = Kyte-Doolittle
Hydrophilicity
Has2
Has1
HasA

FIG. 6B


NH2
COOH
HABM1/HABM2
HABM3 HABM4
Predicted Intracellular Loop


Days of Gestation
7.5
11.5
15.5
17.5
9.5
7.5
4.4
2.4
1.35
Heart
Brain
Spleen
Lung
Liver
Skeletal muscle
Kidney
Has2
GAPDH

FIG. 7



FIG. 8



FIG. 9

```
  1 GTCTTATTTT GGGTGTGTTC AGTGCATTAG TGGACCTCTG GGAATGTACA
 51 GAAACTCCTT GTTGCATGAG TTTGTGGAAG ATTGGTACAA TCAAGAATTT
101 ATGGGCAACC AATGTAGCTT TGGTGATGAC AGGCATCTCA CGAACCGGGT
151 GCTGAGCCTG GGCTATGCAA CAAAATACAC AGCTCGATCT AAGTGCCTTA
201 CTGAAACACC TATAGAATAT CTCAGATGGC TAAAC
```

FIG. 10A

```
HHAS2    1 .................GTCTTATTTTGGGTGTGTTCAGTGCATTAGT 31
MHas2 1301 atatagaaagggcctgccagtcttattttggctgtgtccagtgcataagc 1350

HHAS2   32 GGACCTCTGGGAATGTACAGAAACTCCTTGTTGCATGAGTTTGTGGAAGA 81
MHas2 1351 ggtcctctgggaatgtacagaaactccttgctgcatgaatttgtggaaga 1400

HHAS2   82 TTGGTACAATCAAGAATTTATGGGCAACCAATGTAGCTTTGGTGATGACA 131
MHas2 1401 ctggtacaatcaggaattcatgggtaaccaatgcagttttggtgacgaca 1450

HHAS2  132 GGCATCTCACGAACCGGGTGCTGAGCCTGGGCTATGCAACAAAATACACA 181
MHas2 1451 ggcaccttaccaacagggtgttgagtctgggctatgcaactaaatacacg 1500

HHAS2  182 GCTCGATCTAAGTGCCTTACTGAAACACCTATAGAATATCTCAGATGGCT 231
MHas2 1501 gctcggtccaagtgccttactgaaactcccatagaatatctgagatggct 1550

HHAS2  232 AAAC..................................................  235
MHas2 1551 gaaccagcagacccgatggagcaagtcctacttccgagagtggctgtaca 1600
```

FIG. 10B

```
HHAS2    1 .....................SYFGCVQCISGPLGMYRNSLLHEFVEDWY 29
MHas2  251 WISFLSSVRYWMAFNIERACQSYFGCVQCISGPLGMYRNSLLHEFVEDWY 300

HHAS2   30 NQEFMGNQCSFGDDRHLTNRVLSLGYATKYTARSKCLTETPIEYLRWLN. 78
MHas2  301 NQEFMGNQCSFGDDRHLTNRVLSLGYATKYTARSKCLTETPIEYLRWLNQ 350
```

FIG. 10C

```
  1 GTCCTACTTT GGCTGTGTGC AGTGTATTAG TGGGCCCTTG GGCATGTACC
 51 GCAACAGCCT CCTCCAGCAG TTCCTGGAGG ACTGGTACCA TCAGAAGTTC
101 CTAGGCAGCA AGTGCAGCTT CGGGGATGAC CGGCACCTCA CCAACCGAGT
151 CCTGAGCCTT GGCTACCGAA CTAAGTATAC CGCGCGCTCC AAGTGCCTCA
201 CAGAGACCCC CACTAAGTAC CTCCGGTGGC TCAAC
```

FIG. 11A

```
  1 GTCCTACTTT GGCTGTGTGC AATGTATTAG TGGGCCTTTG GGCATGTACC
 51 GCAACAGCCT CCTTCAGCAG TTCCTGGAGG ATTGGTACCA TCAGAAGTTC
101 CTAGGCAGCA AGTGCAGCTT TGGGGATGAT CGGCACCTTA CCAACCGAGT
151 CCTGAGTCTT GGCTACCGGA CTAAGTATAC AGCACGCTCT AAGTGCCTCA
201 CAGAGACCCC CACTAGGTAC CTTCGATGGC TCAAT
```

FIG. 11B

```
MHas3  1 GTCCTACTTTGGCTGTGTGCAATGTATTAGTGGGCCTTTGGGCATGTACC 50
HHAS3  1 GTCCTACTTTGGCTGTGTGCAGTGTATTAGTGGGCCCTTGGGCATGTACC 50

      51 GCAACAGCCTCCTTCAGCAGTTCCTGGAGGATTGGTACCATCAGAAGTTC 100
      51 GCAACAGCCTCCTCCAGCAGTTCCTGGAGGACTGGTACCATCAGAAGTTC 100

     101 CTAGGCAGCAAGTGCAGCTTTGGGGATGATCGGCACCTTACCAACCGAGT 150
     101 CTAGGCAGCAAGTGCAGCTTCGGGGATGACCGGCACCTCACCAACCGAGT 150

     151 CCTGAGTCTTGGCTACCGGACTAAGTATACAGCACGCTCTAAGTGCCTCA 200
     151 CCTGAGCCTTGGCTACCGAACTAAGTATACCGCGCGCTCCAAGTGCCTCA 200

     201 CAGAGACCCCCACTAGGTACCTTCGATGGCTCAAT 235
     201 CAGAGACCCCCACTAAGTACCTCCGGTGGCTCAAC 235
```

FIG. 11C

```
HHAS3  1 SYFGCVQCISGPLGMYRNSLLQQFLEDWYHQKFLGSKCSPGDDRHL/TNRV 50
MHas3  1 SYFGCVQCISGPLGMYRNSLLQQFLEDWYHQKFLGSKCSPGDDRHL/TNRV 50

      51 LSLGYRTKYTARSKCLTETPTKYLRWLN 78
      51 LSLGYRTKYTARSKCLTETPTRYLRWLN 78
```

FIG. 11D

```
MHas3   276 SYFGCVQCISGPLGMYRNSLLQQFLEDWYHQKFLGSKCSFGDDRHLTNRVLSLGV
HHAS3       ------------------------------------------------------

MHas3   331 RTKYTARSKCLTETPTRYLRWLNQQTRWSKSYFREWLYNSLWFHKHHLWMTYESV
HHAS3       ----------K-------------------------------------------

MHas3   386 VTGFFPFFLIATVIQLFYRGRIWNILLFLLTVQLVGIIKATYACFLRGNAEMIFM
HHAS3       ------------------------------------------------------

MHas3   441 SLYSLLYMSSLLPAKIFAIATINKS
HHAS3       -------------------------
```

FIG. 12A

```
1    ATGCCGGTGCAGCTGACTACAGCCCTGGGTGTGGTGGGCACCAGTCTGTTTGCCCTGGTAGTGCTG
       M  P  V  Q  L  T  T  A  L  R  V  V  G  T  S  L  F  A  L  V  V  L    22
67   GGAGGCATCCTGGCGGCCTATGTGACAGGCTACCAGTTTATCCACACAGAAAAGCACTACCTGTCC
       G  G  I  L  A  A  Y  V  T  G  Y  Q  F  I  H  T  E  K  H  Y  L  S    44
133  TTTGGCCTCTACGGTGCCATCCTGGGTCTACATCTGCTCATCCAGAGCCTGTTTGCCTTCCTGGAG
       F  G  L  Y  G  A  I  L  G  L  H  L  L  I  Q  S  L  F  A  F  L  E    66
199  CACCGTCGAATGCGCAGGGCAGGGCGCCCCCTCAAGCTGCACTGCTCCCAGAGGTCGCGTTCAGTG
       H  R  R  M  R  R  A  G  R  P  L  K  L  H  C  S  Q  R  S  R  S  V    88
265  GCACTCTGCATTGCTGCCTACCAAGAGGACCCCGAATACCTGCGCAAGTGCCTTCGCTCAGCTCAG
       A  L  C  I  A  A  Y  Q  E  D  P  E  Y  L  R  K  C  L  R  S  A  Q   110
331  CGCATTGCCTTTCCAAACCTCAAGGTGGTCATGGTAGTGGATGGCAATCGCCAGGAAGATACCTAC
       R  I  A  F  P  N  L  K  V  V  M  V  V  D  G  N  R  Q  E  D  T  Y   132
397  ATGTTGGACATCTTCCATGAGGTGCTGGGTGGCACTGAGCAAGCTGGCTTCTTTGTGTGGCGTAGC
       M  L  D  I  F  H  E  V  L  G  G  T  E  Q  A  G  F  F  V  W  R  S   154
463  AATTTCCATGAGGCGGGTGAAGGAGAGACAGAGGCCAGCCTGCAGGAAGGCATGGAGCGTGTGCGA
       N  F  H  E  A  G  E  G  E  T  E  A  S  L  Q  E  G  M  E  R  V  R   176
529  GCTGTGGTGTGGGCCAGCACCTTCTCATGCATCATGCAGAAGTGGGGGGGCAAGCGTGAGGTCATG
       A  V  V  W  A  S  T  F  S  C  I  M  Q  K  W  G  G  K  R  E  V  M   198
595  TACACTGCCTTCAAGGCCCTTGGCAACTCAGTGGACTACATCCAGGTGTGTGACTCTGACACTGTG
       Y  T  A  F  K  A  L  G  N  S  V  D  Y  I  Q  V  C  D  S  D  T  V   220
661  CTGGACCCAGCCTGCACCATTGAGATGCTTCGAGTCTTGGAAGAAGATCCCAAGTAGGAGGTGTT
       L  D  P  A  C  T  I  E  M  L  R  V  L  E  E  D  P  Q  V  G  G  V   242
727  GGAGGAGATGTCCAAATCCTCAACAAGTATGATTCATGGATCTCCTTCCTGAGCAGTGTGAGGTAC
       G  G  D  V  Q  I  L  N  K  Y  D  S  W  I  S  F  L  S  S  V  R  Y   264
793  TGGATGGCTTCAACGTGGAGCGGGCCTGCCAGTCCTACTTTGGCTGTGTGCAATGTATTAGTGGG
       W  M  A  F  N  V  E  R  A  C  Q  S  Y  F  G  C  V  Q  C  I  S  G   286
859  CCTTTGGGCATGTACCGCAACAGCCTCCTTCAGCAGTTCCTGGAGGATGGTACCATCAGAAGTTC
       P  L  G  M  Y  R  N  S  L  L  Q  Q  F  L  E  D  W  Y  H  Q  K  F   308
925  CTAGGCAGCAAGTGCAGCTTTGGGGATGATCGGCACCTTACCAACCGAGTCCTGAGTCTTGGCTAC
       L  G  S  K  C  S  F  G  D  D  R  H  L  T  N  R  V  L  S  L  G  Y   330
991  CGGACTAAGTATACAGCACGCTCTAAGTGCCTCACAGAGACCCCCACTAGGTACCTTCGATGGCTC
       R  T  K  Y  T  A  R  S  K  C  L  T  E  T  P  T  R  Y  L  R  W  L   352
1057 AATCAGCAAACCCGCTGGAGCAAGTCTTACTTTCGGGAATGGCTCTACAATTCTCTGTGGTTCCAT
       N  Q  Q  T  R  W  S  K  S  Y  F  R  E  W  L  Y  N  S  L  W  F  H   374
1123 AAGCACCACCTCTGGATGACCTATGAATCAGTGGTCACAGGTTTCTTCCCATTCTTCCTCATTGCT
       K  H  H  L  W  M  T  Y  E  S  V  V  T  G  F  F  P  F  F  L  I  A   396
1189 ACAGTCATACAACTTTTCTACCGTGGCCGCATCTGGAACATTCTCCTCTTCCTGCTAACAGTGCAG
       T  V  I  Q  L  F  Y  R  G  R  I  W  N  I  L  L  F  L  L  T  V  Q   418
1255 CTGGTGGGCATTATCAAGGCTACCTATGCCTGCTTCCTTCGAGGCAATGCAGAGATGATCTTCATG
       L  V  G  I  I  K  A  T  Y  A  C  F  L  R  G  N  A  E  M  I  F  M   440
1321 TCCCTCTACTCCCTTCTCTATATGTCCAGCCTCTTGCCAGCCAAGATCTTTGCTATTGCTACCATC
       S  L  Y  S  L  L  Y  M  S  S  L  L  P  A  K  I  F  A  I  A  T  I   462
1387 AACAAGTCTGGCTGGGGCACTTCTGGCAGGAAAACCATTGTCGTGAACTTCATTGGCCTAATCCCC
       N  K  S  G  W  G  T  S  G  R  K  T  I  V  V  N  F  I  G  L  I  P   484
1453 GTGTCCATCTGGGTGGCAGTTCTTCTAGGGGGGTTAGCCTACACAGCTTATTGCCAGGACCTGTTC
       V  S  I  W  V  A  V  L  L  G  G  L  A  Y  T  A  Y  C  Q  D  L  F   506
1519 AGTGAGACCGAGCTAGCCTTCCTAGTCTCTGGGGCCATCCTGTATGGCTGCTACTGGGTGGCCCTC
       S  E  T  E  L  A  F  L  V  S  G  A  I  L  Y  G  C  Y  W  V  A  L   528
1585 CTCATGCTGTATCTGGCCATTATTGCCCGGAGGTGTGGGAAGAAGCCAGAACAGTATAGCCTGGCT
       L  M  L  Y  L  A  I  I  A  R  R  C  G  K  K  P  E  Q  Y  S  L  A   550
1651 TTTGCGGAGGTGTGA
       F  A  E  V  .                                                       554
```

FIG. 12B



FIG. 13

```
MHas3     --MPVQLTTALR-VVGTSL--------------FALVVLGGILAAYVTGYQFIHTEKHYLSFGLYGAIL
MHas2     -MHCERFLCVLR-IIGTTL--------------FGVSLLLGITAAYIVGYQFIQTDNYYFSFGLYGAFL
MHas1     ----MRQDMPKPSEAARCCSGLARRALTII---FALLILGLMTWAYAAGVPLASDRYGLLAFGLYGAFL
DG42      MKEKAAETMEIPEGIPKDLEPKHPTLWRIIYYSFGVVLLATITAAYVAEFQVLKHEAILFSLGLYGLAM
HasA      ------MPIFKKTLIVLSFIFLISILIYLNMYLFGTST---VGI-YGVILITYLVIKL-------GLSF
                      *                 *   * *   *                 *

MHas3     GLHLLIQSLFAFLEHRRM----RRA-GRPLKLHCSQRSRSVALCIAAYQEDPEYLRKCLRSAQRIAFPN
MHas2     ASHLIIQSLFAFLEHRKM----KKSLETPIKLN-----KTVALCIAAYQEDPDYLRKCLQSVKRLTYPG
MHas1     SAHLVAQSLFAYLEHRRVAAAARRSLAKGPLDAATA--RSVALTISAYQEDPAYLRQCLTSARALLYPH
DG42      LLHLMMQSLFAFLEIRRV----NKSEL-PCSFK-----KTVALTIAGYQENPEYLIKCLESCKYVKYPK
HasA      LYEPFKGNPHDY--------------------------K-VAAVIPSYNEDAESLLETLKSVLAQTYPL
                    *    **    *            ** *                    *

MHas3     LK--VVMVVDGNRQEDTYMLDIFHEVLGGTEQAGFFVWRSNFHE-AGEGET-------EASLQEGMERV
MHas2     IK--VVMVIDGNSDDDLYMMDIFSEVMGRDK-SATYIWKNNFHE-KGPGET-------EESHKESSQHV
MHas1     TRLRVLMVVDGNRAEDLYMVDMFREVFADED-PATYVWDGNYHQPWEPAEATGAVGEGAYREVEAEDPG
DG42      DKLKIILVIDGNTEDDATMMEMFKDVFHGED-VGTYVWKGNYHTVKKPEETNKGSCPEVSKPLN-EDEG
HasA      S--EIYIVDDGSSNTDAIQL-------------IEEYVNRE-------------------VDICRNVIVHR
           *  * *          ***  *         **   *

MHas3     RA----VVWASTFSCIMQKWGGKREVMYTAFKALGNSVDYIQVCDSDTVLDPACTIEMLRVLEEDPQVG
MHas2     TQ----LVLSNKSICIMQKWGGKREVMYTAFRALGRSVDYVQVCDSDTMLDPASSVEMVKVLEEDPMVG
MHas1     RLAVEALVRTRRCVCVAQRWGGKREVMYTAFKALGDSVDYVQVCDSDTRLDPMALLELVRVLDEDPRVG
DG42      INMVEELVRNKRCVCIMQQWGGKREVMYTAFQAIGTSVDYVQVCDSDTKLDELATVEMVKVLESNDMYG
HasA      S-----LVNK----------G-KRHAQAWAFERSDADV-FLTV-DSDTYIYPNALEELLKSFNDETVYA
                *      *        *           **       *      ***      *

MHas3     GVGGDVQILNKYDSWISFLSSVRYWMAFNVERACQSYFGCVQCISGPLGMYRNSLLQQFLEDWYHQKFL
MHas2     GVGGDVQILNKYDSWISFLSSVRYWMAFNIERACQSYFGCVQCISGPLGMYRNSLLHEFVEDWYNQEFM
MHas1     AVGGDVRILNPLDSWVSFLSSLRYWVAFNVERACQSYFHCVSCISGPLGLYRNNLLQQFLEAWYNQKFL
DG42      AVGGDVRILNPYDSFISFMSSLRYWMAFNVERACQSYFDCVSCISGPLGMYRNNILQVFLEAWYRQKFL
HasA      ATG-HLNARNRQTNLLTRLTDIRYDNAFGVERAAQSLTGNILVCSGPLSIYRREVIIPNLERYKNQTFL
          *    * *      ** ** *      *         *       *    **   *      *

MHas3     GSKCSFGDDRHLTNRVLSLGYRTKYTARSKCLTETPTRYLRWLNQQTRWSKSYFREWLYNSLWFHKHHL
MHas2     GNQCSFGDDRHLTNRVLSLGYATKYTARSKCLTETPIEYLRWLNQQTRWSKSYFREWLYNAMWFHKHHL
MHas1     GTHCTFGDDRHLTNRMLSMGYATKYTSRSRCYSETPSSFLRWLSQQTRWSKSYFREWLYNALWWHRHHA
DG42      GTYCTLGDDRHLTNRVLSMGYRTKYTHKSRAFSETPSLYLRWLNQQTRWTKSYFREWLYNAQWWHKHHI
HasA      GLPVSIGDDRCLTNYAIDLG-RTVYQSTARCDTDVPFQLKSYLKQQNRWNKSFFRESIISVKKILSNPI
              *        ** *        *  **                 *    *        *

MHas3     ---W-----MTYESVV----TGFFPFFLIATVIQLFYRGRI--WNILLFLLTVQLVGIIKATYACFLRG
MHas2     ---W-----MTYEAVI----TGFFPFFLIATVIQLFYRGKI--WNILLFLLTVQLVGLIKSSFASCLRG
MHas1     ---W-----MTYEAVV----SGLFPFFVAATVLRLFYAGRP--WALLWVLLCVQGVALAKAAFAAWLRG
DG42      ---W-----MTYESVV----SFIFPFFITATVIRLIYAGTI--WNVVWLLLCIQIMSLFKSIYACWLRG
HasA      VALWTIFEVVMFMMLIVAIGNLLFNQAIQLDLIKLFAFLSI----IFIVALC-------R-NVHYMVKH
                    *  **          *  * **                  *   *  *  * *     **

MHas3     NAEMIFMSLYSLLYMSSLLPAKIFAIATINKSGWGTSGRKTIVVNFIGLIPVSIWVAVLLGGLAYTAY-
MHas2     NIVMVFMSLYSVLYMSSLLPAKMFAIATINKAGWGTSGRKTIVVNFIGLIPVSVWFTILLGGVIFTIYK
MHas1     CVRMVLLSLYAPLYMCGLLPAKFLALVTMNQSGWGTSGRKKLAANYVPVLPLALWALLLLGGLARSVAQ
DG42      NFIMLLMSLYSMLYMTGLLPSKYFALLTLNKTGWGTSGRKKIVGNYMPILPLSIWAAVLCGGVGYSIYM
HasA      PASFLLSPLYGILHLFVLQPLKLYSLCTIKNTEWGTRKKVTIFK•
              *       *         *          *  *   * ** *  *    *    **

MHas3     -CQDLFSET----ELAFLVSGAILYGCYWVALLMLYLAIIARRCG--KKPEQYSLAFAEV•
MHas2     ESKKPFSES-KQ---TVLIVGTLIYACYWVMLLTLYVVLI-NKCGRRKKGQQYDMV-LDV•
MHas1     EARADWSGPSRAAEAYHLAAGAGAYVAYWVVMLTIYWVGVRRLC-RRRSGG-YRVQV•
DG42      DCQNDWSTPEKQKEMYHLLYGCVGYVMYWVIMAVMYWVWVKRCC-RKRSQTVTLVHDIPDMCV•
          *        *      *  **     *** *  * *        *
```

FIG. 14A

```
MHas3   194 KREVMY--TAFKALGNSVD--YIQVCDSDTVLDPACTIEMLRVLEED 236
MHas2   190 KREVMY--TAFRALGRSVD--YVQVCDSDTMLDPASSVEMVKVLEED 232
MHas1   220 KREVMY--TAFKALGDSVD--YVQVCDSDTRLDPMALLELVRVLDED 262
DG42    207 KREVMY--TAFQAIGTSVD--YVQVCDSDTKLDELATVEMVKVLESN 249
HasA    138 KRHAQA--WAFERSDADV----FDTV-DSDTYIYPNALEELLKSFNDE 178
NodC    120 KRKAQI--AAIGQQSSGDL----VLNV-DSDSTIAFDVVSKLASKMRDP 160
cel1    435 KAGAENALVRVSAVLTNAP--FILNLDCDHYVNNSKAVREAMCFLMD 479
Chs2    415 KKKINSHRWLFNAFCPVLQPTVVTLVDWGTRLNNTAIYRLWKVFDMD 461

MHas3   312 KCSFGDDRHLTN-RVLS--LGYRTKYTARSKCLTETPTRYLRWLNQQTRWSKSYFREW 366
MHas2   308 QCSFGDDRHLTN-RVLS--LGYATKYTARSKCLTETPIEYLRWLNQQTRWSKSVFREW 362
MHas1   338 HCTFGDDRHLTN-RMLS--MGYATKYTSRSRCYSETPSSFLRWLSQQTRWSKSVFREW 392
DG42    337 YCTLGDDRHLTN-RVLS--MGYRTKYTHKSRAPSETPSLYLRWLNQQTRWTKSYFREW 390
HasA    253 FVSIGDDRCLTN-YAID--LG-RTVYQSTARCDTDVPFQLKSYLKQQNRWNKSFFRES 306
NodC    236 PSDFGEDRHLTI-LMLK--AGFRTEYVPDAIVATVVPDTLKPYLRQQLRWARSTFRDT 288
cel1    666 YGSVTED-ILTGFKMHCRGWRSIYCMPLRPAFKGSAPINLSDRLHQVLRWALGSVEIF 722
Chs2    557 NMYLAEDRILCWELVAKRDAKWVLKYVKEATGETDVPEDVSEFTSQRRRWLNCAMFAA 613
```

FIG. 14B


Hydrophilicity Window Size = 20
Scale = Kyte-Doolittle
Hydrophilicity
5.00
4.00
3.00
2.00
1.00
0.00
-1.00
-2.00
-3.00
-4.00
-5.00
100
200
300
400
500
Has3
Has2
Has1
HasA
50
150
250
350

FIG. 14C



FIG. 15